SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.ENVIRONMENTAL, SOCIAL, AND GOVERNANCE (ESG)REPORT 2025

Contents

Corporate GovernanceCorporate governance structureSafeguarding shareholders' rights and interestsESG GovernanceESG governance structureCommunication with stakeholdersAssessment of important issues

Compliance in Operation

Risk management and controlProbity and self-disciplineInformation security

Attraction and Retention of Talents

Diversity and equal employmentEmployee rights and benefitsEmployee care and communicationEmployee Training and DevelopmentTraining systemEmployee ability improvementEmployee promotion and development

Occupational Health and Safety

Occupational healthSafety management

Environmental and Occupational Healthand Safety ManagementAddressing Climate ChangeGreen OperationEmissions and waste managementResource and energy management

Product Quality and Safety

Quality management systemProduct quality and safety management

Focusing on R&D and Innovation

Ever-improving R&D and innovation systemR&D and innovation capabilityR&D and innovation resultsIntellectual property protection

Supply Chain Management

Supplier managementSupplier communicationSustainable supply chain management

Responsible Marketing

Responsible marketing managementResponsible brand buildingResponsible marketing trainingCustomer Service QualityCustomer service management and capabilitiesCustomer satisfactionImproving customer service capabilities

ABOUT THIS REPORTMESSAGE FROM THE CHAIRMANABOUT SNIBESNIBE IN 2025MilestonesKey PerformanceHonors and Recognitions

Key Performance Indicator TableAppendix

REGULATING CORPORATEGOVERNANCE

TALENT EMPOWERMENT

Industry Exchange and CooperationIndustry-University-Research collaboration andmulti-center researchAcademic extensionDriving industry standardizationInternational exchanges and cooperationCommunity Commonweal

Support for research and educationSupporting community commonweal

FULFILLING SOCIAL RESPONSIBILITY

PROMOTING GREEN OPERATION

STRICTLY CONTROLLING THE QUALITYOF PRODUCTS AND SERVICES

The year 2025 marks the conclusion of the 14th Five-Year Plan, and the in vitro diagnostics (IVD) industry facesmultiple challenges, including the deepening of centralizedprocurement, cyclical adjustments, and supply chainrestructuring. As an enterprise with the mission of "creatingvalue for human health", we ?rmly believe that the value of anenterprise lies in upholding its original aspirations, persistingin innovation, and bravely assuming its responsibilities in theface of adversity. This year, we have been working diligentlyon standardized governance, independent innovation, greenoperation, and social responsibility, and striving to writea new chapter for Chinese IVD enterprises amidst industry?uctuations.We have solidified the foundation for developmentthrough standardized governance. We firmly believethat standardized governance is the cornerstone for anenterprise to achieve steady and long-term development. Inline with the implementation of the new "Company Law ofthe People's Republic of China", we have comprehensivelyrevised the "Articles of Association" and several governancesystems, added an employee representative director, andfurther optimized the governance structure of the board.Facing the normalization of centralized procurement,we have carried out rigorous audit supervision and anti-commercial bribery efforts, not only strictly controllingmarketing compliance but also improving operationalefficiency through lean management. We place greatimportance on investor relations and, during this period ofindustry valuation reshaping, strive to convey the long-termvalue of the Company's sound operations to the market,e?ectively protecting the rights and interests of shareholders,especially small and medium-sized investors.We adhere to innovation-driven development and de?ne theindustry's standards through technological breakthroughs.Amidst increasingly homogenized competition in the industry,we focus on our strengths, such as chemiluminescence,and continuously push the limits of single-machine speedmeasurement and detection accuracy. We continue to makebreakthroughs in small molecule detection, rare diseases,and the research and development of geriatric, pediatric,and maternal products, allowing innovative achievementsto benefit a wider population. At the same time, we keenlyembrace the wave of "arti?cial intelligence + healthcare". Byempowering R&D with digitalization, we have significantlyimproved both R&D efficiency and success rates. Ourindependently developed fully automated sample processingsystem, SATLARS T8, prioritizes emergency cases andfeatures intelligent scheduling throughout the entire sampletesting process, greatly shortening sample turnaround timeand helping laboratories improve quality and e?ciency with

This is the fifth environmental, social, and governance (ESG) report issued by ShenzhenNew Industries Biomedical Engineering Co., Ltd. According to the principles of objectivity,standardization, transparency, and comprehensiveness, this report discloses detailed informationconcerning the Company's practice and performance in the field of sustainable development in2025, such as environment, society, and governance.This report is an annual report and covers relevant data from Jan. 1, 2025 to Dec. 31, 2025. As someof the data in this report involve continuity and comparability, some contents are appropriatelyextended or traced as needed.This report covers Shenzhen New Industries Biomedical Engineering Co., Ltd. and its subsidiaries.This report is mainly prepared with reference to the "Global Reporting Initiative (GRI) Standards","Shenzhen Stock Exchange Self-Regulation Guidelines for Listed Companies No. 17 - SustainableDevelopment Report (Trial)", "Shenzhen Stock Exchange ChiNext Self-Regulation Guidelines forListed Companies No. 3 - Sustainable Development Report Preparation", and the United Nations"Guide for Business Action on the Sustainable Development Goals (SDGs)", in order to continuouslyimprove the transparency of the disclosure of sustainable development reports and respond to theinformation needs of stakeholders.For better elaboration and understanding, "Shenzhen New Industries Biomedical Engineering Co.,Ltd." is also referred to as "Snibe", "We", or "the Company" in this report.The monetary amounts in this report are measured in RMB unless otherwise speci?ed.This report was approved for release at the 7th Meeting of the 5th Board of Directors of theCompany on Apr. 27, 2026. The Company and all members of the Board of Directors warrant thatthe contents disclosed in this report are true, accurate, and complete, and that there are no falserecords, misleading statements, or major omissions.This report includes paper and electronic versions. You can read and download the electronicversion of this report on Juchao Information Network (www.cninfo.com.cn), the designatedinformation disclosure website of the Shenzhen Stock Exchange, or the o?cial website of Snibe(www.snibe.com), and obtain more company information. If you have any questions or suggestionsabout this report, please send an email to Snibeinfo@snibe.cn or call +86-755-86540062.This report is prepared in Chinese. The English version is the translation of the Chinese version.If there is any ambiguity in the understanding of the English version, the Chinese version shallprevail.

Overview >

Scope ofReporting >

Standards forReporting >

Explanation >

Confirmation andApproval>Access to theReport andFeedback >

ABOUT THIS REPORTMESSAGE FROM THE CHAIRMANABOUT SNIBESNIBE IN 2025ABOUT THIS REPORTMESSAGE FROM THE CHAIRMANABOUT SNIBESNIBE IN 2025

ABOUT THIS REPORTMESSAGE FROM THE CHAIRMAN

0102

intelligent solutions.We strictly control the quality lifeline and safeguardthe well-being of patients with a sense ofresponsibility. In the context of medical insurance costcontrol and centralized procurement price reduction,we have always upheld the enterprise spirit of "Qualityis our life". We further strengthen the full lifecyclequality management system and continuouslyenhance the traceability and risk prevention andcontrol capabilities of the supply chain. What wepursue is not only the accuracy of test results, but alsoto help reduce misdiagnosis rates and unnecessarymedical expenses through technological innovation,so that every reagent and every instrument carriesthe warmth of alleviating the burden of diagnosis andtreatment for patients.We promote green operation and respond to thechallenges of our time with low-carbon practices.With increasing attention to sustainable developmentboth domestically and internationally, we continueour e?orts in energy conservation, emission reduction,and resource recycling, and continuously enhance theefficiency of energy and resource utilization throughtechnological, equipment, and method improvements.We actively respond to China's carbon peaking and

Company Introduction >

Since its founding in 1995, Snibe has focused on the ?eld of IVD and developed itself into a national high-tech enterprisespecializing in the R&D, production, sales, and services of IVD products. Since its inception, the Company has dedicated itselfto the mission of "customer-centric, market-oriented, creating value for human health through continuous innovation" toprovide customers with better IVD products and services. After 30 years of profound development, technology iteration, andcustomer accumulation, the Company's products have broken the monopoly and technology blockade of overseas giants onChina's IVD market, and Snibe has become a leader in China's IVD ?eld and is evolving into a pioneer in the global IVD ?eld.Corporate Culture >

Milestones >

Company's Ownership Structure >As of the end of the reporting period, the actual controller of Snibe is Mr. Weng Xianding, whose direct shareholding ratio is

3.18% and shareholding ratio through Tibet New Industry Investment Management Co., Ltd. is 26.88%, totaling 30.06%. The

second largest shareholder is Rao Wei, the chairman and general manager of the Company, with a shareholding ratio of

13.77%. The third largest shareholder is Tianjin Sequoia Juye Equity Investment Partnership (Limited Partnership) (hereinafter

referred to as: Sequoia Juye), with a shareholding ratio of 10.62% (as of the disclosure date of this report, the shareholdingratio of Sequoia Juye is 8.78%).

The multi-center clinical study on primary aldosteronismwas concluded, contributing to the screening andtreatment of hypertensionThe "Conclusion Meeting of the Series of Studies on DiagnosticMarkers of Primary Aldosteronism and Seminar on the CurrentStatus, Challenges, and Countermeasures of Primary AldosteronismDiagnosis and Treatment", sponsored by the Laboratory andClinical Branch of the Chinese Society of Cardiothoracic andVascular Anesthesiology, co-organized by the Chinese EndocrineHypertension Collaborative Group, and organized by the Company,was grandly held in Shenzhen. The conclusion of this multi-centerresearch on primary aldosteronism screening has promoted thestandardization of primary aldosteronism screening and diagnosisin China.

MAGLUMI? X10, a flagshipfully-auto chemiluminescenceimmunoassay analyzer with athroughput of 1000 T/H, wascertified for market launchMAGLUMI? X10 represents anothersigni?cant breakthrough for Snibein the IVD ?eld, demonstratingits leading strength in clinicalapplication and technologicalinnovation, while also injecting newmomentum and vitality into theglobal healthcare industry.

Biossays? C10, an automaticbiochemistry analyzer with athroughput of 2000 T/H, wascertified for market launchThe launch of the Biossays? C10demonstrates the Company's strongR&D capabilities in ultra-high-speedbiochemistry analyzers, markinganother major breakthrough in the?eld of biochemistry analyzers inChina and moving towards a higherlevel.

The kick-off meeting of "Multi-center Research onthe Clinical Application of High-sensitivity Troponin IConcentration and Changes in the Assessment of AcuteMyocardial Infarction" was successfully heldCardiovascular disease is the "number one killer" that threatenshuman health, seriously endangering national health. Earlydiagnosis and precise treatment are the keys to saving lives.This meeting focused on in-depth discussions on the precisediagnosis and treatment of myocardial infarction and theapplication of high-sensitivity troponin in emergency triage,injecting new momentum into the prevention and control ofcardiovascular diseases.

Customer-centric, market-oriented, creating value forhuman health through continuousinnovation.MissionVisionCore valuesSpirit

0304

ABOUT SNIBE

SNIBE IN 2025

ABOUT THIS REPORTMESSAGE FROM THE CHAIRMANABOUT SNIBESNIBE IN 2025ABOUT THIS REPORTMESSAGE FROM THE CHAIRMANABOUT SNIBESNIBE IN 2025

carbon neutrality strategy, systematically promote greenhouse gas accounting and management, and take concrete actionsto respond to the call for global climate change governance.We empower our employees to grow and unite organizational strength through diversity and inclusion. We always regardtalent as our most valuable core asset. We deepen the concept of diverse and equal employment, improve the training systemand promotion channels, establish a perfect salary and benefit system and incentive mechanism, provide a comfortableworking environment and diverse welfare, and take various welfare and care measures to create a highly sticky environmentfor talents, enhance employees' sense of belonging and achievement, and promote the common growth of employees andthe Company.We ful?ll social responsibility and give back to society's expectations with professional expertise. As a national enterprise,leveraging our professional advantages, we actively promote the allocation of high-quality medical resources to grassrootslevels. Through strategic partnerships with leading healthcare institutions, we drive translational research to enable earlydiagnosis and treatment of chronic diseases and support medical education and talent cultivation. In the grand visionfor global healthcare, we are committed to serving global health needs with intelligent manufacturing from China andcontributing Chinese strength to building a healthier, fairer, and more sustainable future.Sustainable development is an enduring journey. Guided by unwavering reverence for human life and health, we harnessinnovation to address evolving healthcare imperatives and uphold our corporate mission through responsible stewardship.Looking ahead, we will continue to drive innovation and take responsibility, forging new paths amidst change and workinghand in hand with every partner to write a brilliant chapter for Chinese IVD enterprises!

Assume responsibilitybravelyEnjoy challenge persistentlyPursue excellence passionately

To be a leader inChina's IVD fieldTo be a pioneer in theglobal IVD field

Quality is our life

Chairman: Rao WeiApr. 27, 2026

The project "Multi-center Research toEstablish the Reference Interval forHigh-sensitivity Troponin I in ApparentHealthy People in China" was successfullyconcludedLaboratory testing of cardiovascular diseasebiomarkers is susceptible to multiple factors, andtechnologies suitable for precise testing are crucialfor clinical decision-making. This multi-centerresearch on reference interval extensively coverskey factors a?ecting biomarker testing, includingmultiple regions, diverse populations, variousethnicities, and di?erent lifestyles. The research?ndings will open new paths for the prevention,diagnosis, and treatment of cardiovascular diseasesin China, helping laboratory medicine better servepeople's health.

Economic performance

Corporate governance

Quality of products and services

4,576.76

477.77

100%

Business revenue

Investor exchangeInformation disclosure

assessment result

Proportion of employeesreceiving anti-commercialbribery training

Proportion of employeessigning anti-commercialbribery commitments

R&D investmentamount

Overall satisfactionwith customercomplaint handling

MillionRMB

activities

Million

RMB

Nearly

Net pro?t attributable toshareholders of listed companies

Number of validpatents granted

Earnings per share

Number of globally availablechemiluminescenceimmunoreagents

Number of events resultingin ?nes or penalties forbreach of regulationsTotal number of confirmedcomplaints received related toinfringement of customer privacy

Quality managementsystem certi?cates

Number ofrecalled products

1,620.25

A

2.0621

100%100%

MillionRMB

RMB/share

0506

Hemolumi? H6, a high-speed automatedcoagulation analyzer, and Biossays? E6 Plus,a high-speed fully-auto electrolyte analyzer,were certified for market launchThe launch of Hemolumi? H6 and Biossays? E6Plus marks another milestone for the Companyin the IVD ?eld, providing core laboratories withmore comprehensive solutions through modularintegration into total laboratory automation systems.

Several small molecule "sandwich"assay reagents were certified formarket launchBy the end of 2025, the Company's smallmolecule "sandwich" assay reagents haveobtained a total of 15 product registrationcerti?cates. The detection technology isbecoming increasingly mature, and theservice users have expanded from Chinato the world. It is widely used in morethan 100 countries and regions aroundthe world, helping to achieve precisiondiagnosis and treatment and contributingto global healthcare.

Snibe R&D and ProductionBuilding officially commencedconstructionThe Company's Snibe R&D Building(also known as Snibe Phase V Project)o?cially commenced construction inDec. 2025. Upon completion, the projectwill further enhance the Company'sR&D and innovation capability andproduction scale, injecting newmomentum into the Company's globaldevelopment.

The Company's key reagentmaterial and process R&Dteam was awarded the title of"Guangdong Provincial AdvancedCollective"The Company's key reagent materialand process R&D team was awarded thetitle of "Guangdong Provincial AdvancedCollective" for its outstanding innovativestrength and social contribution,demonstrating the Company's strengthin tackling core technologies.

The Company won the 2025 China Industry-University-Research Institute Collaboration Association Science andTechnology Innovation AwardThe Company, in collaboration with top institutions such as FuwaiHospital of the Chinese Academy of Medical Sciences, PekingUniversity People's Hospital, Fuwai Shenzhen Hospital of theChinese Academy of Medical Sciences, and the Second A?liatedHospital of Hainan Medical University, jointly conducted the project"Small Molecule 'Sandwich Method' Ushers in a New Era of PreciseDiagnosis for Primary Aldosteronism". With its groundbreakingtechnological innovation and signi?cant industry demonstrationvalue, it won the third prize of the Innovation Achievement Award.

ABOUT THIS REPORTMESSAGE FROM THE CHAIRMANABOUT SNIBESNIBE IN 2025ABOUT THIS REPORTMESSAGE FROM THE CHAIRMANABOUT SNIBESNIBE IN 2025

Key Performance >

Attraction and retention of talents

Environmental and occupational health and safety

2,785

0.00760.0373

0.5467

21,679.7

73.29%

100%

Number of employees

Energy consumptionintensity

Proportion of employeeswith bachelor degree orabove

Coverage of occupationalhealth examination

tons of standardcoals/10,000 RMB

tons of CO

equivalent/10,000 RMB

m

/10,000 RMBcubic meters

hours

million yuan

Proportion of femaleemployees

Carbon emissionintensity

Proportion of employeescovered by year-endperformance appraisal

Number of employee deaths dueto work-related injuries

Proportion of females inmanagement

Water intake intensity

Total training duration

Investment in environmental andoccupational health and safety

Proportion of females insenior management

Volume of reject waterrecovered

Social insurance coverage

36.62%

100%

30.27%

96,743

4.58

66.67%

100%

National High-tech EnterpriseNational Enterprise Technology CenterMaster Enterprise of "Industry-Education-Assessment"Skills Ecological Chain in Guangdong ProvinceListed in the "White List" of Shenzhen Entry-Exit BiomedicalSpecial Products Pilot Enterprises (Institutions) in 2025Top 500 Enterprises in Guangdong Province in 2025Guangdong Provincial Advanced Collective (KeyReagent Material and Process R&D Team)Forbes Asia's Best Under A Billion 2025 ListChina's Top 20 Most Competitive Pharmaceutical ListedCompanies in 2025Shenzhen's Fourth Batch of Industry-EducationIntegration EnterprisesShenzhen Top 10 Model Platforms for LifelongVocational Skills TrainingPingshan District Science Popularization Education Base2025 Employer of Excellence in Occupational CreditGrade A in information disclosure appraisal (fourconsecutive years)2024 Golden Bull Award - The Most Valuable InvestmentAwardThe 19th China ESG Top 100 Listed CompaniesScored BBB in MSCI ESG RatingScored AA in Wind ESG RatingScored AA in CNI ESG RatingScored AAA in Sino-Securities Index ESG RatingTop 100 A-Share Listed Companies in ESG Performance 2025Top 20 A-Share Listed Companies in ESG Performance inPharmaceutical and Healthcare Industry 2025

Science, Technology, and Innovation Commission of ShenzhenMunicipality, Finance Bureau of Shenzhen Municipality, andShenzhen Tax Service, State Taxation AdministrationNational Development and Reform CommissionHuman Resources and Social Security Department of GuangdongProvinceDevelopment and Reform Commission of Shenzhen MunicipalityGuangdong Provincial Enterprise Confederation and GuangdongProvincial Association of EntrepreneursCPC Guangdong Provincial Committee and People's Governmentof Guangdong ProvinceForbesHEALTHCARE EXECUTIVE MagazineDevelopment and Reform Commission of Shenzhen Municipalityand Shenzhen Education BureauHuman Resources and Social Security Bureau of ShenzhenMunicipalityScience and Technology Innovation Bureau of ShenzhenPingshan DistrictGuangzhou Best Check Human Resources Co., Ltd.Shenzhen Stock ExchangeChina Securities JournalSecurities TimesMSCIWind Information Co., Ltd.Shenzhen Securities Information Co., Ltd.Sino-Securities Index Information Service (Shanghai) Co., Ltd.Sino-Securities Index Information Service (Shanghai) Co., Ltd.Sino-Securities Index Information Service (Shanghai) Co., Ltd.

Honor and recognitionIssuing authority

0708

ABOUT THIS REPORTMESSAGE FROM THE CHAIRMANABOUT SNIBESNIBE IN 2025ABOUT THIS REPORTMESSAGE FROM THE CHAIRMANABOUT SNIBESNIBE IN 2025

Honors and Recognitions >

Corporate governance structure >

The Company, in strict accordance with the "Company Law of the People's Republic of China", the "Securities Law of the People'sRepublic of China", the "Code of Corporate Governance for Listed Companies in China", the "Rules Governing the Listing ofShares on the ChiNext of Shenzhen Stock Exchange", and other relevant laws, regulations, normative documents, and relevantrequirements of China Securities Regulatory Commission, and in consideration of the actual situations of the Company, hasestablished a corporate governance structure consisting of a board of shareholders, a board of directors, and a managementteam, and formulated and improved the "Articles of Association" and other internal control rules and working procedures toguarantee the standardized operation of the corporate governance structure.In addition, the Board of Directors of the Company has set up four special committees: the Strategy Committee, the NominationCommittee, the Remuneration and Assessment Committee, and the Audit Committee, and formulated corresponding workingrules, which formed a relatively scientific and standardized governance system and effectively ensured the standardizedoperation and sustainable development of the Company. Among them, the Audit Committee, as the core supervisory bodyunder the Board of Directors, assumed the functions of the former Board of Supervisors during the reporting period inaccordance with the provisions of the new "Company Law of the People's Republic of China", further strengthening the internalsupervision mechanism and the Company's governance structure, simplifying the decision-making process, and improvinggovernance e?ciency.

Snibe has always regarded robust and standardized corporategovernance as the foundation of sustainable development.We continuously improve the governance framework, enhancesustainable development management, deeply integrate the conceptof sustainable development into daily operations, and activelycommunicate with stakeholders to respond accurately to the concernsof all parties. We continue to strengthen compliance management,build a comprehensive internal control system, and conduct businessin an honest and self-disciplined manner, providing a solid guaranteefor the steady and long-term development of the Company.

Alignment with Sustainable Development Goals (SDGs)

Corporate Governance

REGULATING CORPORATEGOVERNANCE

Corporate GovernanceESG GovernanceCompliance in Operation

Major issues·Corporate governance·Investor relations·Compliance in operation·Sustainable development management·Communication with stakeholders·Information security and privacy protection·Anti-commercial bribery and anti-corruption·Anti-unfair competition

Figure - Corporate governance structure

Internal AuditDepartment

Board ofShareholders

Board of

Directors

StrategyCommittee

Remuneration andAssessment Committee

NominationCommitteeAuditCommittee

Secretary of the Boardof Directors

Special Committees of theBoard of Directors

GeneralManagerGeneral Manager'sO?ceBoard O?ce

Anti-Bribery ComplianceLeading Group

Three meetings held by the Company in 2025 were counted as follows:

Basic information about the Board of Directors and executive team

Composition of the Board of Directors and executive team

Diversification of the Board of Directors and executive team

The Company's Board of Directors consists of 8 directors, including 3 independent directors, 1 employee representativedirector, and 3 female directors. Members of the Board of Directors are highly experienced in ?elds such as biomedicine,?nancial audit, risk control, and law, respectively.The executive team of the Company consists of 6 executives, including 4 female executives. The team consists of professionalsin biomedicine, finance, marketing, clinical testing, etc. With a wealth of management experience, the team is able tocapitalize on market opportunities and put into action e?ectively. The general manager and other executives are appointedor dismissed by the Board of Directors. The general manager presides over the production and operation management of theCompany, organizes the implementation of the resolutions of the Board of Directors, and reports to the Board of Directors.The Company strictly abides by the "Code of Corporate Governance for Listed Companies" and has formulated the"Remuneration Management System for Directors and Senior Management" to establish a scientific and reasonableremuneration structure and achieve a balance between incentives and constraints. The Remuneration and AssessmentCommittee of the Board of Directors is responsible for drafting the remuneration plan and assessment standards forthe Company's directors and executives, reviewing the performance of directors and executives and conducting annualassessments of them, and supervising the implementation of the remuneration of directors and executives in accordancewith the "Working Rules of the Remuneration and Assessment Committee of the Board of Directors". The remuneration planfor directors is decided by the Board of Shareholders, and the remuneration plan for executives is approved by the Boardof Directors, explained to the Board of Shareholders, and fully disclosed. The basic salary of the Company's executives isdetermined based on their positions within the company, job responsibility level, and ability level. The annual performancebonus is directly linked to the Company's operating performance, with the assessment based on the Company's annualoperating goals and the individual's annual performance evaluation indicators.

1112

Twice

66.67%

337.5%37.5%

Board of Shareholders

Directors ofthe Board ofDirectors

Executives

Meetings of theBoard of Directors

Non-independentdirector

Female executives

Meetings of special committeesof the Board of Directors

Independentdirector

Proportion of female executives

Meetings ofIndependent Directors

Femaledirectors

Proportion ofindependent directors

Proportion of femaledirectors

timestimestimes

Corporate GovernanceESG GovernanceCompliance in OperationCorporate GovernanceESG GovernanceCompliance in Operation

Convening of three meetingsThe Company convenes and holds shareholders' meetings in a standardized manner in strict accordance with the "Rulesfor the Shareholders' Meetings of Listed Companies", the "Articles of Association", the "Rules of Procedure for Shareholders'Meetings", and other regulations and requirements, adopts the combination of on-site voting and online voting, counts thevotes of small and medium investors separately when considering major matters a?ecting the interests of small and mediuminvestors, and discloses the voting results of small and medium investors in a timely manner to ensure that all shareholders,especially small and medium shareholders, enjoy equal status and are able to fully exercise their rights.The Board of Directors is responsible to the Board of Shareholders, and the Company convenes and holds the meeting of theBoard of Directors in strict accordance with the relevant provisions of the "Articles of Association" and the "Rules of Procedurefor the Board of Directors". Independent directors are independent of the actual controllers, controlling shareholders, andother related parties of the Company, and are able to make judgments and express opinions independently to e?ectivelysafeguard the interests of all shareholders, especially small and medium shareholders. The directors of the Company,through continuous study, familiarization, and mastery of relevant laws and regulations, are committed to safeguarding thebest interests of the Company and all shareholders, and perform their duties in a faithful, honest, and diligent manner.

Rao WeiWeng HemingRao JieLi XuWu QianhuiShen WeihuaZhi YiHe XinDing ChenliuLi TinghuaLiu HaiyanZhang LeiYuan Jinyun

MaleMaleFemaleMaleFemaleFemaleMaleMaleFemaleFemaleFemaleFemaleMale

√√

√√

√

√√√

√√√√

√

√

√

√

√

√

Basic salary + annualperformance bonusNot on the Company'spayrollBasic salary + annualperformance bonusNot on the Company'spayrollFixed allowance forindependent directorsFixed allowance forindependent directorsFixed allowance forindependent directorsBasic salary + annualperformance bonusBasic salary + annualperformance bonusBasic salary + annualperformance bonusBasic salary + annualperformance bonusBasic salary + annualperformance bonusBasic salary + annualperformance bonus

NamePositionAge

ExpertiseIndustryexperience

Risk man-agement

Accou-ntingLawMarketingGender

RemunerationcompositionChairman and generalmanagerNon-independent directorNon-independent directorNon-independent directorIndependent directorIndependent directorIndependent directorEmployee representativedirectorDeputy general manager,chief ?nancial o?cerDeputy general managerDeputy general managerDeputy general manager,secretary of the Board ofDirectorsDeputy general manager

1314

Corporate GovernanceESG GovernanceCompliance in OperationCorporate GovernanceESG GovernanceCompliance in Operation

Safeguarding shareholders' rights and interests >

Information disclosureGuided by investor needs and based on compliance, Snibe attaches great importance to information disclosure, disclosesrelevant information in a truthful, accurate, timely, fair, and complete manner in strict accordance with relevant laws andregulations, as well as the requirements of the "Articles of Association", the "Information Disclosure Management System", etc.,and actively ful?lls its information disclosure obligations, and the Company designates "China Securities Journal", "SecuritiesTimes", "Shanghai Securities News", and "Securities Daily" as information disclosure newspapers and Juchao InformationNetwork (www.cninfo.com.cn) as the website for information disclosure, so as to ensure that the vast number of investors canobtain accurate information on an equal basis and in a timely manner.In 2025, Snibe issued 95 announcements, including 4 periodic reports and 91 temporary announcements. In the 2024-2025annual information disclosure appraisal for listed companies on the Shenzhen Stock Exchange, Snibe was awarded thehighest grade of "A (Excellent)" for the fourth consecutive year, re?ecting a high level of recognition of Snibe's informationdisclosure by the regulatory authorities and the capital market.Investor relations

Snibe attaches great importance to communication with investors and strictly follows relevant laws and regulations aswell as the "Company's Investor Relations Management System". The chairman is responsible for leading investor relationsmanagement a?airs, the secretary of the Board of Directors is the person in charge of investor relations management a?airs,and the O?ce of the Board of Directors is the functional department of the Company's investor relations management. Inaddition, we continue to learn from excellent investor relations management experience, constantly try to carry out investorrelations management in a more e?ective way, and ensure that all shareholders have equal access to information by openingup diverse communication channels.In 2025, we issued 12 record sheets of investor relations activities, conducted regular brie?ngs on performance reporting,reverse roadshows, and broker strategy meetings, and organized nearly 300 investor exchange activities of various types.With the outstanding comprehensive strength and stable pro?tability, we won the "Most Valuable Investment Award" at the27th Golden Bull Awards for Listed Companies.

ESG governance structure >A robust ESG management mechanism is pivotal for the top-down implementation of the company's sustainability strategy.According to relevant laws and regulations and the sustainable development governance requirements of listed companies,Snibe continues to re?ne its ESG governance framework and optimize internal sustainable management.The Board of Directors serves as the supreme decision-making body for Snibe's ESG governance, and is responsible for leadingand supervising the Company's ESG initiatives, and reviewing and approving ESG-related planning, targets, and policies.Subordinate to the Board, the Strategy Committee is tasked with deliberating on ESG-related topics, reporting periodically to theBoard on ESG performance, providing guidance and recommendations for ESG implementation, and monitoring the executionof improvement plans.Under the Strategy Committee, there are the ESG Work Leading Group and the ESG Work Implementation Group. The ESGWork Leading Group, composed of the general manager and deputy general manager of the Company, drives and monitorsthe implementation of ESG programs while providing decision-support inputs to the Strategy Committee. The ESG WorkImplementation Group is led by the O?ce of the Board of Directors, and the heads of various departments and subsidiariesserve as team members and designated liaisons. This cross-functional team cooperates with various departments andsubsidiaries of the Company to implement ESG-related work, and summarize the progress and performance of ESG-relatedwork.

Communication with stakeholders >Snibe always values and maintains effective communication with stakeholders. We fully consider the impact of our ownoperations on all stakeholders, understand the opinions, suggestions, and expectations of stakeholders by establishing aregular communication mechanism, and actively respond to the concerns of stakeholders, which serve as the basis for theCompany's ful?llment of its responsibility for sustainable development.

ESG Governance

Comply with national laws and regulationsImprove the compliance management systemEstablish an anti-commercial bribery systemStrictly control the product qualityCreate cooperation programs and platformsActively participate in government projectsRespond to government policiesCarry out charitable projects

Addressing Climate ChangeCompliance in OperationAnti-commercial bribery and anti-corruptionProduct safety and qualityIndustry exchange and cooperationCommunity commonweal

Government andregulatory agenciesStakeholderIssue of concernForm and manifestation of communication

1516

Corporate GovernanceESG GovernanceCompliance in OperationCorporate GovernanceESG GovernanceCompliance in Operation

Steps for assessing important issues

With reference to the "ShenzhenStock Exchange Self-RegulationGuidelines for Listed CompaniesNo. 17 - Sustainable DevelopmentReport (Trial)" (hereinafter referred toas the "Guidelines"), GRI Standardsand other international standards,SDGs, and outstanding practices inthe industry, and in combinationwith the Company's business growthand ESG practices, we identi?edother important issues on the 21topics speci?ed in the "Guidelines"of Shenzhen Stock Exchangeand formed a list of topics aftercomprehensive evaluation.

Following the "DoubleMateriality" principle, weinvited stakeholders toconduct a questionnairesurvey on the assessment of"Financial Materiality" and"Impact Materiality".

By comprehensivelyconsidering the results ofpeer benchmarking andstakeholder survey, the issueswere assessed and analyzedfrom two dimensions: theimportance to the economy,society, and environment,and the importance to theCompany's ?nance, andthe issues were ranked byimportance.

Issue identication and update Issue survey

Results analysis andissue ranking

Improve the corporate governance systemImprove the compliance management systemEnhance risk management and controlFul?ll the obligation of information disclosureOrganize and participate in investor exchangesIncrease e?orts in R&D and innovationStrengthen intellectual property managementStrictly control the product qualityIncrease e?orts in R&D and innovationEnhance customer privacy managementMaintain compliance in marketingStrictly abide by business ethicsImprove the service qualityConduct customer satisfaction surveyStrictly control the product qualityStrengthen supplier quality managementOrganize supplier meetings and trainingEstablish an anti-commercial bribery systemStrengthen intellectual property managementOrganize employee care activitiesEstablish communication channels for employeesEmployees' Congress and Labor UnionProvide diverse training programsDevelop a transparent promotion policyImprove the employee salary management andperformance management systemEstablish the environmental and occupationalhealth and safety systemActively carry out industry exchangesCreate cooperation programs and platformsProvide practice and research basesStrictly control the product qualityStrictly control waste dischargesCreate cooperation programs and platformsCarry out charitable activitiesParticipate in volunteer serviceMaintain good communication with the media

Corporate governanceSustainable development managementCompliance in OperationInvestor relationsProduct R&D and innovationProduct safety and qualityIntellectual property protectionProduct safety and qualityProduct R&D and innovationInformation security and privacy protectionResponsible MarketingAnti-unfair competitionCustomer Service QualityProduct Quality and SafetyChain ManagementAnti-commercial bribery and anti-corruptionEqual treatment of SMEsIntellectual property protectionDiversity and equal employmentEmployee rights and bene?tsEmployee training and developmentOccupational Health and Safety

Product R&D and innovationIndustry exchange and cooperationProduct safety and qualityEmissions and waste managementIndustry exchange and cooperationCommunity commonwealBiodiversity conservation

Shareholders andinvestors

Customers

Suppliers andpartners

Employees

Industry associationsand professionalorganizationsCommunity andmedia

StakeholderIssue of concernForm and manifestation of communication

Assessment of important issues >

Snibe attaches great importance to and continuously improves the identification, management and analysis of importantissues, and takes the concerns of various stakeholders as an important consideration in formulating sustainable developmentstrategies, so as to accurately and e?ectively respond to the issues of interest to stakeholders, thereby providing an importantreference for identifying and managing risks and opportunities.This year, we invited stakeholders to participate in the survey in the form of an online questionnaire to understand their keyconcerns, covering all employees, customers, suppliers and partners, shareholders and analysts, media, industry associations,governmental organizations, non-governmental organizations, etc. Guided by the "Double Materiality" principle, that is,"Financial Materiality" and "Impact Materiality", we systematically evaluated and prioritized these issues.

Impact Materiality HighMediumLow

1718

Matrix of importance issues

If product safety and qualitymanagement fails to consistentlymeet regulatory requirements or isinadequate, it may lead to productrecalls, regulatory penalties, anddamage to brand reputation, resultingin customer loss and a decline inmarket share.

The IVD industry is characterized byrapid technological iteration. If theinnovation direction is disconnectedfrom market demand, R&D investmentwill fail to generate expected returns,resulting in sunk costs, missingopportunities in emerging markets,lagging product line iteration,falling into homogeneous low-pricecompetition, and ultimately leading toa decline in pro?tability.Negligence in intellectual propertymanagement and patent portfolio maylead to infringement and imitation ofcore technologies, which will weakenmarket pricing power and competitivemoats.

Against the backdrop of increasinglystringent global regulations in the IVDindustry, any non-compliance maylead to ?nancial losses, and seriousviolations may result in the businessbeing ordered to suspend operationsfor recti?cation, thereby underminingthe foundation of an enterprise'soperation.

Establishing a full lifecyclequality management systemthat is stricter than regulatoryrequirements, strengtheningproduct competitivenessthrough rigorous quality controland quality managementsystems, and enhancing brandvalue and driving businessexpansion by high-qualityproducts and services.Conducting forward-lookingplanning, focusing on clinicalneeds, developing innovativesolutions, building technicalbarriers, exploring newmarkets through di?erentiatedcompetition, and creating newrevenue growth drivers.

Establishing a sound intellectualproperty management systemand patent portfolio, buildingtechnical barriers, protectingcore technologies frominfringement, and developingnew pro?t channels throughpatent licensing and technicalcooperation.Building a sound compliancemanagement system,controlling compliance-relatedrisks, and maintaining excellentcompliance records will helptap into high-end overseasmarkets, enhance customertrust, highlight managementadvantages during industryreshu?ing, and thereby securea stable market share.

Product safetyand quality

Product R&Dand innovation

Intellectualpropertyprotection

Compliance inoperation

ShorttermMediumtermLongterm

ShorttermMediumtermLongterm

MediumtermLongterm

ShorttermMediumtermLongterm

ProductQuality andSafety

Focusingon R&D andInnovation

Focusingon R&D andInnovation

Compliance inOperation

Financialmaterialityissues

Risks and impactsOpportunities and

impacts

Impacttimehorizon

Section ofmanagementmeasures

Corporate GovernanceESG GovernanceCompliance in OperationCorporate GovernanceESG GovernanceCompliance in Operation

Financial MaterialityHighMediumLow

Corporate governanceCompliance in operationSustainable development managementCommunication with stakeholdersInvestor relationsAnti-commercial bribery and anti-corruptionAnti-unfair competition

Product R&D and innovationProduct safety and qualityIntellectual property protectionSupply Chain ManagementCustomer Service QualityResponsible MarketingInformation security and privacy protectionDiversity and equal employmentOccupational health and safetyEmployee Training and DevelopmentEmployee rights and bene?tsIndustry exchange and cooperationEqual treatment of SMEsCommunity commonweal

Addressing Climate ChangeEmissions and waste managementEnergy managementResource managementEnvironmental managementBiodiversity conservation

Environmental categorySocial categoryGovernance category

Product safety and qualityProduct R&D and innovationIntellectual property protectionCompliance in operationAnti-commercial bribery and anti-corruptionCustomer Service Quality

Industry exchange and cooperationEnvironmental management

Responsible MarketingOccupational health and safetyInformation security and privacyprotection

Sustainable development managementSupply Chain ManagementCorporate governanceAnti-unfair competitionInvestor relationsCommunication with stakeholdersEmployee Training and DevelopmentEmissions and waste managementResource managementEnergy managementDiversity and equal employmentEqual treatment of SMEsCommunity commonwealBiodiversity conservationAddressing Climate Change

Employee rights and bene?ts

For the seven issues with high ?nancial materiality, we further identi?ed the associated risks and opportunities and assessedthe potential impact of these risks and opportunities on the Company's strategy, decision-making, financial condition,operating results, cash ?ow, and other factors in the short term (1-3 years), medium term (3-5 years), and long term (morethan 5 years). In addition, for each issue, the corresponding sections of this report will systematically disclose the Company'smeasures in monitoring, prevention, management, control, and mitigation of the impact.

1920

The IVD industry involves hospitalprocurement and distributormanagement, making it a highlysensitive ?eld for corruption.Commercial bribery and corruptionincidents may bring signi?canteconomic costs and legalconsequences to a company.

End customers in the IVD industryrequire continuous services such asinstrument maintenance, technicalsupport, and result interpretation.Slow after-sales service response orinadequate technical support willlead to a decline in end customersatisfaction, directly cause equipmentsuspension and declining reagentsales, and ultimately a?ect thesustainability of the main business.The IVD industry is highly dependenton the technology accumulation ofR&D personnel and the professionalpromotion capability of marketingpersonnel. A lack of a competitiveremuneration system and careerdevelopment channels, or the existenceof employment risks, may lead to theloss of core talent, a?ect product R&Dprogress and market stability, andincrease management di?culty andoperational costs.

Establishing a sound anti-bribery management system,promoting a culture ofintegrity and compliance,and continuously improvingand optimizing internalmanagement systems andprocesses can e?ectively reducethe risk of corruption. At thesame time, an integrity andcompliance brand image canlower marketing and marketentry costs.Leveraging digital services,responding to technical supportpromptly, enhancing customerstickiness and satisfaction,establishing a customerfeedback mechanism, drivinginnovation and optimizingservice experience, continuouslyconsolidating customerrelations, and providing supportfor the long-term developmentof the business through high-quality services.Building a diverse and inclusivework environment, providinga competitive remunerationand incentives system, careerdevelopment opportunities, andhealth and safety safeguards,and establishing a strongemployer brand can attracthigh-quality talent in theindustry, stimulate innovationand motivation, and improveper capita productivity.

Anti-commercialbribery andanti-corruption

Customerservice quality

Employeerights andbene?ts

ShorttermMediumtermLongterm

ShorttermMediumtermLongterm

ShorttermMediumtermLongterm

Compliance inOperation

CustomerService Quality

Attraction andRetention ofTalents

Financialmaterialityissues

Risks and impactsOpportunities and

impacts

Impacttimehorizon

Section ofmanagementmeasures

Corporate GovernanceESG GovernanceCompliance in OperationCorporate GovernanceESG GovernanceCompliance in Operation

Risk management and control >We have established an internal oversight system in accordance with the relevant national laws and regulations and the"Notice on Strengthening the Internal Control Construction of Listed Companies and Proposed Listed Enterprises and PromotingInternal Control Evaluation and Audit", the "Basic Standards for Internal Control of Enterprises" promulgated by the Ministry ofFinance, and the "Guidelines for Internal Control of Listed Companies" issued by Shenzhen Stock Exchange, and continuouslyoptimized the "Manual for Internal Control Management" and the "Internal Audit Management System", providing guidance forinternal audit supervision.The Company has established a sound internal control and risk management framework. The Audit Committee is set upunder the Board of Directors, which is responsible for the supervision, inspection, and evaluation of the Company's internalcontrol, ?nancial information, and internal audit. Under the leadership of the Board of Directors and the Audit Committee ofthe Board of Directors, the Company has established the Internal Audit Department, which is responsible for formulating andimproving internal audit, internal control, and other internal management systems, performing comprehensive risk assessmentand monitoring of various business processes, independently conducting internal audit and routine audit of all businessdepartments and subsidiaries of the Company every year, forming audit reports and recti?cation proposals on the risk mattersidenti?ed through the audits, continuously following up the implementation of recti?cation proposals, assisting the auditeddepartments or subsidiaries in improving relevant business systems and risk management processes, strengthening the riskmanagement capabilities of the departments, and e?ectively reducing the risks in the Company's operation.To further enhance the collaborative e?ciency of risk management, the Internal Audit Department has gradually achieved deepintegration of legal a?airs, compliance, and internal control. By breaking down functional barriers and promoting informationsharing and data integration, the accuracy of risk identi?cation has been signi?cantly improved. The legal function ensures thelegality and compliance of all business activities through contract review, legal consultation, and dispute resolution, therebypreventing legal risks at source. The internal audit function identi?es operational risks through audit projects and supervisesthe implementation of corrective measures to ensure that the Company's operations comply with internal and externalregulations. The coordinated operation of these two functions comprehensively enhances the overall risk management andcontrol level of the Company.In 2025, the Internal Audit Department focused on three core pillars: marketing, supply chain, and corporate functions, andconducted comprehensive and in-depth audits by assigning dedicated auditors to focus on each pillar. This year, we completedaudits of 8 o?ces in China, visits to 156 distributors, contract process management audits of 11 core functional departments,visits and bidding for 36 projects, and final account audits for 32 projects. From offices to distributors and from contractprocesses to project settlements, the Internal Audit Department is committed to promoting e?cient resource allocation andcontinuous process optimization through independent supervision and evaluation functions, thus safeguarding the Company'ssustainable development.

Probity and self-discipline >Snibe strictly abides by laws and regulations such as the "Anti-Unfair Competition Law of the People's Republic of China", the"Criminal Law of the People's Republic of China", and the "Interim Provisions on Prohibition of Commercial Bribery", adheres tothe management concept of "compliance ?rst", bases on the development strategy of "steady operation", and implements thecompliance culture of fairness, integrity, and "Do things right". We hold a "zero tolerance" attitude towards any form of bribery,and strictly prohibit any form of bribery in public or private during the course of business. In 2025, no cases of fraud were found

Compliance in Operation

2122

Corporate GovernanceESG GovernanceCompliance in OperationCorporate GovernanceESG GovernanceCompliance in Operation

in the Company's internal audits, and no internal or external reports of corruption were received.

Anti-bribery compliance managementThe Company has established a comprehensive anti-bribery compliance management system. We have disclosed the "SnibeAnti-Bribery Compliance Policy" on the Company's o?cial website to clarify the Company's overall objectives, policies, andrequirements for anti-bribery compliance management. We have set up an Anti-Bribery Compliance Leading Group, andformulated and implemented the "Anti-Bribery Compliance Management Handbook" as well as a series of compliancemanagement norms and control procedures to ensure the effective operation of the anti-bribery management system.The anti-bribery compliance team, composed of Internal Audit Department and internal auditors of various departments,undertakes anti-bribery compliance functions.Since successfully passing the ISO 37001 anti-bribery management system certi?cation audit, the system has been operatingsmoothly. We have closely monitored external regulatory developments, promptly collected information, and systematicallyoptimized the system control procedures based on the latest anti-bribery policies and guidelines. To further enhance theoperational e?ciency of the system and strengthen the ability of various departments to identify and respond to bribery risks,we comprehensively revised the "Control Procedures for Bribery Risks" and "List of Bribery Risks" during the reporting period,making them more closely aligned with actual business scenarios and signi?cantly enhancing their practical guidance, thuslaying a solid foundation for building a more resilient compliance defense line.Build a corruption-free environmentIn order to enhance the anti-bribery compliance awareness and ability of employees, we regularly conduct on-site anti-briberycompliance training for all employees, and provide special training to new employees, management, compliance team,personnel in important positions such as marketing, ?nance, procurement, and HR, as well as external business partners.We regularly provide employees with publicity of anti-bribery laws and regulations, cases, and the Company's anti-briberypolicies through the Company's o?cial website, internal mails, OA system, etc. As mandated by the "Employee Handbook",all employees are required to sign the "Letter of Commitment for Anti-Bribery Compliance" upon onboarding. Additionally,business partners must sign the "Letter of Commitment for Business Ethics", "Anti-Commercial Bribery Agreement" or otherequivalent anti-corruption documentation prior to commencing collaboration with the Company.We advocate that our business partners join hands with us to maintain su?cient anti-bribery compliance communication andsharing, to jointly build an honest, transparent, and incorruptible anti-bribery compliant environment, and to share the valuecreated by compliant operation.In 2025, we conducted 14 anti-commercial bribery trainings for internal employees and business partners, and 100% ofemployees have received the anti-commercial bribery training and signed anti-commercial bribery commitments.With the growth of overseas business, during the reporting period, we organized targeted compliance training oninternational anti-bribery, sanctions, and export controls in the healthcare industry for the Company's directors, executives,and key personnel in charge of overseas marketing to enhance their compliance awareness and risk prevention capability inconducting overseas operations.

Supervision and improvementAccording to the "Control Procedure for Internal Audit", "Control Procedure for Corrective Action and Preventive Action", andother system and procedure documents, the Anti-Bribery Compliance Team has conducted continuous monitoring of thee?ectiveness of the design and implementation of the anti-bribery management system, and self-recti?ed the defects andde?ciencies. On the one hand, the Internal Audit Department will regularly conduct internal anti-bribery compliance auditsaccording to the annual plan to identify system defects and deficiencies and urge the implementation of rectification. Onthe other hand, we will continuously optimize the system based on the improvement recommendations identi?ed during theannual external surveillance audits to ensure the e?ectiveness of the system.The Company's official website publicly discloses the hotline, email address, and mailing address for reporting issues toensure that external stakeholders can conveniently and safely report problems. Physical complaint mailboxes withoutsurveillance coverage have been set up in public areas within the Company's headquarters campus to e?ectively protect theprivacy of whistleblowers and encourage internal employees to exercise oversight in accordance with regulations. In additionto passively receiving reports, the Internal Audit Department, in conjunction with the General Manager's O?ce, is responsiblefor accepting on-site reports. Meanwhile, the Internal Audit Department proactively collects feedback and complaints fromthe end of the business chain by conducting on-site visits to distributors and suppliers every year, extending oversight to thefront line of cooperation. For potential non-compliance identi?ed through reported clues or audit ?ndings, the Internal AuditDepartment will conduct investigations according to relevant procedures and requirements, and make suggestions on whetherto take disciplinary measures based on the investigation results.

●O?cial website of the Company: https://www.snibe.com/(Supervision and Reporting Module)

●Address: Internal Audit Department, Snibe Building, No. 23 Jinxiu East Road, Jinsha Community, Kengzi

Street, Pingshan District, Shenzhen 518122

●Email: audit@snibe.cn

●Tel.: +86-755-26706462

Reporting channels

Information security >Snibe strictly abides by the "Data Security Law of the People's Republic of China", the "Cybersecurity Law of the People'sRepublic of China", the "Administrative Measures for the Graded Protection of Information Security" and other national laws,regulations and industry norms, fully assumes the responsibilities for information security entities, and continuously deepensthe construction of information security systems. In 2025, the Company reported no information security incidents and noleakage of customer, employee, and business partner information.Information security managementThe Company attaches great importance to information security management, continuously deepens the construction ofinformation security management system, and strengthens its own risk management and control capabilities. We have keptimproving internal management measures such as the "Snibe Information Security Management Policy" and the "SnibeCommunication Security Management Speci?cation" and further standardized the information security management systemand management processes. In 2025, we initiated the formulation of relevant regulations for the security management ofbusiness systems and servers to standardize the security management of application systems throughout their full lifecycle.This year, the Company maintained the effectiveness of the ISO 27001 information security management system andsuccessfully passed the annual external audit. The Company's remote service system Snibe Link retained the certi?cation of"Level III of National Information Security Level Protection" while continuously expanding its information security compliancecoverage.Information security management modeCybersecurity CommitteeExecutives and relevant responsiblepersons of the Company

Executive entity

IT Department

External entity

Suppliers, etc.

Information security training

In 2025, the Company continued to prioritize cultivating employees' information security awareness andcomprehensively improve the digital security literacy of all employees. We adopted a blended teachingmodel combining o?ine in-person training with online live streaming and interaction, and systematicallyorganized a special campaign to raise awareness of information security. The training content closelyaddressed the security pain points in real-worldwork scenarios, and carefully designed practicalcourse modules including phishing emailidenti?cation techniques, key points of personalinformation protection, and demonstrations ofcommon attack methods. The event saw broadparticipation from employees, significantlyenhancing their overall security awareness andprevention capability. It effectively improvedemployees' ability to identify and handleinformation security threats, laying a solidfoundation for the Company to build a digitalsecurity defense line.

Corporate GovernanceESG GovernanceCompliance in Operation

Control and preventive measures

Through the combination of institutionalized management and normalized inspection, the Company has improved itsinformation security protection capabilities.In terms of proactive management, the Company applies technical means such as data loss prevention (DLP) system and ESMstorage medium management module to secure data. Through situation awareness testing, we conduct security monitoringon all servers and user traffic, achieving 100% handling of abnormal alarms. By conducting system penetration testingand bastion host audits, we preemptively identify and mitigate potential cyber threats. We strictly implement a full-servervulnerability scan and repair mechanism every six months to ensure timely closure of system vulnerabilities. Additionally, wehave established a sensitive information retrieval mechanism for public cloud drives to proactively investigate unauthorizedstorage activities and prevent data leakage risks at source. Following the comprehensive upgrade of the 360 Terminal SecuritySystem, we have achieved automatic daily updates of the virus database and forced distribution to terminals, ensuring thatall employees' terminals are in the latest protection state and effectively improving the overall security baseline. Internalemployees access the wireless network through domain account authentication, and visitors access the wireless networkthrough SMS veri?cation code authentication to ensure secure wireless network access.In terms of reactive management, the Company comprehensively upgrades the terminal protection software, implementsthe network access authentication mechanism, introduces the anti-tampering backup system, and optimizes the networkpartition access control policy to build a multi-layered and three-dimensional security and protection system. In terms of thehandling of emergency incidents, the Company has developed an information security emergency response plan to clearlyde?ne the response mechanism, handling process, and measures in case of emergency incidents.Furthermore, the Company places paramount importance on information security awareness initiatives, prioritizes employeesecurity awareness enhancement as a critical component of its cybersecurity strategy, and has carried out multi-dimensionaland multi-tiered security training programs. We not only organize information security training for new employees to instillproper information security practices from day one, but also carry out special information security training for all employeesevery year.

"Quality is our life" is the consistent corporate spirit of Snibe. Guidedby this belief, we continuously optimize the quality managementsystem, increase R&D investment and equipment upgrades, andconstantly improve product quality and supply chain security. Throughpersistent product and technical reformation, we provide clinicianswith more accurate and reliable testing solutions, continuouslycreating value for human health.

Alignment with Sustainable Development Goals (SDGs)

STRICTLY CONTROLLING THE QUALITYOF PRODUCTS AND SERVICESMajor issues·Product safety and quality·Product R&D and innovation·Intellectual property protection·Supply chain management·Responsible marketing·Customer service quality·Equal treatment of SMEs

Snibe has long held the spirit of "Quality is our life".Driven by the spirit, Snibe continues to optimize thequality management system, increase investment in R&Dpersonnel and equipment, and enhance product qualityand supply chain safety. Snibe aims to provide moreaccurate and reliable testing products for clinical doctorsand create value for human health through continuousinnovation.

Quality management system >Snibe has established the policy of "Quality is our life" and set strict quality objectives. Besides a systematic, documented,and well-developed quality management system, an organizational structure with defined responsibilities has been inplace to clarify control requirements for the quality management process. Snibe has also continued to optimize and improvethe quality management system, gaining recognition of its product quality management capability from stakeholders andensuring stable product quality and safety amidst rapid business development.Quality Assurance Department, Key Reagent Material QC Department, Material Inspection Department, Reagent QCDepartment, Instrument QC Department, and Component Inspection Department have been set up to ensure product qualitythroughout the lifecycle. While strictly abiding by external policies such as the "Quality Management System Requirements","Medical Devices - Quality Management Systems - Requirements for Regulatory Purposes", and "Good Manufacturing Practicefor Medical Devices", Snibe has formulated and implemented such internal management systems as the "Quality Manual" and"Control Procedure for Product Monitoring and Measurement" that encompass the quality management process, speci?cationsfor products, and equipment use to realize quality manufacturing.

Product Quality and Safety

Product Quality

and Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer Service

Quality

Product Qualityand Safety

Focusing on R&Dand Innovation

Responsible

MarketingSupply ChainManagement

Customer ServiceQuality

Quality Management System Documentation Structure

Process Relation Diagram of the Quality Management System of the Company

QualityManual(Policy & Objective)Procedural documents

ExternalDocuments

Quality documents & technical documents

(including systems, regulations,specifications, and DMR)Quality record(including DHR'S, QSR)

Quality Management

System GuidelinesDescribe the operatingprocedures of each process

Describe the speci?coperation of each elementQuality ManagementSystem operational

evidence

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Quality management system certi?cation obtained:

2728

Quality Management SystemCertification

Medical Device Quality ManagementSystem Certification

Medical Device Single AuditProgram CertificationISO 9001ISO 13485MDSAP

Product Quality

and Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

To align with the Company's global expansion, we enhanced our Quality Management System (QMS) by fully integrating multi-regulatory compliance requirements, building on the foundation of MDSAP regulatory alignment. This initiative culminated inthe development of a comprehensive "Quality Internal Audit Compliance Manual", which standardized internal audit protocolsand ensured systematic and e?cient internal audits.With the expansion of the Company's IVD new product line business, in order to ensure e?ective quality control of the newlyadded product line, the Company obtained ISO 9001 and ISO 13485 system certi?cates for coagulation products during thereporting period.

Internal audit of quality management systemThe effective operation of the quality management system is not possible without a well-developed internal qualitymanagement team. Snibe has set up internal audit groups according to the "Control Procedure for Internal Audit", andappointed qualified group members. Internal auditors receive expertise and skill training on quality management systemstandards and regulations, and internal audit skills and methods. Moreover, they are assessed to ensure that each canaccurately pinpoint and identify nonconformities or defects in the system.The Company conducts annual internal audits covering the entire product line to ensure compliance with ISO 9001, ISO13485, EU IVDR, and the China GMP for medical devices. For this reason, the Company's management system is e?ectivelyimplemented and maintained, and continuously improved.Improved quality management capabilitiesTo improve the knowledge reserve of personnel in the Quality Assurance Department, a total of 55 training sessions andlearning activities were completed throughout the year, totaling over 12,000 hours, focusing on IVD supervision andupper-level laws and regulations (such as unannounced inspection, supervision, and penalties), facility and equipmentmanagement, R&D processes, risk management, hazardous chemical handling, product registration, and post-marketsurveillance. Through systematic learning and practice, the professional knowledge and skill levels of department personnelwere effectively improved, providing solid technical support and assurance for the operation of the Company's qualitymanagement system.To strengthen the Company's quality management capabilities and promote the strict implementation of the relevantrequirements of the quality management system, in 2025, the Quality Assurance Department conducted a total of 110 trainingsessions on quality management, covering various aspects such as medical device regulations, document control, designchanges, hazardous chemicals management, equipment management, risk management, and post-market surveillance. Thetrainees included relevant personnel of R&D, production, inspection, marketing, quality management, and other departments.Through the above training sessions, the expertise, skill proficiency, compliance awareness, and risk prevention ability ofrelevant personnel have been improved, providing a solid quality management team for the Company's development.

Regular updates and dissemination of regulations

Training on the control of operational documents in the qualitymanagement system

In 2025, the Company conducted 9 regulationknowledge sharing sessions based on regularregulation update tracking, focusing on keyregulatory documents in the industry and carryingout targeted dissemination of information, suchas the List of In Vitro Diagnostic Reagents Exemptfrom Clinical Trials (2025) and the Guidelinesfor Registration Review of Fully AutomatedChemiluminescence Immunoassay Analyzers(2025 revision). These e?orts ensured that relevantpersonnel could keep abreast of the latestregulatory requirements and accurately identifythe potential impact of regulatory updates on theCompany's quality management system, providingstrong support for the compliance maintenanceand continuous improvement of the system.

In 2025, the company conducted a total of 29training sessions related to document control,including comprehensive document controltraining, training on key points of softwaredocument review, and specialized training on keypoints of process document review. The trainingcomprehensively enhanced the awareness andprofessional ability of personnel in documentsuitability and standardization, contributing to thecontinuous improvement of the Company's qualitymanagement system.

●National Health Commission EQA Pass Rate●Domestic Routine EQAS Pass Rate

2022202320242025

98.8%

98.9%

99.7%100%100%100%100%100%

100.0%

98.0%

96.0%

94.0%

92.0%

90.0%

2930

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Product Quality

and Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer Service

Quality

E?ective operation and continuous optimization of quality management systemSnibe conducts comprehensive and independent evaluation through supervision and review by external auditors, andcontinues to optimize the quality management system based on the assessment and on-site inspection results.In 2025, the Company underwent 13 quality management system audits from government regulatory agencies such as theGuangdong Medical Products Administration and the Shenzhen Administration for Market Regulation, as well as externalaudit agencies such as T?V, DEKRA, and SGS, including 8 audits by third-party certification agencies, 2 audits on GoodManufacturing Practice for Medical Devices, and 3 audits on the Guidelines for Veri?cation of Quality Management Systems forMedical Device Registration, covering the quality management systems of all ?nal product manufacturing sites, achieving a100% audit pass rate.Through internal and external audits to continuously track the operation of the quality management system, the Company'squality management system has achieved continuous optimization and quality management capabilities have beencontinuously improved, ensuring the high quality output of products.

In overseas markets, 120 products demonstrated exceptional performance in theEQA programs conducted by leading international accreditation bodies in 2025,including Bio-Rad EQAS, RIQAS, RCPA-QAP, CAP, RfB, UK NEQAS, DEQAS, IFCC, andNGSP, which also validated the reliability of the Company's products.In 2025, Snibe participated in the 25 Hydroxyvitamin D (25-OH Vit D) DEQASand obtained the 2025-2026 Certificate of Proficiency. We also participated inthe certi?cation programs for glycated hemoglobin by IFCC and NGSP, achievedexcellent results, and obtained relevant certi?cates.

Product quality and safety management >External quality assessment

External quality assessment (EQA) is a system for checking, supervising, and verifying the laboratory's performance in orderto maintain a high standard of practice, and EQA results are largely dictated by the samples provided by the laboratory. Toensure the high-level performance of end users, we encourage EQA participation by domestic and overseas end users, whichin turn allows us to follow up on product quality, safety, and performance.In the domestic market, Snibe participated in 51 EQA programs organized by the National Health Commission in 2025,involving 235 items for evaluation, and we have achieved a 100% pass rate in routine EQA for four consecutive years. By theend of 2025, all the registered chemiluminescence reagent projects approved by the National Health Commission have beeninvolved in EQA programs.

Quality improvement of reference measurement laboratorySnibe has built a professional quality management system for the reference measurement laboratory in accordance withthe international standards of ISO/ IEC 17025 and ISO 15195, passed the review by the China National Accreditation Servicefor Conformity Assessment (CNAS), and obtained the accreditation certificate. Besides, high-end measurement devicesand advanced reference materials at home and abroad have been introduced, and reference methods issued by theJoint Committee for Traceability in Laboratory Medicine (JCTLM) and national authorities have been adopted to ensure themetrological traceability of testing results. We work to build kit testing capacity for the reference measurement laboratoryand establish a registered internal testing platform in strict accordance with national/industry standards, supporting productquality inspection.While playing an active role in the cooperative development of reference methods and the collaborative assignment ofreference materials, Snibe has been a stakeholder member of the Joint Committee for Traceability in Laboratory Medicine(JCTLM) and a corporate communication member of committees and working groups of the International Federation of ClinicalChemistry and Laboratory Medicine (IFCC), such as the Clinical Laboratory Management (C-TLM), the Standardization ofThyroid Function Tests (C-STFT), the Bone Metabolism (C-BM), the Apolipoproteins by Mass Spectrometry (WG-APO MS), andthe Commutability in Metrological Traceability (WG-CMT), driving the standardization and harmonization of related projects.Participating in cooperative research on reference systems at home and abroad and strengthening peer exchanges will helpimprove the accuracy and comparability of test results.By the end of 2025, Snibe has established more than 20 reference measurement procedures for vitamins, therapeutic drugmonitoring, non-peptide hormones, enzymes, etc. Among them, 11 procedures have been approved by the China NationalAccreditation Service for Conformity Assessment (CNAS), including 6 for enzymes, 1 for 17-hydroxyprogesterone, 1 for25-hydroxyvitamin D3, 1 for total thyroxine, 1 for total triiodothyronine, and 1 for testosterone. Among them, three proceduresfor enzymes (ALT, CK, α-AMY) have been included in the JCTLM reference measurement service list database. In 2025, theEQA results for the reference measurement laboratory were announced, and Snibe achieved excellent results in 8 IFCC-RELAprograms and 15 NCCL-EQARL programs applied, with a satisfactory pass rate.In 2025, the Company's reference measurement laboratory passed a routine supervision review by the CNAS regulatoryauthority.

3132

The Company standardized the on-site audit management of external suppliers and establishedon-site audit management regulations and corresponding audit guidelines.To implement refined management of facilities/equipment/systems, the Company establishedthe "Management Regulations for Classification Critical/Facility/Equipment Systems" todistinguish between critical and non-critical facilities/equipment/systems and redefine therevalidation/qualification cycle.The Company optimized the organizational environment, stakeholder needs, and risk andopportunity control procedures, and established risk assessment criteria for the qualitymanagement system.

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Product Qualityand Safety

Focusing on R&Dand Innovation

Responsible

MarketingSupply ChainManagement

Customer ServiceQuality

Improved product quality management capabilitiesIn 2025, the Company made a lot of efforts to improve internal quality control, further improving its product qualitymanagement capabilities. At the same time, the Company also promoted a culture of quality management through variousmeans to enhance employees' quality awareness.

Adverse events and product recalls

The Company continuously tracks and monitors the occurrence of post-market adverse events, while closely following updatesand changes in relevant domestic and international post-market regulations and industry standards. On this basis, theCompany continuously optimizes and improves processes for post-market adverse event monitoring, recalls, and advisorynotices to comprehensively enhance the e?ectiveness of post-market supervision.To guide, organize, and manage adverse event monitoring for medical devices, the general manager is in charge ofoverall control and resource coordination. At the same time, we have set up a steering group that brings together di?erentdepartments, and developed the "Control Procedure for Adverse Event" and supporting procedures and documents to collectfeedback on adverse events from medical institutions, businesses, regulatory authorities, and other relevant parties in a timelymanner.The Company regularly reports the regulatory situation to the Medical Device Adverse Event Monitoring Working Group. Forany adverse events that occur, we strictly implement the investigation and evaluation process, conduct in-depth analysis ofpotential product risks, and regularly issue periodic risk assessment reports for medical devices. Through data analysis, weactively promote continuous improvement after product launch, achieving continuous monitoring of the full product lifecycle.

Product label and traceability managementIn accordance with the "Control Procedure for Identi?cation and Traceability", the Company has taken measures to preventidenti?cation mix-ups and misuse throughout the process of product implementation. We have established a unique deviceidenti?er (UDI) for all medical devices we sell to ensure their traceability.

In addition, the Company relies on the after-sales service stations in various regions to ensure a timely response within24 hours after receiving customer complaints, provide perfect after-sales service, and quickly solve customer problems.Information such as customer hotline, email, and fax is provided on product labels and the o?cial website of the Company toensure that customers have su?cient channels to complain and inquire about product problems.The Company formulated the "Control Procedure for Feedback and Complaint Handling", specifying the critical workflowmilestones in feedback and complaint handling, and the categories of feedback information, so as to guide regionalprofessional engineers to investigate, analyze, and follow up on feedback and complaints in accordance with therequirements of the procedure document.In 2025, 100% of complaints received have been addressed.The Company formulated the "Control Procedure for Recall of Medical Devices", which was cross-linked with complaints,adverse events, and post-market supervision. At the same time, we timely analyzed, investigated, and evaluated the collectedinformation to ensure that a recall was readily initiated according to regional laws and regulations.In 2025, Snibe had no product recall and received no regulatory warning or punishment on our product or service quality.

2025 assembly skills competitionTo enhance the professional skills of the assembly team, strengthen the awareness of quality andefficiency, promote the spirit of craftsmanship, and facilitate teamwork and experience exchange, theCompany held the "Craftsmanship for Excellence, Efficiency for Quality" assembly skills competitionin 2025. Through this competition, the Company promoted a quality culture and facilitated theimplementation of quality culture and awareness.

ReportFollow-up

Report to ornotify theauthorizedrepresentativesunder localadverse eventregulations

Adverse eventsupportingreportCollectInvestigate, Analyze

& Evaluate

Methods:

● Regulator systems or

notices

● Feedback and

complaints

● Clinical experience

● Academic literature

● Others

● Investigate

● Analysis of

causes

● Relevance

evaluation

● Risk

assessment

Adverse eventinvestigation

report

Response to adverse events

We have built an efficient datamanagement architecture to achievecentralized storage, intelligentassociation, and dynamic updatesthroughout the product lifecycle. Ourbusiness teams can work together basedon the single source of truth to ensureinformation integrity and accuracy andreduce redundancy and communicationcosts. At the same time, data traceabilityand version management capabilities ofthe system have been optimized, whichallows the efficient reuse of researchand development results and facilitatesknowledge accumulation and innovationbreakthroughs.

We have implemented robustprocess controls across criticalproduct lifecycle phases,covering product definition,engineering change, andversion management, toensure the transparency,standardization, andtraceability of the processes atall stages, effectively reducedevelopment risks, and shortenthe product launch cycle.

Supported by the R&Dmanagement platform,we can systematicallymanage product quality,including design verification,engineering changetracking, and qualitysystem compliance, toensure that products meetindustry regulations andhigh standards, and furtherimprove product stability andsafety.

Intelligent data managementto improve R&D collaborationefficiency

Systematic processcontrol to improve projectexecution

End-to-end qualitycontrol for productexcellence

3334

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Innovation is our lifeblood and core competitiveness.Snibe works to improve our R&D capabilities throughcontinuous R&D process optimization so that we cancreate more innovative quality products, continue todevelop a whole product lineup, and constantly createvalue for human health.

Ever-improving R&D and innovation system >Instrument R&D platformThe Company has built and kept optimizing the product lifecycle management platform in line with its own characteristics.Through standardization, process, and data-based management, we have improved the reliability, predictability, andcompliance of R&D projects, enabling product development to be more robust and efficient. After years of practice anditeration, our R&D management platform has become increasingly mature, providing strong support for product innovation,quality improvement, and market competitiveness, so that the Company can continuously launch high-quality products thatmeet customer needs and market expectations.

Reagent R&D platformSnibe takes chemiluminescence immunoassay products as the core business. After nearly 20 years of continuous innovationand accumulation, we have mastered the core technologies such as antigen-antibody labeling technology, magnetic sphere-antigen/antibody coupling technology, and chemiluminescence reagent preparation technology, and achieved revolutionarytechnological breakthroughs in the ?eld of small molecules. The Company has established a complete reagent developmentplatform, covering immunodiagnostics, biochemical diagnostics, immunochromatography, molecular diagnostics,coagulation, and other IVD areas.Guided by GB∕T 42061-2022 IDT ISO13485:2016 "Medical Devices - Quality Management Systems - Requirements forRegulatory Purposes" and the actual situation of the Company, the Reagent R&D Department has formulated the "ControlProcedure for Design and Development" to de?ne requirements for every phase of new product design and development.Additionally, department-specific processes and standards have been developed and continuously optimized for criticaldesign and development stages, including the commercial demonstration and project initiation planning process for reagentproducts, the process finalization and validation protocol for reagent products, the R&D-to-production transition processfor reagent products, and the design change control process for reagent products, to standardize the management of newproduct development process.Given the large number of projects and abundant information in the rapidly-changing IVD reagent market, it is important toidentify key customer needs. We need to do the right thing in the business environment. To better serve the market with preciseprovision of necessary products, our reagent R&D team adheres to the strategies of "market-oriented product development"and "lifecycle business demonstration", and establishes a decision support mechanism for project initiation. In this way, wecan determine whether a project meets market demand and is available for initiation and delivery.The business demonstration process is shown below:

Focusing on R&D and Innovation

3536

Age distribution

of R&Dpersonnel

Educationalbackgrounddistribution ofR&D personnel

30 years old or below

75.29%

31-40

22.28%

41 years old or above

2.43%

Bachelor's degree or below

50.32%

Master's degree

48.66%

Doctor's degree

1.02%

In 2025, our R&D investment wasa year-on-year increase of accounting for

of our revenue. 5.33%

10.44%

477.77

million yuan

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer Service

Quality

Product Qualityand Safety

Focusing on R&Dand Innovation

Responsible

MarketingSupply ChainManagement

Customer ServiceQuality

R&D and innovation capability >

After more than 20 years of hard work, Snibe has built a mature R&D system that spans the entire industry chain. There are fourtechnology platforms targeting the R&D of magnetic microspheres, key reagent materials, diagnostic reagents, and automaticdiagnostic instruments.

Over 30 years of technologyaccumulationProprietary magneticmicrosphere preparationtechnologyOne of the few manufacturerswith such an advanced R&Dplatform in the industry

Recombinant protein expressionAntibody preparationProtein and small moleculemodi?cationPrimer and probe synthesisReagents for chemiluminescenceimmunoassay, biochemicalanalysis, nucleic acid analysis, andcoagulation analysisCNAS-accredited referencelaboratoryStakeholder Member of the JointCommittee for Traceability inLaboratory Medicine

Microelectronics R&DSoftware R&DMechanical design andmanufacturing

MagneticmicrospheresR&D technicalplatform

IVDinstrumentR&D technical

platform

Key reagentmaterial R&Dtechnicalplatform

IVD reagentR&DTechnicalplatform

R&Dplatform

R&D investment and team building

Snibe has maintained friendly exchanges and communication with key universities and developed long-term on-campusrecruiting plans to ensure a steady stream of talents. At the same time, Snibe has been recruiting social talents andindependently training R&D professionals and persons in charge. By far, it has built an e?cient and high-quality team thatidenti?es with corporate culture.By the end of 2025, we have engaged 781 R&D professionals, accounting for 28.04% of the total number of employees. Amongthem, 97.57% are aged 40 or below, and 49.68% have a master's or doctor's degree. A young and high-quality R&D team iscontributing to our R&D and innovation.

R&D capability enhancement

●Improvement of instrument R&D capabilities

The research and development of IVD instruments is a highly integrated work, covering electronics, mechanical engineering,software engineering, and many other ?elds. We are committed to building an industry-leading R&D system, continuouslyimproving our core competitiveness, and developing more breakthrough IVD instrument products. To this end, we have madeconstant e?orts to deepen and improve our R&D capabilities in the following ?ve areas.Strengtheninginterdisciplinarycooperationand technologyintegrationBuilding asystematicintellectual propertymanagementsystem

Stimulatinginnovative thinkingand cultivatingexploring spiritImprovingthe incentivemechanism andcreating a culture ofinnovation

Increasing R&Dinvestment andconsolidating thetechnical foundation

We actively foster an open R&D ecosystem by establishing long-term cooperative relationswith universities and research institutions, driving the application-driven translation ofcutting-edge technologies. For example, we set up a postdoctoral innovation practice baseand bring experts from different disciplines into R&D projects. Through interdisciplinarycollaborative innovation, we continue to expand the boundaries of technology and acceleratethe implementation of new technologies in instrument research and development.We have established a complete intellectual property management and protection system,covering patent applications, technical confidentiality, and intellectual property riskmanagement and control. The Company has a dedicated intellectual property managementteam, responsible for the evaluation and protection of technological achievements, toensure that innovative achievements are legally and effectively safeguarded. At the sametime, through regular training and internal publicity, we raise R&D personnel's awarenessof intellectual property and promote the continuous generation of high-value patents andsoftware copyrights.We advocate an innovation-driven development model, and encourage R&D personnel tokeep an open mind and dare to challenge the traditional technology path. The Companyprovides su?cient experimental resources and exploration space for the R&D team, supportscutting-edge technology research and new product concept verification, and encouragescontinuous optimization of product design from experiment and iteration to promotetechnological breakthroughs.We have built a multi-level innovation incentive system, including project meritoriousservice award, technology innovation award, patent incentive plan, and promotion incentivemechanism, to fully stimulate the creativity of the R&D team. Meanwhile, the Companyadvocates a proactive and scienti?c R&D culture, and supports technology exploration andinnovation experiments within a reasonable range. Under a strict quality control system, weempower the R&D team to systematically advance product solutions through data analysisand experimental veri?cation, and promote technological progress, while ensuring productsafety and reliability.We insist on large R&D investment, providing advanced equipment and perfect experimentalconditions for instrument R&D. In 2023, Snibe completed the Phase III construction of R&DBuilding, creating a better o?ce and experimental environment for the R&D team and furtherenhancing the overall strength of instrument R&D and industry competitiveness.

3738

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer Service

Quality

Product Qualityand Safety

Focusing on R&Dand Innovation

Responsible

MarketingSupply ChainManagement

Customer Service

Quality

During the reporting period, the Company's instrument R&D team continued to improve the R&D governance system, focusingon the goals of high-quality development and sustainable innovation. We deeply integrated digital R&D tools, data-drivendecision-making, and cross-departmental collaboration mechanism into the full product lifecycle management. By combiningcutting-edge technologies and scientific methodologies, we built an agile, efficient, green, and sustainable innovationecosystem. This transformation further enhanced the technical barriers and quality excellence of our products, helping theCompany maintain its leading position in industry competition.

In 2025, relying on the in-depth practice of the instrument R&D governance mechanism, the Company's instrument R&Dcapabilities and quality robustness continued to improve. On the decision-making side, R&D decisions became more data-driven, and the ability to identify risks at the front end was signi?cantly enhanced; on the execution side, the trend of designrework and repeated trial production was e?ectively controlled, and the e?ciency of R&D resource utilization was continuouslyoptimized; on the product side, reliability, manufacturability, and maintainability were continuously improved; in terms ofteam collaboration, cross-departmental collaboration became smoother, the pace of project progress and the e?ciency ofproblem closure were further improved, and the ability to develop digital and complex systems was signi?cantly enhanced.This series of advancements signifies that the Company's instrument R&D system has acquired high-quality, sustainableendogenous growth momentum.

Improving the R&Dmanagement andquality controlsystem

Digitalempowerment andcollaborative R&Dpractices

?We incorporated digital design, virtual validation, and cross-disciplinary review mechanisminto the R&D project management process and quality control nodes to strengthen theinstitutionalization and traceability of the R&D process.?We established a joint review mechanism covering multiple functional roles such as R&D,testing, process, quality, and after-sales service to improve the governance capability anddecision-making transparency of complex projects.?We continued to advance the mechanism for accumulating R&D knowledge assets andsystematically managed historical project experience, test data, and improvement records tosupport the organization's long-term learning and capability accumulation.?We integrated the concepts of green design and resource conservation into R&Dmanagement requirements, guiding projects to simultaneously focus on material utilization,manufacturability, and maintenance convenience during the design stage.(I) Digital design and virtual validation?In the conceptual design and scheme demonstration stages, 3D modeling and virtualprototype technology were routinely applied to carry out system-level layout, interferencechecks, and assembly feasibility analysis in advance.?Through an online review platform, multi-disciplinary collaborative reviews were organizedto achieve visual display and e?cient communication of the design scheme.(II) Simulation analysis and data-driven optimization?A closed loop of simulation analysis and measurement validation was carried out in keymodules to continuously optimize design parameters.?Standardized test schemes and closed-loop problem management processes wereestablished, shifting quality risks forward to the design and validation stages.(III) Collaboration between 3D technology and manufacturing?Assembly simulation and process validation were applied to reduce repeated modi?cationsto prototypes and lower resource consumption.?During the mass production preparation stage, joint review of R&D and manufacturing waspromoted to improve process maturity.(iv) Agile R&D and cross-departmental collaboration?By adopting a phased review and short-cycle iteration model, the pace of problemidenti?cation and resolution was accelerated.?By incorporating end-user feedback and after-sales experience into R&D improvementinputs, product reliability and maintainability were continuously optimized.

●Reagent R&D capability enhancement

In 2025, to drive the synergistic improvement of R&D product quality, e?ciency, and sustainability, our R&D system, drivenby processes and systems, established standardized and visualized R&D management systems and a knowledge basecenter. This system encompasses the full product lifecycle, including key milestones such as project initiation review, designacceptance, design and development transfer, and product registration. Through continuous process/system iteration, itidenti?es best practices in the product development process and achieves the greatest balance between product qualityand e?ciency.In terms of R&D personnel cultivation, professional skills training was provided to employees based on the needs ofdi?erent positions in the R&D department. In 2025, the Reagent R&D Department conducted a total of 213 training sessions,including project experience sharing, professional basic knowledge explanation, and the use of professional tools tohelp R&D personnel consolidate their theoretical foundation and master core operational skills. For new employees inthe Reagent R&D Department, the Company developed a systematic training plan. In 2025, a total of 169 professionalskills enhancement courses were delivered, providing strong support for the growth of new employees, ensuring talentavailability for the e?cient operation and sustainable development of the department, and laying a solid foundation forthe Company's reagent R&D capability enhancement.

●Improvement of R&D capabilities in key reagent materials

Through relentless technological innovation and product development, the Company has achieved groundbreakingadvancements in the field of small molecules. The key reagent material R&D team has established the R&D platformfor anti-neoepitop antibodies (antibodies that form new epitopes after the complexation of small molecule antigenswith their specific antibodies). Such breakthrough has accelerated the development of the Company's small moleculeimmunization project. The result of small molecule sandwich assay is highly consistent with that of mass spectrometry,which well compensates for the shortcomings of the competition method. The registration of 16 small molecule dual-antibody sandwich assay reagents, including 25-hydroxyvitamin D, aldosterone, estradiol, progesterone, testosterone,androstenedione, tacrolimus, vitamin B12, folic acid, free triiodothyronine, total triiodothyronine, free thyroxine, totalthyroxine, reverse triiodothyronine, cyclosporine, and angiotensin I, has been completed.In terms of antibody preparation, the Company has established a single-B cell preparation technology platform to drive thehigh-quality development of rabbit monoclonal antibodies and other novel antibodies, thereby further improving reagentperformance, significantly shortening the development cycle for primary antibodies in small molecule projects, andimproving the overall quality of antibody development. At present, the Company has realized the self-production of ironpowder, a key component of the magnetic sphere, which helps to control the quality of in-house iron powder and reduceits batch-to-batch variability. Thus, the supply problem of iron powder was solved, the cost of the kit was further reduced,and the market competitiveness and product accessibility were improved. In addition, the Company has kept increasinginvestment in personnel and equipment for the research and development of key reagent materials, so as to improve theR&D capabilities of key reagent materials.

Gas ChromatographFully Automated Synthesis Workstation

3940

SATLARS mini-T8Laboratory Automation SystemSATLARS mini-T8 is an intelligent assembly line designed for compact spaces in the laboratory department. It highly integratessample pre- and post-processing functions, enabling unattended automated operation from sample loading to testing,storage, and disposal.No additional scattered pretreatment or transfer equipment is required, e?ectively solving the pain points of equipment clutterand low space utilization in the laboratory department and reducing manual transfer and handover steps by more than 80%.Equipped with AI vision-based serum quality identi?cation and automatic quality control functions, it eliminates problems suchas sample contamination, missed or erroneous testing, and information entry deviations at source, signi?cantly streamliningthe operation procedures of the department, improving sample turnaround e?ciency, and helping the laboratory departmentachieve standardized, intelligent, and e?cient operations of samples.

Biossays C6/Biossays C6PAutomatic Biochemistry Analyzer

Biossays C6/Biossays C6P are mid-to-high-end automaticbiochemistry analyzers under development by the Company.The biochemical module has a throughput of 1000T/H. Forthe electrolyte testing module, Biossays C6 is equippedwith a self-developed direct method electrolyte modulewith a throughput of up to 500T/H, while Biossays C6P isequipped with an indirect method electrolyte module witha throughput of up to 600T/H, meeting the requirements ofdi?erent terminals.Both analyzers support direct loading of whole bloodwithout pretreatment, enabling e?cient clinical diagnosis.Adopting a modular design, they can be interconnectedwith the MAGLUMI X6 chemiluminescence immunoassayanalyzer to form a biochemical immunoassay automationsystem. They also support connection to a total laboratoryautomation system, better meeting the needs of large-scaleterminals.

SATLARS T8Laboratory Automation System (aliquoter module added)SATLARS T8 is an open automation system developed by Snibe with completely independent intellectual property rights. Itfully integrates the ?ve modules of biochemistry, immunoassay, electrolyte, coagulation, and molecule. The whole process ofsample loading, transport, processing, testing, and storage is automated, greatly reducing manual intervention and improvingtesting e?ciency. The unique two-way four-track design makes sample scheduling more ?exible toward dynamic balance.Modular design and multi-type tracks can be adapted to di?erent laboratory spaces and meet di?erent testing requirementsthrough flexible configuration. Emergency priority and intelligent scheduling can greatly shorten the TAT of samples. Aspecialized data processing and information management system can help departments realize better quality management.The development of the SATLARS T8 aliquoter module was completed in 2025.

Product Quality

and Safety

Focusing on R&Dand Innovation

Responsible

MarketingSupply ChainManagement

Customer Service

Quality

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

R&D and innovation results >With the original intention of "making medical examinations more a?ordable for the public", Snibe has pursued independentinnovation while developing our core business as a socially responsible employer. We work to create value for human health,thus making quality medical resources available to all.Instrument R&D resultsThanks to enhanced R&D e?orts, we have delivered a lineup of instruments with increased accuracy and e?ciency, providingreliable data for clinical diagnosis and promoting the accessibility of medical resources. Among them, the SATLARS mini-T8Laboratory Automation System and the Biossays C6/Biossays C6P Automatic Biochemistry Analyzer are the company's keyinstrument products under development in 2025. These two products aim to reduce the a?ordability of medical terminals andimprove testing e?ciency.

4142

Rare diseaseProductAtypical haemolytic uraemicsyndrome, aHUS

sC5b-9, soluble terminal complementcomplex assay kit (magnetic particle basedchemiluminescent immunoassay)

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

In 2025, the Company's integrated biochemical and immunoassay analyzer Biolumi CX10 was a ?nalist in the InternationalDesign Excellence Award (IDEA), and the Company's electrolyte analyzer Biossays E6Plus won the Gold Award at the FrenchDesign Award. The two design awards stand as a strong testament to the innovation capabilities of our instrument R&D teamand the growing global in?uence of our brand. These two products are also the ?rst products to receive such awards.

Reagent R&D resultsDuring the reporting period, the Company completed the registration of 9 new chemiluminescence reagents and 9 newbiochemical reagents, which enriched the Company's reagent type in autoimmune antibodies, liver ?brosis, and infectiousdiseases.Attention to rare diseasesSnibe focuses on the study of rare diseases. We actively develop relevant products so that the life and health of patients withrare diseases are guaranteed. In addition to the rare diseases previously disclosed, the rare diseases we are working on duringthe reporting period are as follows:

Attention to chronic disease management and preventionWith the increasing aging of population in China, chronic diseases have become a major health threat. Under the value-basedhealthcare framework, to address this dilemma and further optimize chronic disease diagnosis and treatment pathways,we have launched appropriate and precise testing technologies through the innovation and application of cutting-edgetechnologies in laboratory medicine, which provides a new direction for chronic disease management guided by value-based healthcare and helps optimize the full lifecycle management of chronic diseases and clinical diagnosis and treatmentpathways.

Diabetes is a highly prevalent chronic disease worldwide. According to the 2021 report by the International DiabetesFederation, approximately 537 million adults worldwide have diabetes, and this number is projected to rise to 784 million by2045. China has the largest number of diabetes patients in the world, with approximately 140 million patients, accountingfor about 26% of the global total. To improve the diagnosis rate of diabetes, the Company developed an anti-zinc transporter8 antibody (Anti-ZnT8) assay kit (magnetic particle based chemiluminescent immunoassay) during the reporting period.According to the positive rate of glutamic acid decarboxylase antibody (GADA) in the population with newly diagnosed classictype 1 diabetes mellitus (T1DM) in China, the combined detection of protein tyrosine phosphatase antibody (IA-2A) and Anti-ZnT8 can increase the positive rate by 10% to 15%. The launch of the Anti-ZnT8 product e?ectively ?lls the diagnostic gap,improves the detection e?ciency, promotes the precise subtyping of T1DM, and enables early warning and individualizedtreatment decisions.In the cardiovascular ?eld, Snibe successfully developed the 11-dehydrothromboxane B2 assay kit (magnetic particle basedchemiluminescent immunoassay) based on the small molecule sandwich technology R&D platform. Leveraging the technicaladvantages of small molecule sandwich materials and methods, it breaks through the sensitivity limitations of traditionalELISA, quanti?es the degree of platelet activation, accurately identi?es patients with biochemical resistance, provides a basisfor intensive intervention in high-risk populations, and guides the adjustment of medication regimens. The kit is also suitablefor primary healthcare institutions, enabling screening and triage of low-risk patients at the grassroots level, thereby freeingup resources at Grade A tertiary hospitals and implementing tiered diagnosis and treatment. It directly serves the core goal ofthe "Healthy China 2030" initiative to reduce the mortality rate of cardiovascular diseases.Promoting the R&D of geriatric, pediatric, and maternal productsThe Company actively responds to the requirements of documents like the national "Healthy China 2030 Planning Outline", the"State Council's Opinions on Implementing Healthy China Initiative", the "14th Five-Year Plan for National Health" and WHOinitiatives to promote the research and development of geriatric, pediatric, and maternal diagnostic products.The global treatment cost for Alzheimer's disease (AD) is projected to reach $1.89 trillion by 2050. Early screening anddiagnosis can slow disease progression, reduce the need for mid-to-late stage care, and help achieve the goal of "healthyaging". To this end, the Company has carried out the R&D of cerebrospinal ?uid and blood detection products related to AD,helping to comprehensively promote the prevention and control of dementia in the elderly. As of the end of the reportingperiod, the Company had completed the development of multiple AD blood test kits (Aβ1-40, Aβ1-42, p-Tau-181, p-Tau-217,etc.), which are of great signi?cance for the prevention and control of AD. First, this technology breaks through the bottleneckof early identi?cation. Cerebrospinal ?uid testing and PET scans are invasive, expensive, and di?cult to popularize, whileblood-based neurological biomarker testing, with its high sensitivity and speci?city, non-invasiveness, and cost-e?ectiveness,has become the key to breaking the deadlock. It also supports large-scale community screening, enabling convenient anduniversal early diagnosis. Second, blood biomarkers allow for dynamic monitoring of disease progression and treatmente?cacy to guide precise intervention, and combined monitoring can quantify pathological progression. Finally, China hasthe largest number of AD patients in the world (over 11 million patients aged 60 and above), with higher risks in rural areasand among women. This technology can e?ectively address the challenges of China's aging population and optimize thepublic health prevention and control system. It provides a core tool for building a full-chain system of "screening-diagnosis-treatment-prevention" for China's aging society, and is of strategic significance for reversing disease progression andalleviating public health pressure.In 2024, China's State Council issued the "Several Measures on Accelerating the Improvement of the Fertility Support PolicySystem and Promoting the Construction of a Fertility-Friendly Society", which would implement in depth the Maternal andInfant Safety Promotion Action Plan and the Birth Defects Prevention and Treatment Capacity Enhancement Program. Humanparvovirus B19, a pathogen capable of maternal-fetal transmission, may compromise fetal development. In alignment withnational policies, the Company has accelerated the development of human parvovirus B19 antibody detection solutions andenhanced its comprehensive and high-quality TORCH screening panels. As of the end of the reporting period, the HumanParvovirus B19 IgG Antibody Test Kit (magnetic particle based chemiluminescent immunoassay) had obtained the registrationtest report and entered the clinical registration phase.

4344

Facilitating the improvement of global public health servicesRespiratory tract infections pose a long-term challenge to global public health. Their high transmissibility, pathogen diversity,and symptom similarity place enormous pressure on clinical diagnosis, treatment, and disease prevention and control.As a pioneer in the global in vitro diagnostics field, we deeply understand that diagnostic products are not only medicaltools, but also an important component of the public health defense system. In 2025, we conducted R&D of a series oftesting products aimed at improving public health services and combating infectious diseases. These included respiratorymultiplex testing products that detect pathogens such as in?uenza A, in?uenza B, respiratory syncytial virus, adenovirus, andMycoplasma pneumoniae. The goal is to accurately identify pathogens through a single sampling and testing, especially forvulnerable groups such as infants, young children, and the elderly. This provides comprehensive etiological evidence to guideprecise medication, thereby curbing the spread of antibiotic resistance at the source, reducing the burden on the medicalsystem, and safeguarding public health.

Facilitating early screening, early diagnosis, and personalized diagnosis and treatment of cancerGuided by China's policy of early diagnosis and treatment, the Company actively advances the development of early screeningand diagnostic products for cancer, aiming to promote its early screening, early diagnosis and early treatment and to reducecancer incidence and mortality rates.DNA methylation detection, as a rapidly developing molecular detection technology for cancer in recent years, has shownpromising application prospects in early cancer risk assessment and auxiliary diagnosis. It features non-invasive or minimallyinvasive sampling and the ability to capture potential early signals, making it suitable for risk assessment and clinicaldecision support in speci?c populations. In addition, DNA methylation biomarkers are being explored for disease progressionassessment and prognostic analysis in some studies and speci?c application scenarios.The Company has achieved breakthrough progress in the field of methylation-based early cancer screening. Based onmethylation-speci?c PCR technology, the Company has developed single-cancer screening or auxiliary detection products formultiple high-incidence cancers, covering application scenarios such as colorectal cancer and cervical cancer. These productsare used to detect the methylation of speci?c genes in the population using various sample types, including fecal samples,human peripheral blood plasma, and cervical exfoliated cells, assisting clinicians in disease diagnosis. Regarding methylationinstruments, the R&D of methylation instruments had been completed by the end of the reporting period, facilitating earlyscreening and early diagnosis of related diseases.Malignancies have become one of the major disease burdens worldwide. The traditional "trial-and-error" approach ofchemotherapy not only delays patient treatment, but also results in enormous waste of medical resources and patientsu?ering. As a "navigator" for precision medicine, the core value of companion diagnostics lies in ?nding the right drug for theright patient at the right time. To this end, the Company has introduced a digital PCR platform through strategic cooperation,which, with its high sensitivity and excellent quanti?cation capabilities, provides more precise medication guidance for cancerpatients. During the reporting period, relying on this technology platform, the Company achieved key breakthroughs in twomajor cancers, breast cancer and non-small cell lung cancer.By dynamically monitoring drug-resistant mutations using the digital PCR platform, treatment regimens can be adjusted ina timely manner, supporting personalized diagnosis and treatment and avoiding the huge medical expenditures incurredby ineffective targeted therapies, as well as the radiation exposure and resource consumption from unnecessary imagingexaminations. This approach not only respects life but also maximizes the use of limited medical resources.Promoting access to quality medical resourcesAdhering to the original intention of "making medical examinations more affordable for the public", the Company iscontinuously promoting accessibility to high-quality medical resources. In 2025, the Company's Instrument R&D Departmentconsistently prioritized enhancing accessibility to medical services, improving clinical user experience, and reducing total costof ownership as key directions of R&D governance. The concept of accessible and a?ordable healthcare was systematicallyembedded in the product planning, design, development, and validation phases. Through the coordinated development of

centralized and decentralized testing solutions, the Company assisted medical institutions at di?erent levels in enhancing theirtesting capabilities. The speci?c activities undertaken are as follows.Incorporatinghealthcareaccessibilitygoals intoR&D strategy

Expandinghealthcareservicecoveragethroughinnovativedesign andplatform-based R&D

?Incorporate product planning for centralized terminals and primary healthcare settings into theannual R&D roadmap, with a focus on supporting regional laboratory capacity building and thedevelopment of the tiered diagnosis and treatment system.?At the new project initiation stage, concurrently assess equipment deployment conditions, sta?nglevels, operational costs, and long-term maintenance requirements, and treat accessibility anda?ordability as key decision dimensions.?Establish a cross-departmental collaboration mechanism, uniting marketing, after-sales, clinicalsupport, and supply chain teams, to incorporate end-user feedback and public health needs intoproduct planning inputs.?Embed energy efficiency, durability, and life-cycle cost management requirements into the R&Devaluation system, to promote the economic viability and sustainability of products over long-termoperation.(I) Product R&D planning for centralized terminalsThe Company is developing two new products for medium-throughput centralized testing terminalscenarios, including a medium-speed biochemistry analyzer and an integrated sample processingsystem, both soon to be launched:

?Both products are designed to enhance the testing capabilities of regional laboratories, optimizemanpower allocation, and improve operational e?ciency, meeting centralized testing needs.?The system architecture emphasizes modular design and scalability, enabling medical institutionsto gradually con?gure equipment based on testing volume, thereby reducing the pressure of one-time investment.?By integrating sample pre-processing, automated transmission, and information system integrationfunctions, manual operations are reduced and process stability is improved.?During the design phase, attention is also given to deployment space, power conditions, andenvironmental adaptability to enhance applicability across medical institutions in di?erent regions.(II) Optimizing product design to improve usability?Continuously improve the user interface and interaction logic to reduce training costs;?Strengthen intelligent reminders, operation monitoring, and remote support capabilities to improvethe transparency of equipment operation;?Introduce multi-scenario use validation during the R&D phase to ensure product suitability fordi?erent medical environments.(III) Adopting a modular and standardized design to improve a?ordability?Promote platform-based architecture and standardization of core components to control R&D andmanufacturing costs;?Optimize part and component selection and process solutions to enhance supply chain stability;?Adopt a durable design and maintenance-friendly structure to reduce life-cycle operation andmaintenance costs.(IV) Supporting applications in primary and resource-limited regions?Optimize installation and deployment methods to improve operational reliability in complexenvironments;?Promote low-energy-consumption design to reduce operational burden;?Fully cover scenarios of continuous operation and simplified maintenance during the validationphase.(V) Using digital tools to empower laboratory e?ciency?Use data analysis and operational monitoring functions to help laboratories shorten testingturnaround time;?Strengthen system interconnection capabilities to support laboratory informatization;?Upgrade software to extend equipment life-cycle.

Product Quality

and Safety

Focusing on R&Dand Innovation

Responsible

MarketingSupply ChainManagement

Customer Service

Quality

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

4546

Product Quality

and Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

By systematically embedding the concept of healthcare accessibility into R&D governance and product development practices,the Company made positive progress in promoting healthcare coverage in 2025, which also re?ects its commitment to socialresponsibility.In the future, the Company's R&D department will continue to promote technological innovation and process optimization,and remain committed to creating more high-quality and cost-e?ective medical devices, further improving the accessibility ofmedical resources, and contributing to the sustainable development of the global medical industry.Green R&D

The Company's instrument R&D team continues to delve into the field of sustainable development, integrating the greensustainability principle into every detail of products' life-cycle management. From the design iteration of core componentsto the optimization of production and assembly, and then to subsequent use and resource recycling, the team consistentlyleverages technological innovation to minimize environmental impact. By upholding and upgrading its green developmentconcept, the Company provides customers with efficient and environmentally friendly solutions while continuouslystrengthening its sense of responsibility in the ?eld of green medical equipment.

The Company's SATLARS mini-T8 Laboratory Automation Systemembodies green concepts and life-cycle design

Green design: Advancing lightweight and intensive design

?Structural lightweighting to lower both material and energy consumption: For SATLARS mini-T8's coldstorage unit, we optimized its structural design through simulation analysis while maintaining thestructural advantages of SATLARS T8. Under the premise that part strength requirements were met, theweight was reduced by approximately 36%, effectively reducing material usage and directly loweringcarbon emissions during subsequent transportation, thereby extending the green value contributed at thedesign phase.?Storage efficiency upgrades to optimize resource utilization: Through systematic design upgrades,SATLARS mini-T8's cold storage unit achieved a simultaneous improvement in storage density per unitvolume and overall energy e?ciency ratio, truly realizing the green design goal of "create higher valuewith fewer resources" and indirectly reducing energy consumption during use.?Part integration and simplification to reduce resource consumption at the source: A comprehensivestructural integration and simplification was carried out on SATLARS mini-T8's sample processingunit. By optimizing wiring, simplifying transmission and support structures, and integrating functionalcomponents, the number of part types was reduced by approximately 14% and the number of partsby approximately 11%. This simpli?ed material management and resource consumption at the source,facilitated subsequent maintenance and upgrades, and reduced resource waste caused by productreplacement.?Snap-?t connection optimization to reduce consumable usage: The innovative snap-?t ?xing solutionreplaced some traditional connection methods, which not only simplified the assembly process andimproved e?ciency, but also signi?cantly reduced the number of small consumables such as screws used,facilitating subsequent maintenance and recycling, and lowering resource consumption during use anddisposal.

Green production: Promoting e?cient and low-carbon collaborative manufacturing?Material and process optimization to reduce production energy consumption: Relying on lightweight andintegrated front-end design, the demand for raw materials and processing complexity were directly reduced.The simplified structure reduced material consumption and energy input during production, while thestreamlined assembly process also reduced labor hours and energy consumption, thus achieving low-carbonmanufacturing.?Supply chain collaboration for full-chain carbon reduction: The reduction in the total number of parts enabledupstream suppliers to consume raw materials more precisely, reducing the production and waste risks of excessmaterials; the product's overall weight reduction and structural optimization further lowered fuel consumptionand carbon emissions during logistics and transportation, promoting the green transformation of the full supplychain.?Precise consumable management and control to reduce waste volume: For SATLARS mini-T8's sampleprocessing unit, the reduction in the number of standard parts such as screws used (reduced by approximately15%) and the optimization in part structures signi?cantly lowered the amount of processing consumables usedduring production and reduced manufacturing waste; the standardized and intensive design also reducedresource input for subsequent consumable replacement and maintenance, forming a full-cycle green materialmanagement system.Green packaging: Practicing sustainable logistics?Continued application of environmentally friendly materials: In this new product, we still actively promoted thereplacement of plastics and wood with paper, and used recyclable paper-based substrates and environmentallyfriendly cushioning materials, signi?cantly reducing dependence on traditional plastics and wood, and loweringresource consumption and environmental pollution.?Lightweight packaging design: By optimizing the packaging structure and using high-strength thin materialsand multi-module combination solutions, the total volume and weight of the packaging were effectivelyreduced, which not only saved storage and transportation space, but also directly reduced energy consumptionand carbon emissions during logistics.?Strict adherence to international standards: All packaging materials strictly complied with internationalenvironmental regulations and recycling standards, ensuring they are recyclable and biodegradable. Weare committed to providing customers with green packaging solutions that meet global environmentalrequirements, supporting the development of a sustainable supply chain.

4748

Product Quality

and Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Product Qualityand Safety

Focusing on R&Dand Innovation

Responsible

MarketingSupply ChainManagement

Customer Service

Quality

Cumulative number ofpatents filed

Number of valid patentsgranted

Cumulative number of validtrademarks registeredIncluding valid inventionpatents

Cumulative number ofsoftware copyrights743426742

Intellectual property protection >Snibe strictly abides by and implements national and regional laws, regulations, and standards, such as the "Patent Law ofthe People's Republic of China" and "Trademark Law of the People's Republic of China", formulates the "Intellectual PropertyManagement Procedure", "Patent Management Procedure", "Trademark Management Procedure", "Works ManagementProcedure" and other management documents, and continuously improves the construction of intellectual propertymanagement system.We pay attention to intellectual property protection. With a dedicated team of professionals and a mature managementsystem, we integrate intellectual property creation and protection into our R&D and innovation system to provide strongsupport and guarantee for our product R&D and technological innovation. Internally, the Intellectual Property Departmentadopts early warning for project research, project initiation, R&D, and product launch to manage risks throughout thedevelopment process and protect our technological innovations. Externally, investment, financing, and technologicalcooperation are conducted with an early warning mechanism to reduce potential risks. At the same time, we actively organizetraining sessions to help employees understand intellectual property compliance and obligations, and strengthen theirawareness and professional competence in intellectual property protection.With the outstanding performance in the creation, application, protection, and management of intellectual property rights,Snibe won the title of "National Intellectual Property Demonstration Enterprise" in 2023 and won the title of "NationalHigh-tech Enterprise" in 2024, fully demonstrating Snibe' exemplary and leading role in the independent control of coretechnologies and the strategic deployment of intellectual property rights.By the end of 2025, the Company has had 743 patents ?led, 426 valid patents granted (including 197 valid invention patents),742 valid trademarks registered, and 60 software copyrights.

A stable, safe, and quality supply chain provides an importantguarantee for us to offer high-quality products all the time.Guided by "The Bidding Law of the People's Republic of China"and other relevant laws and regulations, Snibe has developed asound supplier management system. In addition to the qualityof products and services, the Company also pays attentionto the management of suppliers in terms of business ethics,environmental awareness, occupational health and safety, andcontinues to convey the concept of sustainable development tosuppliers to ensure the quality and sustainability of suppliers.

Supplier management >Management systems such as the "Bidding Management System", the "Control Procedure for Procurement", the "Anti-BriberyControl Procedure for Procurement Transactions", and the "Supplier HSF Management Regulations" have been formulatedto systematically supervise and manage supplier development and admission, ordering, performance evaluation, re-evaluation, quali?cation management, and supplier elimination, forming closed-loop management to ensure the fair ande?ective operation of the procurement supply chain.We continuously optimize supplier management and, in accordance with relevant system requirements, achievecomprehensive and high-standard management of our major business partners. We conduct anti-commercial briberyinvestigations and annual reviews for our major business partners, with a coverage rate of 100%, to prevent compliancerisks at the source. Mandatory anti-bribery training sessions with competency assessments are organized for suppliers,accompanied by the signing of "Letter of Commitment for Anti-Commercial Bribery" or "Anti-commercial Bribery Agreement",internalizing integrity-based cooperation as a common principle for both parties. We have completed the signingof "Environmental and Occupational Health and Safety Policy Notice" across our partner network and the signing of"Supply Chain Information Security Agreement" with major suppliers, establishing risk control measures for environment,occupational health and safety, and information security. In addition, this year we have newly formulated the "Supplier On-site Audit Management Regulations", which not only standardizes the audit management of external suppliers, but alsoproactively urges and guides suppliers to improve their management in areas such as quality management, anti-commercialbribery, environment, occupational health and safety, and information security.

Supply Chain Management

4950

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

By the end of 2025, the proportion of suppliers inthe Chinese mainland was

and the proportion of suppliers in Hong Kong,Macao, Taiwan, and overseas was

96.3%3.7%

Supplier admissionSupplier re-evaluationSupplier elimination

Preliminary investigationProduction and R&D capabilitiesQuality assurance abilityIntellectual Property RightsEnvironmental health and safetySocial responsibility and ethicalstandardsSample validationEnquiry and quotationOn-site certi?cation and reviewAnti-commercial BriberyInvestigation

Supplier classi?cationmanagementSupplier quali?cationmanagementRisk management of supplierOrganizational StructurePrice levelProduction CapacityQuality assurance abilityEnvironmental riskassessmentAnti-commercial BriberyInvestigation

Supplier monitoringEliminating abnormalsuppliers···········

··········

Supplier communication >Technical exchange is an important measure to ensure product quality. Whenever quality anomalies are identi?ed duringregular supplier performance reviews, we immediately coordinate with relevant departments and suppliers to jointly discusssolutions. A regular communication and feedback mechanism has been established around the monthly incoming materialpass rate and on-time delivery rate. For suppliers not up to standards or ranking low in performance, we proactively organizespecial meetings to invite them to review their quality performance in person. Through in-depth discussions on qualitystandards, we establish mutually agreed control standards, and on this basis, formulate e?ective corrective and preventiveactions as well as quality improvement measures, thereby further enhancing material quality levels. In 2025, we organizedmore than 330 online and o?ine meetings with suppliers.In the on-site audit stage before the new supplier was admitted, the Procurement Department would jointly conduct on-site visits and exchanges with the personnel of relevant upstream and downstream departments such as R&D and qualityinspection. Based on the annual evaluation results of suppliers and the problems found in their daily management process,we would formulate an annual visit plan or arrange an unannounced audit, timely discuss with suppliers about the qualityand sustainable development issues found in the audit, and discontinue the supply from suppliers to be recti?ed to mitigatesupply risk. In 2025, we conducted a total of 26 pre-admission and annual on-site audits.

Sustainable supply chain management >To ensure the quality and supply safety of important materials, Snibe divides suppliers into three categories of A, B, and Cby the importance of supplied materials management to the product. Suppliers are reviewed and evaluated with category-speci?c indicators and standards based on the types of their materials and the nature of business. Category A suppliers arerequired to establish a sound quality management system and sign a quality assurance agreement.After years of technology accumulation, we have established a well-developed supply chain risk management system. Onthe one hand, we enhance the safety inventory management of core components and include more alternative suppliers.On the other hand, we join hands with domestic manufacturers to develop and apply for major special projects of Shenzhento promote the R&D and substitution of domestic core components. For key components, Snibe and suppliers need to workclosely on all-round material recognition to fully guarantee the safety of materials. For some key materials, Snibe hasformulated Plan B to deal with sudden risks in the supply chain. For materials with a large amount of consumption, we usuallypurchase them from two or three suppliers at the same time to avoid the situation that the production of products is a?ectedby the shortage of materials. Amidst the push to replace foreign goods with domestic alternatives in the manufacturingindustry, Snibe has opted for more domestic materials after veri?cation, consolidating supply chain security. Furthermore, thestrong R&D team for key reagent materials serves as a solid backbone to guarantee the stable supply of raw materials for ourreagent products. At present, most of the Company's key reagent materials have achieved self-su?ciency, e?ectively reducingthe risk of limited raw material procurement channels and ensuring the stability of the key reagent material supply.As for supply chain operation and inventory management, the annual demand forecasting is updated on a rolling basis (2 + 3,short-term + long-term) so that both suppliers and Snibe can maintain dynamic safety inventory for quick response to ?exibledemand. At the same time, based on production needs and procurement plans, we collaborate with suppliers to discuss andformulate reasonable inventory quantities and delivery schedules, and continuously update these to ensure smooth supplychain operations and improve delivery ?exibility and response speed.When selecting supply resources, we prioritize suppliers that are geographically close to us and have a relatively completesystem to ensure flexible delivery and timely, effective communication and audit in quality control, as well as in-depthcommunication and careful evaluation during R&D cooperation to guarantee stable supply after delivery.

In accordance with the "Control Procedure for Procurement", the Company conducts annual requali?cation audits for bothprobationary and approved suppliers. Suppliers not up to standards are included on the "List of Unqualified Suppliers"based on the type of materials they supply. Rectification and guidance support are available to urge and help suppliersimprove their management processes and measures, thus ensuring the stability and improvement of the supplier quality,and eliminating unquali?ed suppliers. Meanwhile, by establishing supplier management ?les, we regularly record suppliers'qualification changes, cooperation updates, and performance. Based on these records, we periodically review and auditsuppliers, monitoring and strictly assessing whether to retain their cooperation eligibility.In 2025, the Company added 50 new suppliers and removed 4 suppliers due to quality issues.

5152

Product Quality

and Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Product Qualityand Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer Service

Quality

Snibe has always put the rights and interests of users first.Through strong brand building, and the domain-specificexpertise competency enhancement of the marketing andafter-sales service personnel, the Company unswervinglyimplements responsible marketing, continuously elevatesclient service capabilities, empowers customers, and fostersindustry exchanges and cooperation to expand the Company'sleadership in the industry.

Responsible marketing management >Management systems such as "Control Procedure for Customer-Related Processes", "Regulations on the Managementof Domestic Distributors", "Regulations on the Management of Overseas Distributors", "Regulations on the Managementof Publicity Materials", "Regulations on the Management of Intellectual Property Rights in Advertising and Exhibitions","Regulations on the Management of Intellectual Property Rights in Market Sales", and "Anti-Bribery Control Procedure forDistributors' Sales Business" have been established to form a sound marketing management framework to ensure theprotection of customer rights and interests and improve customer satisfaction during the course of business.In both domestic and overseas markets, we adhere to the ?ve principles of equality and mutual bene?t, integrity and legalcompliance, win-win result and long-term cooperation, daily management with regular evaluation, and zero tolerance forbribery to manage distributors.

As required by the "Regulations on the Management of Domestic Distributors", Snibe strictly abides by the "Anti-UnfairCompetition Law of the People's Republic of China" and the "Interim Provisions on Prohibition of Commercial Bribery". Forbrand building and market development, we have formulated the "Management System for Domestic Academic Conferences"to regulate the organization of academic conferences and academic promotion. An internal customer management platform,which covers ?ve modules of customer management, market management, product management, distributor management,and database, has been developed to help marketing personnel master information on customer relations, meetingprocedures, product information, and online distributor management. This is how we realize responsible marketing.In overseas markets, under the framework of the Company's ISO 13485 quality management system, we follow the"Regulations on the Management of Overseas Distributors", implement the ISO 37001 anti-bribery management systemstandard, and require overseas distributors to conduct business as per local laws and regulations. To ensure global regulatorycompliance of post-market products, the Company strictly abides by the regulatory requirements of various countries/regions for medical devices, and sets appropriate labels when selling products to ensure that the end users are fully awareof the product information. For example, for distributors in the EU, we adapt our products and business to the latest IVDRand transitional provisions, for example, adding the information of EU importers and updating compliance declaration. Tosafeguard the interests of distributors and end users, we proactively communicate with customers and end-user hospitalsregarding products undergoing phase-out or discontinuation, providing advance noti?cation of discontinuation timelines toestablish transition periods for users, while simultaneously o?ering optimized alternative solutions.

Responsible brand building >Brand control and supervisionDuring product marketing and promotion, the Marketing Department submits the new products and promotional materials(including the commissioned design of advertisements) to the Intellectual Property Department for review in strict accordancewith the requirements speci?ed in the "Regulations on the Management of Intellectual Property Rights in Advertising andExhibitions" and the "Regulations on the Management of Intellectual Property Rights in Market Sales", so as to ensurecompliance with the Company's requirements for patent, trademark and copyright protection. At the same time, we requirethat the content of promotional materials be truthful and scienti?c, and must not contradict the content of product labelsand instructions. Exaggerated statements are prohibited, and the use of text, names, images, or other similar labels that maymislead users regarding the intended use, safety, or performance of products is forbidden. Furthermore, all materials sent toexternal parties must undergo strict internal approval.The Marketing Department is responsible for market supervision and risk control and prevention in the product releaseand publicity process. The Company also closely monitors the behaviors that damage our brand building, and clari?es theresponsible departments and measures to deal with violations against our intellectual property rights to maintain Snibe'sbrand image.Brand building

In 2025, the Company launched several major instrument products, including the ultra-high-speed fully-autochemiluminescence immunoassay analyzer MAGLUMI X10, the ultra-high-speed biochemistry analyzer Biossays C10, thehigh-speed fully-auto electrolyte analyzer Biossays E6 Plus, and the high-speed automated coagulation analyzer HemolumiH6. The successive launches of these products provide important opportunities for the Company's brand building. TheCompany actively promotes brand building across all departments. We continue to carry out brand promotion throughvarious channels and forms such as exhibitions, academic conferences, and official WeChat accounts to enhance theCompany's industry in?uence.

Responsible Marketing

Identification

of productrequirements

Review of

productrequirementsDetermination

of productrequirements

Implementationof bidding andcontract/order

After-sales

feedback

Communication with customers

International Symposium on Laboratory MedicineOn Aug. 24, 2025, the International Symposium on Laboratory Medicine was held at the headquartersof Snibe in Shenzhen. The conference was jointly organized by the International Federation of ClinicalChemistry and Laboratory Medicine (IFCC) and Snibe, and invited 14 lecturers and over 300 participants.The conference was honored to have the attendance of Professor Tomris Ozben (President of the IFCC),Professor Khosrow Adeli and Maurizio Ferrari (former Presidents of the IFCC), and Professor Mario Plebani(President of the European Federation of Clinical Chemistry and Laboratory Medicine [EFLM]).

Promotion of MAGLUMI X10 and Biossays C10

Promotion of T8 total laboratory automation, coagulation analyzer, andelectrolyte analyzer

In Mar. 2025, at the Annual Conference & EXPO, China Congress for Diagnostics & Laboratory Medicine(CCDLM) and the 22nd China International In Vitro Diagnostic Expo (CACLP), the Company exhibitedand launched the fully-auto chemiluminescence immunoassay analyzer MAGLUMI X10 and the next-generation biochemistry analyzer Biossays C10 for the ?rst time in China. MAGLUMI X10, with its ultra-fastimmunoassay throughput of 1000 tests per hour, MPC micro-precision sampling technology, as well aszero-contamination, zero-pulsation, and zero-degradation steady-state washing technology, ensureshigh e?ciency, accuracy, and stability of immunoassays.

In Sep. 2025, the 14th National Conference of Clinical Laboratory Management (NCCLab), organized bythe Chinese Hospital Association, was held in Chengdu. As an important academic exchange platformin the ?eld of clinical laboratory management in China, the Company made a stunning appearance atthe conference with a series of high-quality laboratory solutions and disease diagnosis and treatmentsolutions, including SATLARS T8, the high-speed fully-auto electrolyte analyzer Biossays E6 Plus, and thehigh-speed automated coagulation analyzer Hemolumi H6.

5354

Product Quality

and Safety

Focusing on R&Dand Innovation

Responsible

MarketingSupply ChainManagement

Customer Service

Quality

Product Quality

and Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

In terms of brand building in overseas markets, the Overseas Sales Department and Overseas Marketing Department haveheld academic exchanges such as Snibe Day to enhance the Company's international brand in?uence."Snibe Day" is jointly organized by the Company, the International Federation of Clinical Chemistry and Laboratory Medicine(IFCC), and globally renowned medical associations and laboratories. Focusing on current challenges, future directions,and key issues in medical laboratory immunoassays, the event brings together renowned experts in international medicallaboratory science to share the latest clinical applications and research advances, promoting the translation of research?ndings into clinical practice and vigorously facilitating knowledge sharing and cross-border cooperation in the ?eld of invitro diagnostics.In 2025, we successfully held more than 10 "Snibe Day" brand events, which were launched in China and many countriesoverseas. The "Snibe Day" events transcend one-way communication. With an open attitude, the Company invited key globalpartners to come together, experience the smart production line, and witness how precision instruments were born; theyalso visited hospitals to see how the equipment drove e?cient diagnosis and treatment. When manufacturing strength meetsclinical needs, we jointly create a closed loop of trust. This is not just a showcase, but a commitment: Snibe ensures thatevery technology withstands the test of real-world application.

5556

Product Quality

and Safety

Focusing on R&Dand Innovation

Responsible

MarketingSupply ChainManagement

Customer ServiceQuality

Product Quality

and Safety

Focusing on R&Dand Innovation

ResponsibleMarketingSupply ChainManagement

Customer ServiceQuality

Enhancing Snibe's brand influence through participation in internationalexhibitions

In 2025, the Company participated in more than 140 international exhibitions worldwide, includingimportant industry platforms such as Medlab Middle East, EUROMEDLAB, ADLM, and Medica. On thesestages, we systematically showcased cutting-edge laboratory technologies and innovative solutions, andcollaborated closely with global partners to address real-world challenges in the diagnostics ?eld andactively shape the future direction of medical diagnostics.

Responsible marketing training >The Company highly values the professional and academic capabilities of its marketing team. It has established a systematic,regular, and e?ective training system that closely aligns with business strategies and e?ectively empowers the marketingfrontline and support teams.In 2025, the domestic marketing center organized 54 regular training sessions, covering areas such as promotion strategies,case sharing, knowledge training (luminescence, instrumentation, biochemistry, coagulation), and policies. Details are asfollows:

The domestic marketing center has established a weekly, ?xed-time joint training mechanism for the three teams (productmanagers, sales personnel, and technical service engineers) to ensure information synchronization. The training contentincludes: (1) product and technical knowledge, with in-depth training on clinical applications, report interpretation, andpromotional advantages across six major areas, including bone metabolism, hypertension, and tumor biomarkers; (2)interpretation of market dynamics and policies, with timely launch of courses on the rationale for test panels; (3) regularsharing of excellent promotion cases as well as distributor cultivation and benchmark hospital construction experience;

(4) regular special strategy training for regional directors, deputy directors, and other management personnel to unify the

promotion consensus of regional leaders and ensure the accurate implementation of strategies.To ensure training e?ectiveness, the domestic marketing center adopts the "Learn-Test-Evaluate" approach. Post-trainingtests are released via an online platform to enable immediate assessment of learning outcomes. By analyzing the distributionof test scores, the center continuously re?nes training content and formats to ensure high relevance to actual work.

Customer service management and capabilities >

We practice the "service +" concept to continuously improve customer service experience, and provide carefree servicesfor customers. We have formulated and implemented management systems such as the "Control Procedure for ServicingActivities" to standardize the customer consultation and complaint handling process. Through systematic training andprofessional guidance, we continuously strengthen the team's professional ability and service awareness, and optimize thequality of customer service.By 2025, the Company has built 190 service stations and upgraded on-site services in various regions across China, ensuringcustomer response in 1–2 hours. To help technical engineers in di?erent regions solve customer problems in a systematic way,we have developed the remote service system Snibe Link on our own to ensure a comprehensive and professional customerservice. We are committed to providing customer-centric, rapid-response, and professional services to create worry-free andvalue-added experiences.In overseas markets, Snibe implemented regional management with independent marketing, after-sales, market, andbusiness for each region. Product sales and after-sales personnel are better connected to improve the regional product andservice performance. More foreign technical service personnel were recruited to ensure timely response to the urgent needsof distributors and end customers. As we expand our product lines, the number of overseas channels is also expandingin terms of both breadth and depth to bring quality products and services to more customers across the world. In majorcountries and markets, the Company strengthens localization through the establishment of overseas subsidiaries. Up tonow, we have set up overseas subsidiaries in 16 countries. By recruiting local employees and applying for product circulationlicenses, overseas subsidiaries boost localized operations for more meticulous and comprehensive market coverage andpremium service for end customers.

With the core strategic concept of "customer-centric, market-oriented", Snibe keeps optimizing customer service solutionsin all aspects by understanding customer needs, timelyresponding to customer complaints, providing professional andaccurate services, and investigating customer satisfaction, soas to provide customers with safe, reassuring, and innovativeproducts and services.

Customer Service Quality

Product Quality

and Safety

Focusing on R&Dand Innovation

Responsible

MarketingSupply ChainManagement

Customer ServiceQuality

Customer satisfaction >We truly adhere to the principle of delivering timely, efficient, dedicated, professional, thorough, and quality service tocustomers. In case of any product problems, customers can get in touch with us through the "400" hotline, official mail,and "External Information Feedback Form" on the official website. In addition, our technical service personnel strictlyfollow Snibe's "Control Procedure for Feedback and Complaint Handling" for closed-loop management through regularmaintenance & customer visit and timely communication with customers. In 2025, 100% of the complaints received have beenhandled, with a customer satisfaction rate of 100%.We regularly conduct customer satisfaction surveys to understand the opinions and suggestions of customers on theCompany's products and services. In 2025, the domestic and foreign customer satisfaction reached more than 98%.Improving customer service capabilities >We maintain proactive two-way communication through a customer-centric approach to deliver sustained customerempowerment. ISO 15189 is an internationally recognized standard for quality and competence management in medicallaboratories. To help the medical laboratory departments establish a standardized quality management system and improvethe accuracy and mutual recognition of test results, we have provided ISO 15189 full-process support. This year, we continuedto provide ISO 15189 training and guidance to end customers in various regions, and built a combined online and o?ineplatform for specialized training and exchanges, to fully empower customers to apply for accreditation. During the dailyservice process, we discussed with laboratory teachers the problems and questions encountered in the validation analysis,to enhance their understanding of immunoassay product applications, help them master product applications and analysisvalidation methods, and improve laboratory quality management.We attach great importance to the construction and training of technical service engineers. In 2025, we organized trainingfor domestic technical service engineers and provided on-site and online training for technical service engineers of overseasagents to comprehensively enhance their professional service capabilities. At the same time, through the "Snibe Forum"online platform, we delivered knowledge to technical service engineers of our agents to promote their understanding of thelatest product-related information. On this platform, product-related information is constantly updated, and those engineerscan learn to operate the product quickly.

Snibe deeply practices the concept of sustainable development,strictly aligns with environmental protection, conservation, and safetyproduction management standards, and continuously strengthensthe construction of its environmental and occupational health andsafety management system. We integrate the concepts of greenoperation and safe production into all aspects of daily operations.While ensuring employee safety and health, we strive to create anefficient and environmentally friendly operation model, promotingthe deep integration of green development and safe operation.

Alignment with Sustainable Development Goals (SDGs)

PROMOTING GREENOPERATIONMajor issues·Addressing climate change·Emissions and waste management·Environmental management·Resource management·Energy management

Environmental and Occupational Health and Safety ManagementAddressing Climate ChangeGreen Operation

Waste management: Strictly implement the "Wastewater, Emissions, and Noise ManagementSystem" and the "Environmental Protection and Harmless Treatment System", and implementclassified storage, compliant disposal, and full-process monitoring of various wastesgenerated from production and daily activities, ensuring full compliance with environmentalregulations and e?ectively safeguarding the environment.

Resource and energy management: Continuously implement the "Resource and EnergyConsumption Control Management System" to regulate employees' practices in conservingwater and electricity. Post water and energy conservation signs to improve employees'awareness of energy saving and emission reduction. Implement quota control for officesupplies. Integrate green design concepts into product design and production processes, andoptimize the use of raw and auxiliary materials to reduce resource waste at the source.Hazardous waste management: Establish the "Hazardous Waste Management System" toclarify the requirements for identification, classification, labeling, storage, transfer, anddisposal of hazardous waste. Maintain hazardous waste management records, implementthe declaration and transfer manifest system, and eliminate environmental risks.Domestic water management: Establish the "Management System of Drinking Water forDomestic Use" to clarify water quality testing standards for domestic drinking water tanks,limits for key indicators, and water quality testing standards for direct drinking water.Commission external agencies to conduct water quality testing biannually, entrust third-party agencies to inspect water fountains routinely, and clean the internal tanks of waterdispensers quarterly, ensuring that the Company's domestic drinking water fully complieswith the national standards for drinking water quality.

Occupational health management: Establish the "Management System for the Preventionand Control of Occupational Diseases". Sign the "Job-Speci?c Occupational Disease HazardsNotice" with employees in high-risk positions, which clearly outlines job-related hazards.Provide compliant and necessary personal protective equipment to all employees in high-risk positions. Conduct annual monitoring of occupational hazard factors. Organize pre-employment, in-service, and post-employment occupational health examinations foremployees in high-risk positions. Maintain employee occupational health records to timelyidentify and address occupational health issues.Canteen safety management: Establish the "Canteen Management System" to strengthencanteen hygiene management. All the canteen staff are on duty with certificates. Conductregular inspections of food quality and hygiene management. Develop record forms for keysteps in the meal preparation process to ensure full traceability and risk control of canteenmanagement. Formulate a special emergency response plan for food safety, clarifyingemergency response procedures, responsibilities, and handling processes for suddenincidents such as food poisoning.Work-related injury management: Strictly implement the "Work-related Injury ManagementSystem" to ensure proper reporting, investigation, identification, and medical treatmentprocedures for work-related injuries, safeguarding employees' legitimate rights andinterests.

Environmentalmanagement

Healthmanagement

AreaInitiatives

Environmental and Occupational Health and Safety ManagementAddressing Climate ChangeGreen Operation

Employee safety and environmental protection constitute thecornerstone of our continuous and stable development. Snibehas always adhered to the policy of "Environment protection,health and safety, compliance with regulations, and sustainabledevelopment" to continuously strengthen the Company's overallsafety and environmental protection construction. Snibe maintainsstrict adherence to laws and regulations like the "Labor Law of thePeople's Republic of China", the "Environmental Protection Law ofthe People's Republic of China", the "Safety Production Law of thePeople's Republic of China", the "Fire Control Law of the People'sRepublic of China", and the "Law of the People's Republic of Chinaon Prevention and Control of Occupational Diseases", and hasdeveloped relevant supporting management systems accordingto those laws and regulations and internal management needs tocontinuously improve environmental and occupational health andsafety management.In 2025, the Company invested 4.58 million yuan in environmentand occupational health and safety.

Environmental and occupational health and safety management policy and objectives >

Policy: Environment protection, health and safety, compliance with regulations, and sustainable development.Objectives:

(1) Zero ?re incidents

(2) Zero chemical leaks and explosions

(3) Zero work-related fatalities or serious injuries

(4) Zero occupational diseases

Environmental and occupational health and safety management initiatives >Environmental and OccupationalHealth and Safety Management

Environmental and Occupational Health and Safety ManagementAddressing Climate ChangeGreen Operation

6162

Emergency procedure management: Establish the "Emergency Preparedness and ResponseControl Procedures" to de?ne the organization process, evaluation criteria, and improvementmechanisms for emergency drills, and standardize the drill record template, promoting thestandardization and traceability of emergency management. Focusing on major risks suchas ?re and hazardous chemical leaks, regularly organize comprehensive emergency drillsinvolving multiple departments to test the effectiveness of emergency plans and improveemployees' capabilities in emergency evacuation, initial response, and coordinated action.

Emergency resource management: Strictly implement the requirements for medicineallocation, inspection, replacement, and documentation as speci?ed in the "First Aid Kit andMedicine Management System" to ensure that ?rst aid medicines and equipment in all areasare always in good condition and ready for use. Establish a ?rst-aider team with basic ?rst-aid knowledge and skills.Equipment safety management: Establish various safety operation procedures and safetymanagement systems, strictly implement pre-employment safety training, and ensure thatspecial equipment operators/special operation personnel hold valid certi?cates. Regularlyinspect and maintain production equipment, electrical wiring, and safety protection facilitiesto ensure the safe and stable operation of equipment and facilities.Hazardous operations safety management: Establish the "Hazardous OperationsManagement System" to improve the approval and management requirements for high-risk operations such as hot work, high-place work, and confined space work. Strengthenpre-operation risk identification, safety briefings, and implementation of protectivemeasures, and assign dedicated personnel for on-site supervision to ensure that the entireprocess of hazardous operations is under safe control.

Hazardous chemicals safety management: Strictly implement relevant hazardous

goods management systems, fully standardizing the management requirements for theclassification, storage, labeling, use, and waste disposal of hazardous chemicals. Assigndedicated personnel to manage and document chemicals inventories, deploy firefightingfacilities and emergency response equipment, and regularly inspect their e?ectiveness.

Fire safety management: Strictly abide by relevant fire safety regulations and systems.Establish the "Fire Equipment and Facilities Management System" to clarify the organizationand implementation of daily ?re safety management. Equip all areas with appropriate ?reequipment, emergency exit indicator lights, etc., as required. Regularly conduct inspectionsand maintenance of ?re equipment, and organize company-wide ?re drills and ?re safetytraining.

Emergencymanagement

SafetyManagement

AreaInitiatives

We actively monitor climate trends and havedeveloped an extreme weather emergencyresponse plan tailored to local conditions.We pay close attention to weather warninginformation, and implement the followingpreventive measures prior to forecastedextreme events: conduct safety inspections,clear drainage systems, repair roofs,reinforce perimeter walls, install waterbarriers, strengthen ventilation, enhancecircuit leakage protection, improve?re?ghting capacity, etc.The Company has proactively implementedenergy management strategies, includingtechnology upgrades, source-level energyconsumption controls, intensi?ed energyconservation and emission reductionpropaganda, etc. to reduce energyconsumption and carbon emissions.

The Company has actively responded toinvestors' concerns, and voluntarily initiatedclimate risk identi?cation, greenhousegas emission management and otherprograms for disclosure. Moving forward,the Company will further develop GHGreduction objectives in line with the needsof enterprise development.

Snibe operates in a coastal city,where increased frequency orintensity of extreme weather events,like heavy rains and typhoons, maydisrupt facility power supply, leadingto water/power outages or damageto warehouses and equipment. Suchrisks threaten both property securityand our operational stability.

At present, Snibe's main energyconsumption relies on externallysourced electricity. Environmentalprotection regulations are becomingincreasingly stringent, with nationaland local governments rolling outpolicies to restrict corporate carbonemissions. Rising fossil fuel priceshave also driven up energy-relatedoperational costs.Snibe recognizes that domestic andinternational investors prioritizetransparency in greenhouse gas(GHG) emissions and emissionreduction targets. Failure to activelymanage GHG emissions could leadto ESG rating downgrade, negativepublicity, reputational damage,and ultimately restricted ?nancingchannels and higher capital costs.

Heavy rains,typhoons andother extremeweather occurfrequently orincrease inintensity

Energy pricesrise as countriesrespond to climatechange

Investors areincreasinglyfocused oncorporate climateaction

Entity risk

Transformationalrisk

TypeInfluencing factorsSpecific impactCountermeasures

Environmental and Occupational Health and Safety ManagementAddressing Climate ChangeGreen Operation

Snibe recognizes that the physical impacts of global climatechange and mitigation actions may pose significant risks orcreate opportunities for our business. During the reportingperiod, we identi?ed relevant entity risks, transformation risks andopportunities based on the business development and operationof the Company, and formulated corresponding countermeasures.

Addressing Climate Change

The energy usage of Snibe in 2025 is detailed as follows:

Snibe's carbon emission reduction target: To maintain a stable carbon emission intensity before the completion of Phase V ofthe R&D and production base, and to achieve a steady decline in carbon emission intensity after the completion of Phase Vand the normal operation of the R&D and production base. The main basis is that Phase IV of the R&D and production base willbe completed in 2025 and the base will then be put into use. With expanding business operations, electricity consumption isexpected to rise signi?cantly year-on-year, creating substantial short-term pressure on carbon intensity metrics.

① Direct emissions (Scope 1) encompass emissions directly generated by the Company through the consumption of fossil fuels, including gasoline, diesel, and natural

gas, as well as direct emissions resulting from escape of refrigerant. Indirect emissions (Scope 2) include emissions resulting from the consumption of purchasedelectricity by the Company. Total emissions represent the aggregate of direct and indirect emissions. The accounting methodology for electricity emission factors primarilyreferences the national average CO

emission factor for electricity outlined in the "Announcement on Release of 2023 CO

Emission Factor for Electricity", issued by theMinistry of Ecology and Environment of the People's Republic of China on Dec. 31, 2025. Additionally, calori?c value coe?cients and emission factors for other energysources are mainly derived from the "Guidelines for Compiling Provincial Greenhouse Gas Inventory" and the "General Rules for Calculation of the Comprehensive EnergyConsumption".

2,589.9614,481.5217,071.48

0.0373

Direct emissions (Scope 1)Direct emissions (Scope 2)

Total emissions of Scope 1

and Scope 2

Carbon emission intensitytons of CO

equivalent

tons of CO

equivalent

tons of CO

equivalent

tons of CO

equivalent/10,000 RMB

6364

27,281,049.87Purchased electricityNatural gasGasolineDiesel

kWhcubic meters tons tons

25.1651,7199.89

Environmental and Occupational Health and Safety ManagementAddressing Climate ChangeGreen OperationEnvironmental and Occupational Health and Safety ManagementAddressing Climate ChangeGreen Operation

Snibe is closely tracking diagnosticdemands linked to climate-sensitivediseases and proactively advancing R&Dof targeted testing products.

Through energy conservation andemission reduction initiatives, includingtechnological transformation andequipment upgrading, the Companycontinuously improves energyand resource utilization e?ciency,achieving cost reduction and e?ciencyenhancement.

Global climate and environmentalshifts, particularly risingtemperatures, are increasing thelikelihood of infectious diseaseoutbreaks and respiratory healthrisks, which creates new productopportunities for IVD companies.Reduced energy and resourceconsumption lowers both corporateemissions and operational costs. Byadopting more e?cient productiontechnologies, the Company canincrease production capacity andrevenue while enhancing resourcee?ciency.The Company's greenhouse gas emissions predominantly stemmed from the utilization and consumption of electricity,natural gas, gasoline, and diesel in its production and operations, direct emissions resulting from the escape of refrigerants,and indirect emissions resulting from the consumption of purchased electricity. During the reporting period, we commissionedSGS, an international authoritative certi?cation body, to carry out a comprehensive and detailed greenhouse gas veri?cationaudit, and obtained the ISO 14064-1:2018 Greenhouse Gas Veri?cation Statement Certi?cate issued by SGS.In 2025, the total carbon dioxide emissions (Scope 1 and Scope 2) resulting from the Company's operations amounted to

,071.48 tons of CO

equivalent. Among these, direct emissions (Scope 1) accounted for 2,589.96 tons of CO

equivalent,while indirect emissions (Scope 2) stood at 14,481.52 tons of CO

equivalent. The carbon emission intensity was 0.0373tons ofCO

equivalent per 10,000 yuan

① .

Climate changeleads to increaseddemand for newproducts

Climate changepolicies promotetechnologicalupgrading ofenterprises andincrease bene?ts

OpportunityTypeInfluencing factorsSpecific impactCountermeasures

Rigorously adhering to the "Water Pollution Prevention and Control Law ofthe People's Republic of China", the "Law of the People's Republic of China onthe Prevention and Control of Atmospheric Pollution", the "Law of the People'sRepublic of China on the Prevention and Control of Environment Pollution Causedby Solid Wastes", the "Regulations on the Administration of Medical Wastes", andother laws and regulations, the Company has formulated management systemssuch as the "Control Procedure for Environmental Issues", the "Resource andEnergy Consumption Control Management System", the "Wastewater, Emissions,and Noise Management System", and the "Hazardous Waste ManagementSystem", so as to e?ectively utilize resources and energy and strictly oversee thedisposal process of hazardous wastes. The Company has not been listed as akey pollutant discharge entity by the environmental protection authority. In 2025,the Company did not violate any environmental law or regulation, and was notsubject to administrative penalties by the environmental protection authority.

Green Operation

The Company places emphasis on fostering water conservation awareness among all employees. Through various meanssuch as posting water conservation slogans in o?ce areas and sending internal notices, we advocate employees adoptinggood water-saving habits and guide them to embrace the concept of "taking pride in saving water and feeling ashamed ofwasting it", collectively creating a green, low-carbon, and resource-conserving o?ce environment.Focusing on water conservation and efficiency improvement, we proactively optimize water management measures. Byscientifically adjusting the operating pressure of water supply equipment and rationally controlling the water pressureand volume of faucets in restrooms, water consumption is effectively reduced without compromising employees' normalwater needs. This also reduces the operating load of basement water supply equipment, achieving dual bene?ts of waterconservation and equipment maintenance. In the Company's daily operations, the reject water generated mainly comes fromthe puri?ed water preparation process. The quality of this reject water has been tested and fully complies with the "Reuse ofUrban Recycling Water — Water Quality Standard for Urban Miscellaneous Use" (GB/T 18920-2020). Adhering to the principleof resource conservation and waste reduction, we have installed reject water storage tanks for recycling and reuse. Currently,100-cubic-meter and 180-cubic-meter reject water storage tanks have been installed to supply water for toilet ?ushing andpark irrigation in the Company's Phase II and Phase III parks, respectively, e?ectively reducing tap water consumption.We prioritize water balance testing as a cornerstone of water resource management, and conduct systematic testing,data collection, and analysis to establish precise water usage equilibrium. By scrutinizing every aspect of water usageand optimizing processes with data-driven insights, we ensure stable operations while maximizing water efficiency andconservation.In 2025, the Company's total waterintake amounted to 250,223 cubicmeters,with a water intake intensityof 0.5467 cubic meters per 10,000yuan, and 21,679.7 cubic meters ofreject water recovered.Energy managementThe Company actively controls the rational use of energy, continuously enhances energy e?ciency through technologicaladvancements, equipment upgrades, and various measures, and strengthens the publicity and practice of green concepts tomaximize energy e?ciency.To ensure electricity safety, we prioritize core facilities such as generator sets and power supply and distribution systemsin routine inspections, and conduct comprehensive maintenance regularly. Through continuous routine inspections andpreventative maintenance, we focus on operating conditions and circuit safety, and promptly replace aging or damaged partsand components to eliminate safety hazards at the source and ensure the stable and e?cient operation of the power system.A comprehensive survey of primary, secondary, and terminal power distribution cabinets is conducted, and standardizedsigns are posted to clearly distinguish between daily and emergency power supplies, preventing the emergency powersupply from being occupied and enabling rapid identi?cation and response during emergencies.We strengthen energy-saving awareness among all employees by posting slogans and sending notices to promote behaviorssuch as saving electricity, double-sided printing, turning o? lights when leaving, saving water, and actively reporting waterleaks. Signs are posted on switches and air conditioner panels to remind employees to use air conditioners scienti?cally: setto no lower than 26 °C in summer and no higher than 20 °C in winter. Employees are guided to start with small actions andjointly create a green o?ce environment.We continuously promote refined management by scientifically regulating air conditioning units and reasonably settingparameters based on seasonal changes and office needs. While ensuring office comfort, this approach maximizesoperational e?ciency and reduces power consumption, achieving a balance between comfort and energy e?ciency. For keyareas such as the Phase III plant's special workshops and underground garages, the lighting on/o? times and brightness arescienti?cally adjusted to eliminate the phenomenon of "lights left on all the time", ensuring e?cient use of lighting resources.A centralized control device is installed at charging stations of underground garages, which is linked with the mobile phoneto set a scheduled shutdown time, thereby avoiding a potential safety hazard and power waste caused by long-term standbycharging. The time-controlled system is deployed for courtyard lights, parking lot lights, and LOGO lights in the parks,enabling precise remote control via mobile phones to signi?cantly reduce energy consumption. Solar panels are regularlycleaned and maintained to improve thermal conversion e?ciency and maximize green energy bene?ts.

250,223

0.5467

21,679.7

Total water intakeWater intake intensity

Volume of reject waterrecoveredcubic metersm

/10,000 RMBcubic meters

Environmental and Occupational Health and Safety ManagementAddressing Climate ChangeGreen Operation

Emissions and waste management >Wastewater managementAll sewage undergoes treatment following the principles of "rain and sewage diversion, collection at source, and reuse".Snibe implements environmentally friendly sewage management practices. Wastewater is categorized into rainwater,domestic sewage, and production wastewater by source. Following a classi?ed management approach, we collect each typeof wastewater accordingly. The sources of liquid medical waste and air filtration wastewater are collected and managedby accredited facilities. Meanwhile, the reject water without any chemical reagents and additives generated during thepreparation of puri?ed water is directed to a dedicated reject water recovery pool for toilet ?ushing and park irrigation, anddischarged from the municipal domestic wastewater pipe network into the Shatian Water Puri?cation Plant, contributing toresource conservation and waste reduction.Waste gas managementAll waste gases produced by the Company are subject to the principle of "classi?ed collection, centralized treatment, andstandards-compliant discharge". The production waste gases are treated through the waste gas treatment facility to meetregulatory standards before discharge, with regular emissions testing conducted. Independent waste gas collection coversand fume hoods are installed in production workshops and locations or areas where waste gas is generated within eachproduction line. The waste gas treatment device is equipped with activated carbon boxes and spray towers to ensure thatlaboratory waste gas is discharged in compliance with environmental standards. The ?ow directions in waste gas collectionpipelines are clearly marked, and regular testing of waste gas by third-party institutions ensures alignment with relevantlaws and regulations on emissions.Waste managementSnibe has established a dedicated task force for environmental pollution prevention and control to perform classifiedmanagement of medical and hazardous wastes. Medical wastes, including infectious waste, sharps waste, and chemicalwaste, are centrally collected in specialized medical waste bins, and then disposed of by accredited facilities. The ten typesof hazardous wastes, including waste activated carbon, waste engine oil, waste lamp tubes, waste circuit board, wastethermometer, waste ink carbon ribbon, waste rust-proof oil, waste chemicals, waste packaging, and spray tower wastewater,are centrally transported and disposed of by third-party organizations after collection.The Company actively implements the requirements for solid waste pollution prevention and control, fully promotes thedomestic waste classi?cation system, and continuously advances the re?ned and eco-friendly management of solid wastes.For general solid wastes (domestic waste, kitchen waste, etc.) generated in daily operations, the Company strictly implementsclassi?ed management and entrusts quali?ed third-party organizations to carry out standardized transportation, utilization,and disposal. At the same time, the Company rigorously reviews the technical capabilities of the entrusted parties to ensurefull-process compliance. Recyclable materials such as o?ce waste paper and cardboard are handed over to professionalrecycling facilities for resource utilization.To further enhance employees' awareness of waste classi?cation and improve the accuracy of waste disposal, the Companycontinuously optimizes the classification facility configuration and signage within its premises. For domestic waste andkitchen waste on each ?oor, the layout and speci?cations of bins have been specially upgraded to improve their visibilityand ease of disposal. A regular waste battery recycling mechanism has been established, with dedicated recycling binsplaced at ?xed locations. The waste battery collection and disposal process has been standardized to reduce the potentialenvironmental impact of heavy metals and other pollutants.

Resource and energy management >

Water resource managementThe Company rigorously regulates water resource usage, increases the proportion of recycled water, and enhances waterresource utilization e?ciency through measures like water recycling and equipment adjustments.A regular inspection and maintenance mechanism for water facilities has been established and improved, incorporating key water facilities such as domestic water tanks and solar hot water systems into routine inspections.Comprehensive inspections and maintenance are carried out regularly, focusing on facility operation stability and pipelinesealing. Aging or damaged parts and components such as valves, pipes, and faucets are replaced promptly to eliminateleaks at the source, ensuring that all facilities remain in good working condition, thereby guaranteeing water safety ande?ciency. A remote smart meter has been installed on the master water meter to monitor the water consumption in real timethrough the intelligent system, so as to e?ectively avoid manual meter reading errors, quickly detect abnormal water use,and timely troubleshoot water leaks or equipment failures.

Environmental and Occupational Health and Safety ManagementAddressing Climate ChangeGreen Operation

Attraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and Safety

Talent is the core driving force for sustainable corporate development. Snibeconsistently prioritizes its talent strategy as the key to overall development,continuously advances the construction of the employer brand, andcomprehensively enhances the professional level of human resource management.Embracing an open and inclusive philosophy, we have established diversifiedtalent recruitment mechanisms while protecting the legitimate rights and interestsof employees according to laws. By establishing a sound vocational training systemand clear career development channels, we create a fair and transparent growthplatform for employees and fully stimulate organizational innovation vitality. Wecontinuously improve the occupational health, safety management, and welfaresystems, and better bind employees and bring them happiness, so as to achievethe value creation and common growth of the enterprise and its employees.

Alignment with Sustainable Development Goals (SDGs)

TALENTEMPOWERMENTMajor issues·Diversity and equal employment·Employee rights and bene?ts·Employee training and developmentt·Occupational health and safety

Attraction and Retention of Talents

Diversity and equal employment >

Equal employment

In strict accordance with laws and regulations such as the "Labor Law of the People's Republic of China" and "Labor ContractLaw of the People's Republic of China", Snibe has formulated internal systems such as the "Human Resources ControlProcedure", "Employee Handbook", "Employee Internal Transfer Management System", and "Intern Management System"to standardize the recruitment and talent management process, and build a high-quality and diversified talent team. Itis clearly stated in the "Human Resources Control Procedure" that Snibe prohibits the employment of child labor, opposesdiscrimination in gender, health, and age, advocates diversity, and offers equal opportunities for every employee andjob seeker. It is also explicitly specified in the "Anti-Discrimination and Anti-Harassment Management System" that Snibeprohibits unfair treatment of employees in the process of recruitment, training, promotion, etc. on the basis of race, socialclass, nationality, religion, disability, gender, etc.In 2025, Snibe embraced a "hard worker focused" concept for exploration and practice in such ?elds as talent organizationand management, workplace environment, corporate culture, remuneration and welfare, and training system. For the ?rsttime, we built and launched a LinkedIn Life page, shaping ourselves into a quality employer. In addition, we received thehonor of "2025 Employer of Excellence in Occupational Credit" from Guangzhou Best Check Human Resources Co., Ltd.Attraction and reserve of talentsSnibe values a well-layered talent pipeline by formulating comprehensive talent development strategies and exploringflexible and diverse ways to absorb talents. On-campus and off-campus recruitment are two major ways Snibe brings inneeded talents.For on-campus recruitment, we persist in working with universities on university-enterprise cooperation projects andensuring ongoing communication. At present, we have signed university-enterprise cooperation agreements with topdomestic universities and built internship & practice bases. Nearly 600 faculty members and students have visited Snibe inthe past year. By establishing joint postgraduate bases and employment bases, as well as joint post-doctoral research basesand employment bases, and holding lectures on career development in colleges and universities, we continue to deepenthe university-enterprise cooperation, and have established long-term cooperation with many colleges and universities toprovide internship opportunities for their students. There are more than 150 interns in the Company. We provide one-on-one mentorship for interns who join early and prioritize full-time conversion opportunities for students who have excellentpractice performance. These cooperation programs allow us to offer various practice and employment opportunities touniversity students and help them transform theoretical knowledge into practical skills. In turn, this provides us with access toa huge talent pool.

Attraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and SafetyAttraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and Safety

To recruit off-campus talents, we not only work with mainstream recruitment platforms and experienced headhuntinginstitutions at home and abroad, but also encourage our employees to recommend potential candidates. An array of talentintroduction channels helps to fuel our talent-driven development, foster a team of scarce cutting-edge talents, and integrateexcellent talents to ful?ll our strategic goals.Employee diversitySnibe remains committed to building a workplace of diversity, equality, and tolerance. With a diversified and inclusiverecruitment policy, we gather together top talents from across the world and encourage employees with differentbackgrounds to give full play to their talents. We treat every employee equally and secure their rights and interests inrecruitment, promotion, development, remuneration, and welfare regardless of gender, age, race, nationality, etc.We actively cultivate a diverse workforce and champion workplace inclusivity. We focus on empowering underrepresentedgroups and providing employment opportunities for individuals with disabilities. To respect the religious and culturaldifferences of foreign employees, we provide dedicated prayer rooms in the Company, and assist foreign employees inobtaining legal work permits and residence permits to ensure their legal employment in China. We offer re-employmentopportunities for retired employees. Retirees are welcomed back and provided with competitive benefits while fullyconsidering the operational needs.By the end of 2025, Snibe had 2,785 employees with 168 from minority groups, of whom 36.62% were female, and 30.27% ofmanagerial positions were held by women.

Employees bygender

Employees byage

Employees by

educationalbackground

Management bygenderMale

63.38%

30 years old or below

58.42%

Associate's degree or below

26.73%

41–50 years old

5.35%

Master's degree

20.43%

Male

69.73%

Female

36.62%

31–40 years old

35.73%

Bachelor's degree

52.42%

Over 50 years old

0.50%

Doctor's degree

0.43%

Female

30.27%

Employee rights and benets >Remuneration and welfare systemTo establish a fair and competitive remuneration system, effectively attract, retain, and motivate talent, and support theachievement of strategic goals and sustainable development, the Company has formulated the "Employee RemunerationManagement System", providing employees with a competitive remuneration system. The Company implements aremuneration system based on job value and performance results. The total annual remuneration of an employee consists of"monthly base salary + allowances/subsidies + performance bonus". In addition, we provide employees with annual salaryadjustment opportunities, and reward teams and individuals who are dedicated to their work, have outstanding abilities, andachieve remarkable results, in recognition of their exceptional contributions to the Company.According to national and local regulations, we ensure that our employees are entitled to statutory holidays and leaves,contribute to social insurance and housing accumulation fund for all employees, and provide comprehensive non-salarybene?ts, including supplemental commercial insurance, annual checkups, health testing and consultation, festival activities,and team-building activities, to meet employees' physical and mental health needs. For our female employees, we not onlyprovide paid marriage leave, maternity leave, breastfeeding leave, and other holidays stipulated by national laws to femaleemployees of reproductive years, but also build baby care rooms for working mothers, o?er yoga classes, and hold Women'sDay and Mother's Day activities.

Work-life balanceSnibe cares about employees' life after work and offers a variety of cultural activities and holiday care activities. Allemployees are encouraged to participate in such activities. Employee activities include:

By the end of 2025, we have signed labor contracts with and paid social insurance for

100%

of our employees.

● Holiday allowance

● Staff quarters

● Staff canteen

● Shuttle bus

● Annual lottery

● Commemorative gift

● Activity funds

● Assistance in employee's settling

down

● Supplemental commercial

insurance

● Occupational health examination

● Health consultation hotline

Health lectures and free medicalclinics

● Library

● Gym

● Yoga class

● Basketball court

● Team-building activities

● Festival activities

● Club activities

● Amateur cultural activities

● Statutory holidays

● Statutory leaves, including sick leave, work

injury leave, marriage leave, funeral leave,prenatal check-up leave, maternity leave,paternity leave, breastfeeding leave, andannual leave

● Social insurance, including pension,

medical insurance, unemployment insurance,work-related injury insurance, maternityinsurance, etc.

● Housing accumulation fund

● Other statutory benefits

Statutory BenefitsEmployee WelfareWork-life Balance

7172

●Snibe organizes online and o?ine activities during traditional holidays, annual celebrations, and annual meetings. During

festivals such as Women's Day, Dragon Boat Festival, and Mid-Autumn Festival, special activities are successively held,including gamified check-in challenges, skincare classes, plaster printmaking, and lantern making. This year marked theCompany's 30th anniversary. We organized a series of activities, including a fun sports meeting and a themed marketplace,produced a 30th-anniversary promotional video, successfully completed the unveiling ceremony of the corporate culturespiritual fortress and the departmental tree adoption activity, and customized anniversary T-shirts, refrigerator magnets, andexclusive name tags for all employees, further enhancing employees' sense of participation, honor, and belonging.

●To promote the inheritance of Snibe's culture and the realization of its strategy, and to commemorate the hard work and

dedication of "Snibers", this year, we held an award ceremony for employees serving the Company for 15 years and above, andpresented them with service commemorative coins and trophies. Commemorative coins were also given to employees whohad served the Company for 1, 3, 5, and 10 years. To foster a culture of relentless pursuit of excellence, the Company convenedthe 2025 Annual Performance Review & Honors Gala to formally recognize individuals and teams who delivered exceptionalimpact on mission-critical initiatives this year.

●To help employees relax and keep ?t, Snibe has built an in-house gym, a yoga room, a library, a basketball court, etc.,

and employed external professional yoga teachers to regularly conduct yoga classes at the Company. In addition, footballand badminton courts rented outside the Company are also available on a regular basis, providing a platform for employeesto keep fit and enrich their spare time. In collaboration with culture and sports authorities, we organize free events suchas watching movies and stage plays, fostering a harmonious and healthy work atmosphere and continuously enhancingemployee well-being.

●This year, we held a Family Day event for the ?rst time, inviting employees' family members to visit the company, tour the

workplace, and experience the corporate culture, thereby strengthening family support for employees and enhancing theirsense of identi?cation. In conjunction with the Pingshan District Party-Mass Service Center, we organized several employeesocial events to build a communication and dating platform for young singles, deepening the humanistic care for youngpeople.

●To help new employees get familiar with the parks quickly, better adapt to the corporate culture, and enhance sense of

belonging, we presented the "Guide to Park Life" and explained it in person on the day of employment. We organized awelcome party for fresh graduates to help them better know each other and blend in with the big family of Snibe.

Women's Day activities

Unveiling of corporate culture spiritual

fortress

Mid-Autumn Festival lantern making

Anniversary basketball game

Commemorative Coin Award Ceremony

Welcome party for fresh graduates

Attraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and SafetyAttraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and Safety

Employee care and communication >Establishing multi-dimensional communication channelsSnibe values listening to employees' voices and fully respects their opinions and feedback. To facilitate communicationbetween employees and the management, Snibe builds feedback platforms of di?erent types at all levels for equal, e?cient,and constructive communication within the Company.We conducted an annual satisfaction survey for all employees, covering eight dimensions: their own work, internalcommunication and management, career development, work environment and o?ce software, remuneration and welfare,corporate culture, industry environment and company development, and overall satisfaction. This year, the employeesatisfaction rate was 89.2%. Through systematic categorization and data analysis of survey results, we identified thatemployees' concerns were primarily concentrated in three areas: remuneration and benefits, their own work, as wellas management and communication. This provides a data foundation and decision-making basis for further improvingmanagement and services. Based on employee feedback, we will continuously optimize our initiatives, enhance employeesatisfaction and well-being, and work together with employees to create a better working environment.

Labor Union and Employees' CongressThe labor union at Snibe forms a bridge of communication between the management and general employees. TheEmployees' Congress aims to protect the rights, interests, and welfare of employees and keep the company dynamic. The

We conduct an annual satisfaction survey for all employees and report the pooledsurvey results to the Company's management. Relevant departments are tasked withimplementation and progress tracking based on the Company's decisions.Through our year-end performance appraisal process, we systematically gather theopinions or suggestions of all employees on all aspects of the Company's management,and report them to the management, with designated departments tasked withimplementation and progress tracking. We collect feedback and recommendationsfrom new employees and reply to them through symposiums and other forms. Wealso interview employees who intend to leave to improve the talent retention plan in atargeted manner.We continue to optimize the Snibe Smart Park Online Platform, and encourage employeesto give feedback on the staff canteen, equipment repair and various park servicesthrough the platform."The Snibers", an in-house magazine, serves as the main medium to promote corporateculture and highlight our employees. It includes such columns as company news,management policies, employees showcase, reflections on work, the voice, and sparetime life, which focus on listening to employees and uniting all together.A dedicated feedback email and an anonymous submission portal are available foremployees to voice concerns or proposals. Management responses to substantivesuggestions will be fed back to the employees.Heads of each department stay informed of employees' demands through departmentmeetings and annual performance talks.

Employee SatisfactionSurveyRegular FeedbackCollection

Smart Park PlatformIn-house Publication

Dedicated FeedbackEmail and AnonymousSubmission PortalDepartment Meetings

Feedback PlatformFeedback and Communication Mechanism

7374

New EmployeesTurnover Rate

①

2128.21%

①Turnover rate = annual employee departures/average annual headcount

We keep improving and optimizing various training systems and processes. Committed to "people-oriented, making thebest use of everyone's abilities", we have put in place a training operation system that focuses on both "talent construction"and "product empowerment". A diverse training system of all layers and categories is being built, along with talent trainingmechanisms of all types, to fuel the internal business operation at all positions. A combination of both online and offlinetraining, including onboarding, induction/transfer training, external expert-led management training, special training forserving sta?, and special training on quality, instrumentation, and safety production, improves employees' hard and soft skillsand overall workplace capabilities, drives their career development, supports the Company's ongoing business expansion andoptimization, and shapes a talent pipeline for continuous business development.In 2025, we o?ered

33,899

training opportunities of

96,743

hours for our employees.

Attraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and SafetyAttraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and Safety

Labor Union regularly holds the Employees' Congress as required and maintains close communication with all employees toget them involved in the decision-making of important a?airs. Rules and regulations are also being optimized and improvedto better safeguard the rights and interests of employees.In 2025, the Company held the Employees' Congress two times to review and approve systems such as the "Technical GradeEvaluation Measures for Engineers in Domestic and Foreign Technical Service Departments" and the "Management Measuresfor the Professional Knowledge and Skills Assessment of Product Managers in the Domestic Market Department", furtherimproving the talent evaluation and cultivation system. At the same time, the Congress successfully completed the electionof employee representative directors to the Company's board of directors, effectively guaranteeing employees' rights toparticipate in the Company's democratic management and supervision.Talent introduction and retention for 2025:

Employee Training and Development

Training system >

Diverse training systemSnibe believes that employee training boosts the corporate development. On top of the "Training Management System",Snibe has formulated a series of training management measures, detailed rules, and operational guidelines such as the"Operational Guidelines for the Implementation of Training Process" and the "Operational Measures for the Implementationof Training System" to support and standardize training.

Employee ability improvement >All-round ability improvementWe have been developing and upgrading training courses that target and serve the company's development strategy andbusiness needs.

●Cultivation of fresh graduates

We have established a training framework for fresh graduates, including three stages: "entry", "growth" and "success". Grouptraining after joining the company helps new employees to get the basics of the company, swiftly learn and adapt to thecorporate culture, and complete the transformation from campus to workplace. Tutoring, job rotation, and panel discussionsenable fresh graduates to quickly ?t into the team and master essential job skills. With the guidance of the direct supervisorand tutors, these new employees can establish a solid groundwork for independently undertaking key tasks in the future.

●General knowledge and soft skills enhancement

Product basics popularization and work-related comprehensive soft skill enhancement are realized through Snibe Lecturewith the help of an online learning platform "DingTalk". Through years of continuous exploration and experimentation, wehave initially established a framework for general workplace knowledge and skills training. This year, we launched 37 onlinecourses across ?ve series: AI, communication and presentation, medical science popularization, summary and reporting, andfour major chronic diseases. For the ?rst time, we successfully repurposed online courses into o?ine courses, which becamehighly popular upon release. A total of 40 sessions were held throughout the year, with more than 6,300 attendances and anaverage learning time of approximately one hour per person, meeting employees' learning needs for general skills.

●Improved management capabilities

We have comprehensively strengthened the reserve and development of mid-level and frontline managers. This year,we focused on carrying out special training on personnel management capabilities for the marketing team. For overseasmarketing centers, we specially hired external experts to conduct a 3-day full-time intensive training themed "Building High-Performance Cross-Cultural Teams — Talent Identification and Utilization in Sales Teams". The training comprehensivelyimparted experience and skills in talent "selection, utilization, development, retention, and motivation" to managers, from fourdimensions: "managing goals, managing processes, managing capabilities, and managing willingness", thereby enhancingthe management capabilities of the marketing team. For the domestic marketing center, a two-day full-time intensive trainingthemed "Annual Goal Management and Efficient Execution Workshop" was conducted by rehiring external experiencedexperts. The training covered four aspects: "understanding and upgrading of the manager's role, goal management and planexecution, team development and motivation, as well as communication skills and practical application". Managers wereguided to engage in deep learning and self-re?ection, supplemented by learning methods such as scenario simulations androle-playing, which reinforced the training outcomes.

●Enhancement of professional skills

Leveraging our part-time internal trainer team and the "Cloud Classroom" online platform, we have launched a series

Quali?cation and talent recognitionWe have been developing and upgrading training courses that target and serve the company's development strategy andbusiness needs.

● Support for employee quali?cation

Snibe encourages and rewards all employees to take the exams for relevant skills certi?cates and gain post quali?cations bycovering all associated costs, including exam fees and annual reviews. Employees participating in o?-job training can alsoget subsidies of transportation, catering, etc. By the end of 2025, employees had obtained more than 100 skill certi?cates,covering professional skill quali?cation certi?cations in ?elds such as special equipment safety, internal audit, medical devicelifecycle management, drug validation, electronic product testing, statistical technology application, metrological veri?cationand standard substance development, chemical management, corporate compliance, and occupational health.

● Assistance in talent recognition and professional title application

We assist quali?ed employees in applying for high-level talent recognition and professional titles under the talent policies oflocal governments, and we encourage employees to further their professional competitiveness. We also hold skills festivalswith Shenzhen colleges and universities to identify the ?eld-operational experts with excellent skills. In 2025, 54 employees inthe Company obtained professional titles in their respective ?elds.

7576

of training programs, including "Product Optimization and Upgrade", "Performance Verification", "Annual RotationalTraining", and "New Product Empowerment", thereby meeting employees' professional learning needs and solidifying theirunderstanding and knowledge of new products. This year, we have further expanded training programs on the themesof "Quality, Instrumentation, and Safety", the "Medical Device Assembler·Job Level Certification" series, and the "ReagentProduction Quality and Efficiency Improvement" special program, to meet employees' more refined, deeper, and broaderneeds for professional upgrading. What's more, we actively communicate with industry experts, suppliers and other partners,and host activities like "Clinical Testing Lecture", "Snibe Day", and "Inspection Industry Experts/Specialized Exchange Meeting"to further meet the learning needs of personnel in specific functions/positions for "advanced, specialized, cutting-edge"knowledge, and provide support and momentum for internal technical reformation and product innovation.In addition, we provide employees with more opportunities and platforms for learning and growth by investing more andmore in talent cultivation and integration. In 2023, we were o?cially certi?ed as a "Shenzhen High-skilled Talents TrainingBase". In 2024, we received the "Top Ten Demonstration Carriers of Shenzhen Lifelong Vocational Skills Training" award fromthe Human Resources and Social Security Bureau of Shenzhen Municipality. These recognitions o?er a promising platform forfuture employee development and talent cultivation.

Attraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and SafetyAttraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and Safety

Employee promotion and development >Diverse promotion and development pathsTo "make the best use of talents", we set up clear and detailed promotion channels for employees with a series of clear internalpromotion systems, including the "Rank Management Measures", "Rank Promotion Management Measures for Reagent R&DPersonnel", "Supplementary Rules for Promotion and Management of R&D Personnel", "Technical Grade Evaluation Measuresfor Engineers in Domestic and Foreign Technical Service Departments", "Rank Promotion Management Measures for ProductManagers in Domestic Marketing Departments", etc. At the same time, the Rank Evaluation Committee, the highest authorityfor rank promotion and development, has been established to ensure fair, reasonable, scienti?c, and compliant selection.Snibe aspires to grow with employees together and set position requirements in line with the corporate goals and employeecareer goals. Clear, exact, and fair career paths have been designed for employees of all ranks and all positions. Weencourage employees to leverage their talents and challenge new positions. We set three career development paths of"expertise", "management", and "business" to provide fair and impartial career choices and development opportunities forall employees. With the promotion method integrating "technical expertise" and "management ability", employees withoutstanding contributions or special talents are promoted more than one grade at a time, while employees with exceptionalcomprehensive and professional ability are promoted and cultivated, so as to guide employees to leverage their own edges inenhancing professional skills and overall competitiveness.To promote talent mobility, we implement a flexible internal transfer mechanism, regularly monitor and evaluate thework performance and professional skills of employees who wish to transfer and provide appropriate support. We offercross-departmental and cross-functional transfer opportunities to employees who are willing and qualified to transfer,breaking down job restrictions, stimulating employee development potential, and enhancing organizational vitality andinnovation capabilities. Moreover, we continue to optimize the talent management by adjusting the existing rank evaluationrequirements, so that employees can have a clearer understanding of their development direction. The talent analysis reportand human resources management report of each center are regularly output, so as to timely identify and motivate employeeswith outstanding work performance.In 2025,

100%

of employees received year-end performance appraisals, and more than

employees applied for andcompleted internal transfer.

7778

Deaths fromoccupational injury

Occupational injuries excludingdeaths and serious injuriesSerious injuries fromoccupational injury

Losses of working hours dueto occupational injuries

071,7790

hours

Attraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and SafetyAttraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and Safety

Employee Career Development System

Employee Promotion Channels

Employeecareerlevelappraisal

Careerdevelopmentpath/level/standard

Employeecareerdevelopmentplanning

Where am ICareer

development path

Where to go?

How to go?

Deputy generalmanager

Management path

Chief engineer

Professionaltechnology path

Deputy general managerof marketing center

Businesspath

Director/deputydirector

Sta? engineer

Regional deputydirector/directorManager/deputy

manager

Senior engineerRegional managerSupervisor

Intermediateengineer

Assistant/trainee

District manager

Team leader/specialist

Engineer

New employee

Sales manager

Occupational Health and Safety

Occupational health >Snibe believes in "people first" in its management and always puts employee health in the first place. Various measuresare taken to safeguard the physical and mental health of employees. The Company strictly abides by relevant laws andregulations on occupational health and safety like the "Safety Production Law of the People's Republic of China", andthe "Law of the People's Republic of China on the Prevention and Control of Occupational Diseases", and has developedmanagement systems such as the "Control Procedure for Hazards", the "Management System for the Prevention and Controlof Occupational Diseases", and the "Work-related Injury Management System" to identify, analyze and manage potential risksin daily operations and protect the health and safety of employees.

Occupational disease prevention and controlSnibe continuously regulates occupational health monitoring to prevent occupational diseases. The Human ResourcesDepartment conducts statistical analysis and management of occupational hazards. During employee onboarding, thedepartment truthfully informs employees about the occupational disease hazards associated with their positions, includingpotential consequences, protective measures, and relevant benefits. The Company implements occupational diseaseprevention measures and requires employees to sign the "Job-Speci?c Occupational Disease Hazards Notice".The Company sets up bulletin boards in prominent positions in the production workshops to issue rules and regulations on theprevention and control of occupational hazards, operating procedures, emergency rescue measures for occupational hazardsaccidents, and the detection and evaluation results of occupational hazards in the workplace. The Company organizesoccupational health examinations for employees who are exposed to occupational disease hazards and special operations instrict accordance with the relevant regulations based on the types of occupational disease hazards and the level of exposure.The physical examination report is added to personal health records, and the employee is informed of the actual results ofoccupational health examination.Safeguarding physical and mental health

The Company places a strong emphasis on the physical and mental health of its employees, regularly organizes occupationalhealth checkups, and routinely conducts activities such as traditional Chinese medicine health lectures, free clinic services,and stress relief workshops. In collaboration with commercial insurance providers, the Company also o?ers health screenings,including retinal scans and TCM pulse-taking machine assessments. A mental health hotline has been established to supportemployees' overall well-being.To ensure the hygiene of food and the safety of drinking water in the Company canteen, all canteen sta? are required to be

Emergency Response Drill for Hazardous Chemical Leaks

Extreme Weather Emergency Response

In May 2025, we conducted a special drill for hazardouschemical leaks in key areas such as hazardous chemicalwarehouses and hazardous waste storage rooms.Prior to the drill, more than 1,000 personnel, includingwarehouse managers, operators, and emergencyresponse team members, received systematic training,which focused on the hazardous characteristics ofchemicals, safety identification, and emergencyresponse procedures for leaks. The drill simulatedthe entire process of a leak accident, including itsoccurrence, reporting, initial response, and evacuation,effectively strengthening the risk prevention andcollaborative response capabilities of key personnel.

In Sep. 2025, Super Typhoon Ragasa struck. TheAdministration Department responded swiftly, formingan emergency task force and inspection teams. Weadhere to source control, thoroughly clean up sewers inadvance, reinforce objects on the ground and rooftops,and build a solid safety barrier. At the same time, westrengthened routine precautions, conducted regularlightning protection inspections, regularly maintainedgenerator sets, and worked with professional third-party maintenance organizations to issue professionalmaintenance reports to ensure the safety and reliabilityof emergency facilities and equipment.

7980

certi?ed and regularly inspect food quality and hygiene. Key aspects of the food service process are managed through record-keeping forms to ensure full traceability. In addition, a food safety emergency plan has been developed, and procedures forhandling emergencies have been clearly de?ned. Regarding drinking water, clear testing standards and limit values for watertanks and direct drinking fountains have been established. The Company regularly commissions external agencies to testwater quality. Direct drinking fountains are cleaned at regular intervals and their ?lters are replaced to ensure that drinkingwater complies with the national standards for drinking water quality.Safety management >

Snibe always regards safe production as the lifeline of enterprise development, and unswervingly implements theresponsibility system for safe production. To fortify safety safeguards, the Company conducts regular safety awarenesscampaigns and training programs. These initiatives systematically elevate employees' safety consciousness through multi-dimensional and in-depth approaches, comprehensively enhance their occupational safety competencies, and effectivelyreduce various safety risks.Strengthening the foundation of safetyIn terms of safety training and awareness building, the Company has established an education mechanism of "mandatorytraining upon onboarding + annual refresher training". This year, a total of 6 special safety training sessions for new employeesand 2 safety retraining sessions for all employees were conducted, achieving full coverage of all positions. By leveragingkey occasions such as "Safety Production Month" and "Fire Prevention Publicity Month," and through various forms such asknowledge lectures and case studies, we create a cultural atmosphere where "everyone talks about safety," continuouslystrengthen the safety awareness and sense of responsibility among all employees, and build a solid ideological defense.In terms of special equipment safety operation and maintenance, the Company has established a management systemcovering the entire lifecycle of equipment, strictly implements the daily inspection and regular maintenance system forelevators, and completes the review and veri?cation of special equipment safety standardization certi?cates and the updatingof technical files to ensure that the equipment is always in a compliant, safe, and reliable operating state, eliminatingpotential hazards from the source.At the level of fire safety management, the Company thoroughly implements the working policy of "prevention first,combining prevention and firefighting", continuously optimizes the configuration of fire protection facilities, establishes a"daily inspection, monthly testing, and annual maintenance" mechanism, and regularly conducts equipment function tests.The Company strictly abides by the national regulations and standards to ensure that the ?re passages in the o?ce area areunblocked, and standard ?re protection facilities and equipment are well equipped. Designated personnel is responsible forconducting regular inspections to eliminate potential safety hazards in a timely manner.In terms of hazardous goods management, the Company strictly implements effective control measures for hazardousgoods. We properly classify, store, and protect various chemicals, flammable and explosive materials according to theirspecific characteristic. Hazardous chemical warehouses are equipped with adequate protective equipment, fire protectionand emergency response facilities, and have obvious warning signs. Hazardous chemicals are classi?ed according to theircharacteristics and SDS documents are stored in the corresponding hazardous chemical storage cabinet, which is managedand registered by designated personnel in accordance with the regulations. Hazardous goods are counted by warehousekeeper on a quarterly basis.In terms of emergency management, the Company establishes an emergency preparedness and response mechanism. Weclearly de?ne emergency response plans for various types of accidents, including ?res, hazardous chemical accidents, andobject strikes. In accordance with the requirements of the emergency plans, we equip ourselves with emergency supplies,equipment, or facilities, and designate the persons responsible for their daily storage and inspection. In terms of emergencyresource allocation, we form a first-aider team and equip medical kits and first-aid equipment, among others. In termsof emergency evacuation, the signage management of safety exits and evacuation routes in office and production areasshould be fully standardized to ensure that escape routes are clearly identi?able. The responsibilities of the ?oor supervisorsand evacuation guides are clearly de?ned, establishing a well-de?ned emergency command system that provides a solidguarantee for the rapid and orderly evacuation of personnel in emergency situations.

Emergency drills and responseThe Company consistently implements its emergency response plan system for safe production. In 2025, we organized morethan 20 emergency drills and specialized training sessions to enhance our practical emergency response capabilities. These

Attraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and SafetyAttraction and Retention of TalentsEmployee Training and DevelopmentOccupational Health and Safety

drills comprehensively covered key risk scenarios. In addition to emergency drills such as ?re evacuation, hazardous chemicalaccidents, highly toxic substances, and hazardous waste pollution disposal, we also organized specialized emergencydrills such as dormitory ?re emergency drills, hepta?uoropropane gas extinguishing system emergency drills, and elevatoraccident emergency drills. These drills effectively strengthen the emergency response awareness and practical handlingcapabilities of all personnel.

Industry Exchange and Cooperation

Industry-University-Research collaboration and multi-center research >

In active response to the "14th Five-Year Plan for Pharmaceutical Industry Development" and the "Healthy China 2030Planning Outline", Snibe has continuously focused on addressing the pain points and needs of front-line clinical andlaboratory medicine, and attached great importance to industry-university-research-hospital-application cooperation.Snibe has joined hands with universities, hospitals, and enterprises for all-round cooperation targeting disease diagnosisand treatment, medical technology development, IVD research and development, technology commercialization, and talenttraining. By leveraging respective strengths, all parties aim to promote product diversi?cation and technological innovationin IVD. Amidst the national endeavor to prevent and control the four major non-communicable diseases, Snibe has carriedout relevant research with medical institutions to help early diagnosis and treatment of chronic diseases.

Industry Exchange and CooperationCommunity Commonweal

While steadily advancing its own development, Snibe has neverforgotten to fulfill its corporate social responsibility. Relying on ourcompetencies and technological expertise, we actively participatein industry exchanges and cooperation, promote the popularizationof medical examination knowledge, and facilitate the overalldevelopment of the industry. We collaborate with multiple medicalinstitutions to conduct scientific research, promote early diagnosisand treatment of chronic diseases, and continuously support scienti?cresearch and education, contributing our efforts to the training ofdiagnostic personnel and the advancement of medical research.

Alignment with Sustainable Development Goals (SDGs)

FULFILLING SOCIALRESPONSIBILITY

Major issues·Industry exchange and cooperation·Community commonweal

Multi-center Research on Screening of Aldosterone and Renin in Patientswith Primary Aldosteronism, Establishment of Diagnostic Cut-off Values,and Clinical Application EvaluationOn Mar. 29, 2025, the "Multi-center Research onScreening of Aldosterone and Renin in Patients withPrimary Aldosteronism, Establishment of DiagnosticCut-o? Values, and Clinical Application Evaluation" andthe " Multi-center Research on Aldosterone and ReninReference Interval Establishment in Di?erent Regions ofChina" participated in and supported by the Companywere concluded in Shenzhen. This multi-centerresearch has promoted the standardization of primaryaldosteronism screening and diagnosis in China, andwill help to further promote primary aldosteronismscreening at the grassroots level.

Multi-center Research on the Clinical Application of High-sensitivityTroponin I Concentration and Changes in the Assessment of AcuteMyocardial Infarction

Real-World Research on the Establishment of a Spectrum of EndocrineSystem Toxicity Related to Tumor Immunotherapy and Its Impact on PatientClinical Outcomes

On Apr. 19, 2025, the Company held a launch meetingin Nanjing for the "Multi-center Research on the ClinicalApplication of High-sensitivity Troponin I Concentrationand Changes in the Assessment of Acute MyocardialInfarction," in which it participated and supported. Thismulti-center research will combine machine learningalgorithms to transform static data into time-seriesdynamic, multi-modal diagnostic models, and developmore flexible, accurate, and more suitable diagnosticsolutions for the Chinese population. This also marks anew milestone for the Company in the ?eld of clinicalapplication research of myocardial biomarkers.

On Dec. 14, 2025, our Company launched a "Real-World Research on the Establishment of a Spectrumof Endocrine System Toxicity Related to TumorImmunotherapy and Its Impact on Patient ClinicalOutcomes" in collaboration with 20 top-tier tertiaryhospitals. This multi-center research promotes aprofound shift in cancer treatment from "disease-centered" to "patient-centered" by systematicallyconstructing a toxicity management model.

Industry Exchange and CooperationCommunity Commonweal

8483

Industry Exchange and CooperationCommunity Commonweal

Academic extension >

Supporting chronic disease management and value-based healthcare practices

China's healthcare system is undergoing profound changes. The comprehensive advancement of DRG/DIP payment reformmarks a shift in the healthcare value evaluation system from "payment based on quantity" to "pricing based on e?ectiveness,"and the concept of value-based healthcare is gradually gaining popularity. The Company fully leverages its leading positionin the ?eld of laboratory medicine to promote the exploration and practice of chronic disease management and value-basedhealthcare. In 2025, the Company continued to conduct a number of chronic disease management activities, and the relevantconference convened experts and scholars from the ?eld of laboratory medicine to discuss in depth the strategies, cutting-edge concepts, latest technologies and practical challenges of disease prevention and treatment, aiming to promote theaccurate diagnosis and clinical management of chronic diseases and contribute to the high-quality development of chronicdisease management in China. "Appropriate and precise" solutions are provided for achieving the strategic goals of "HealthyChina 2030".Participating in the preparation of laboratory medicine books and clinical manualsAs the editor-in-chief, Snibe participated in the preparation of "Medical Laboratory Equipment and Application" (immunologysection, biochemistry section, laboratory intelligence and informatization section), "Expert Consensus on the Developmentand Evaluation of In Vitro Diagnostic Products", and "In Vitro Diagnostic Enterprise Operation and Management" led byrenowned experts in Chinese laboratory medicine, transforming our technical accumulation in chemiluminescence,biochemistry, automated assembly line, reagent research and development, laboratory intelligence construction and other?elds into standardization knowledge and consensus. Through the authoritative and practical guidance of these publications,the Company promotes the standardization of industry technology, makes the research and evaluation of in vitro diagnosticproducts more in line with current needs, and contributes to the high-quality publication of innovative textbooks for thecultivation of medical laboratory technology professionals under the background of new medicine.In active response to the national policy on optimizing test panel profiles, the Company takes the lead in compiling the"Handbook for Conducting Clinical Test Items" to assist medical institutions in conducting truly meaningful and clinicallyvaluable test items, as well as enabling precision testing for related disease screening, treatment, and prognosis, thusempowering value-based healthcare.

Supporting clinical academic research

By the end of 2025, Snibe users worldwide had published over 600 international journal articles and approximately 200academic posters related to Snibe products. Snibe has partnered with several authoritative hospitals to conduct 16 medicalstudies on its small molecule "Snibe-NACA" testing product, and 25 related academic papers have been published to date.Extensive real-world customer research data shows that the "Snibe-NACA" testing technology e?ectively addresses clinicalpain points and facilitates precise disease diagnosis and treatment.Popularizing laboratory knowledgeActively promoting the popularization of clinical medical knowledge is an important part of our social responsibility as abiopharmaceutical company. We popularize laboratory medicine knowledge through professional articles, popular scienceposters, and online professional knowledge exchanges.The Company, in collaboration with DXY, conducted online academic exchanges through medical forums and organized 13o?ine academic exchange conferences to popularize knowledge of laboratory medicine and promote industry exchange andcooperation.

8685

In 2025, the Company's overseas marketing department leveraged the Company's self-owned media platforms to promotelaboratory medicine knowledge through promotional posters on the occasion of major global health awareness days, therebyful?lling its corporate social responsibility.

Collaborative assignment, uniformity andstability tests completed; released.Collaborative assignment, uniformity andstability tests completed; to be released.Collaborative assignment, uniformity andstability tests completed; released.Collaborative assignment completed; to bereleased.Collaborative assignment completed; to bereleased.Periodic veri?cation experiment completedCollaborative assignment completed; to bereleased.Collaborative assignment completed; to bereleased.Collaborative assignment and suitability studycompleted; to be released.

HCGFSHTSHtPSAfPSAIGF-1TNF-αIL-617α-OHP

Human chorionic gonadotropinFollicle-stimulating hormoneThyroid stimulating hormoneTotal prostate-speci?c antigenFree prostate-speci?c antigenInsulin-like growth factor-1Tumor necrosis factor-alphaInterleukin-617 α-hydroxyprogesterone

NationalstandardsTypeAssay AbbreviationNameStatus

Industry Exchange and CooperationCommunity CommonwealIndustry Exchange and CooperationCommunity Commonweal

Driving industry standardization >

Deeply engaging in the development of standardization organizations

The Company actively participates in the development of industry standardization organizations, takes the initiative toparticipate in the work of standardization technical committees at all levels, and actively applies for committee memberqualifications, using its professional capabilities to help the industry and standardization work achieve high-qualitydevelopment. In 2025, the Company successfully joined two national and international counterpart standardization technicalorganizations: Rao Jie was selected as a member of the WG3 (In Vitro Diagnostic Products Group) of the domestic technicalcounterpart working group for ISO/TC212 Medical Laboratories and In Vitro Diagnostic Systems, and Du Kai was selected asa member of the TC136 Clinical Laboratory Testing and In Vitro Diagnostic Test Systems. Leveraging its role as a committeemember, the Company will participate more deeply in industry standardization efforts and continue to contribute itsprofessional expertise to the industry's standardization and high-quality development.Engaging in standards development and standard system establishment and revisionSnibe actively integrates itself into both domestic and international standardization systems. The Company not onlyparticipates in the research of national and international standards, but also contributes to the formulation of nationalstandards, industry standards, and group standards in an all-round way. With excellent professional capabilities andextensive industry experience, Snibe demonstrates its leadership in facilitating the mutual recognition of test results.During the reporting period, the Company engaged in the development and collaborative calibration of 20 nationalstandards, national references, and international standards, led or participated in the drafting of 11 reagent-relatednational standards, industry standards, and group standards, and established 1 reference method, further strengtheningthe traceability consistency and result mutual recognition of the aforementioned diagnostic products. By doing so, scienti?cnorms and guidance are in place for the industry development, effectively promoting the standardization process of theindustry.During the reporting period, the development of standards and references, as well as the compilation of national/industry/group standards that Snibe is involved in, include:

8887

Industry Exchange and CooperationCommunity CommonwealIndustry Exchange and CooperationCommunity Commonweal

Collaborative assignment and suitabilitystudy completed; to be released.Collaborative assignment and suitabilitystudy completed; to be released.Assignment and application preparationstageCollaborative assignment completed; to bereleased.Collaborative assignment completed; to bereleased.Collaborative assignment completed; to bereleased.Collaborative assignment completed; to bereleased.Collaborative assignment completed; to bereleased.Collaborative assignment completed; to bereleased.Collaborative assignment completed; to bereleased.Collaborative assignment completed; to bereleased.

We participated in standarddrafting, and the standardwas released in Oct. 2025.We participated in standarddrafting, and the standardwas submitted for approval.We led the standard drafting,and the standard wasreleased in Jun. 2025.We participated in standarddrafting, and the standardwas submitted for approval.We participated in standarddrafting, and the standardwas submitted for approval.

PROGTESTALDAnti-HCVCMV IgMB19 IgMToxo IgMRubella IgMHBs Ag(chemiluminescence)HBs Ag (rapid test)TNF-α

Automatic sample processing system formedical useIn vitro diagnostic medical devices— Information supplied by themanufacturer (labelling) — Part 1: Terms,de?nitions and general requirements17 α-hydroxyprogesterone assay kit(labeled immunoassay)In vitro diagnostic medical devices —Practical guidance for establishingmetrological traceability of values — Part1: Traceable to SIBlood ammonia test kit

ProgesteroneTestosteroneAldosteroneHepatitis C virus antibodyCytomegalovirus IgMantibodyHuman parvovirus B19 IgMantibodyToxoplasma gondii IgMantibodyRubella virus IgM antibodyHepatitis B surface antigen(chemiluminescence)Hepatitis B surface antigen(rapid test)Tumor necrosis factor-alpha

Clinical Laboratory Testingand In Vitro Diagnostic TestSystems (SAC/TC136)Clinical Laboratory Testingand In Vitro Diagnostic TestSystems (SAC/TC136)Clinical Laboratory Testingand In Vitro Diagnostic TestSystems (SAC/TC136)Clinical Laboratory Testingand In Vitro Diagnostic TestSystems (SAC/TC136)Clinical Laboratory Testingand In Vitro Diagnostic TestSystems (SAC/TC136)

Nationalstandards

Nationalreferences

Internationalstandards

Nationalstandardformulation

Industrystandardformulation

Type

Type

Assay Abbreviation

Name

Name

Sponsor

Status

Status

We participated in standarddrafting, and the standardwas submitted for approval.We participated in standarddrafting, and the standardwas released in Jul. 2025.We participated in standarddrafting, and the standardwas submitted for approval.We participated in standarddrafting, and the standardwas released in Jan. 2025.As the deputy editor-in-chief,we participated in standardwriting; drafting in progress.We participated in standarddrafting, and the standardwas submitted for approval.The method has beenestablished and validated;the article is in the process ofpublication.

Cortisol testing kitVascular endothelial growth factorassay kit (magnetic particle basedchemiluminescent immunoassay)Immunoassay - evaluation ofmeasurement uncertaintyGuidelines for construction andevaluation of smart laboratory Part2: Medical laboratoryTechnical requirements forinformation technologyconstruction of regional medicallaboratoriesFully-Auto ChemiluminescenceImmunoassay AnalyzerDevelopment of a standardreference method for FT3/FT4small molecule free hormonesby liquid chromatography-massspectrometry

Clinical Laboratory Testing andIn Vitro Diagnostic Test Systems(SAC/TC136)China Inspection and TestingSocietyChinese Society forMeasurementChina Association of ProductivityPromotion CentersHospital Management andInformation TechnologyConstruction Branch of theNational Association of HealthIndustry and EnterpriseManagementStandardization WorkingCommittee of China Associationfor Promoting InternationalEconomic & TechnicalCooperationNational Center for ClinicalLaboratories, GuangdongProvincial Hospital of TraditionalChinese Medicine

IndustrystandardformulationGroup standardformulation

Establishmentof test referencemethod

TypeNameSponsorStatus

Driving laboratory quality management standardization

Laboratory quality management and testing competency serve as fundamental safeguards for achieving inter-institutionalconsistency in diagnostic outcomes, forming the essential basis for mutual recognition of test results. ISO 15189 is currentlythe most authoritative international standard for accreditation of medical laboratories. Guided by national policies, theCompany has launched a standardized laboratory construction solution, which covers ISO 15189 accreditation services,quality supervision services, and grassroots quality improvement services, comprehensively covering the multi-dimensionalstandardized construction needs of laboratories and promoting the "standardization" of laboratories.To promote the adoption of ISO 15189 certi?cation, ISO 15189 training and guidance were provided to 82 hospitals in 2025,of which 87% were tertiary hospitals. The Company continues to improve service solutions, driving the standardization in the?eld of health care and intelligent laboratory construction, and the implementation of the "test results mutual recognitionstrategy".

Supporting the development ofpublic healthcare

In Oct. 2025, in order to promote the developmentof public health and medical services and advancescienti?c research on laboratory medicine-relatedprograms, the Company donated RMB 500,000to the Zhong Nanshan Medical Foundation ofGuangdong Province.

On Mar. 30, 2025, Hon. Kwabena Minitah Akandoh, Ministerof Health of Ghana, and Ms. Liu Haiyan, Deputy GeneralManager of Snibe, jointly signed a strategic cooperationmemorandum in Shenzhen.

In Dec. 2025, Snibe's representatives participated in aforum panel discussion at the WHX Leaders in Ghana.

On Oct. 26, 2025, Dr. Raiva Simbi, Minister of Health ofZimbabwe, and Ms. Liu Haiyan, Deputy General Manager ofSnibe, jointly signed a strategic cooperation memorandumin Shenzhen.

In Nov. 2025, during the China-Africa Medical DevelopmentForum held in Tunisia, the Tunisian Minister of Health visitedSnibe's booth.

9089

Industry Exchange and CooperationCommunity CommonwealIndustry Exchange and CooperationCommunity Commonweal

Medical laboratory accreditation and quality management training course

In Jul. 2025, the "Medical Laboratory QualityManagement Training Course and ISO 15189 InternalAuditor Training Course" hosted by the GuangdongAssociation of Chinese Integrative Medicine was heldat the company headquarters to help promote thestandardized construction of the medical laboratoryquality management system, improve the laboratory'squality management and technical capabilities,and help medical institutions achieve high-qualitydevelopment.

International exchanges and cooperation >

Strategic cooperation

In 2025, we signed strategic cooperation memorandums with health departments of governments and authoritativelaboratory medicine associations in more than 20 countries around the world, and added partners in Latin America, CentralAsia, and Oceania. The types of signing institutions have also expanded from mainly professional associations to a widerrange of ?elds, such as governments, enterprises, universities, and international alliances. This move signi?es the Company'sdeepening cooperation and increasing in?uence in the international laboratory medicine ?eld, and will help promote thefurther dissemination and popularization of high-quality in vitro diagnostic products.

laboratory medicine in underdeveloped regions. We have systematically shared in vitro diagnostic solutions and localizationpractices suitable for resource-constrained environments, and held practical discussions on key issues such as improvingthe capabilities of primary laboratories, optimizing public health screening networks, and strengthening personnel trainingand technology transfer. By building an open and collaborative dialogue platform, Snibe is committed to promoting thewidespread availability of appropriate technologies, facilitating knowledge sharing and capacity building in the field oflaboratory medicine between China and Africa, and contributing professional expertise to improving healthcare accessibilityin underdeveloped regions such as Africa and contributing to global health equity and accessibility.

Supporting clinical testing in countries of the Belt and Road Initiative

Snibe actively responds to the "Belt and Road" initiative, vigorously advances business expansion in Africa, and is committedto strengthening China-Africa cooperation in the process of "going global" to achieve mutual bene?t and win-win results.We actively participate in the China-Africa Health Cooperation Forum, working with health officials, medical institutionrepresentatives, and industry experts from various African countries to focus on the development path and future planning of

Community Commonweal

Support for research and education >Supporting scientific workWe actively fulfill our corporate social responsibilities bycontributing our fair share to promote inclusive diagnosticknowledge, advance sustainable laboratory development,cultivate diagnostic talent, and support education and medicalresearch.In 2025, the Company officially became an official sponsorof the EFLM GREEN LABS program, deeply involved in andsupporting this important industry initiative that promotesthe sustainable development of clinical laboratories. Initiatedby the EFLM "Green and Sustainable Labs Committee", thisprogram is dedicated to promoting the transformation oflaboratory medicine into a sustainable healthcare system. Itaims to make e?cient use of resources from ecological, social,and economic dimensions, reduce energy consumption, waterwaste, and the use of hazardous chemicals while ensuringthe quality of medical services, and help Europe achieve itscarbon neutrality goal by 2050.

Sponsoring outstanding young researchers

On May 14, 2025, at the opening ceremony of Euromedlab inBrussels, Snibe participated in and supported the IFCC YoungInvestigator Award as a special sponsor of this important award.The award aims to recognize young scholars under the age of40 who have made outstanding scienti?c achievements in the?elds of clinical chemistry and laboratory medicine. This year'slaureate is Dr. Christopher Farnsworth. Ms. Liu Haiyan, DeputyGeneral Manager of Snibe, was invited to present awards tothe laureate, further showcasing Snibe's corporate image andprofessional in?uence to industry experts and clients in Europeand around the world.

9291

Industry Exchange and CooperationCommunity CommonwealIndustry Exchange and CooperationCommunity Commonweal

Supporting community commonweal >As a listed biopharmaceutical company with a strong sense of social responsibility and national commitment, the Companyhas always deeply integrated corporate social responsibility into its development strategy and proactively shouldered itssocial responsibility mission.Education is of paramount importance to both the country and the Party. Snibe attaches great importance to the high-qualitydevelopment of education and actively engages in science popularization and public welfare education, contributing to thevigorous development of socialist education with practical actions. In 2025, the Company was awarded the title of "SciencePopularization Education Base" by the Science and Technology Innovation Bureau for its solid practice and outstandingcontributions in the field of science popularization education, which further consolidated the foundation of sciencepopularization education work. Upholding its commitment to social responsibility, the Company has carried out sciencepopularization and education activities. In 2025, it hosted teachers and students from Pingshan Foreign Language Schooland Shenzhen Pingshan Eastern Greater Bay Experimental School for visits and exchanges, totaling more than 60 visits. Thisprovided students with a window to understand cutting-edge technologies and industry development in the ?eld of medicaldevices, e?ectively stimulating young people's interest and enthusiasm for scienti?c exploration and the biomedical ?eld, andful?lling the Company's responsibility for science popularization and education.At the same time, in response to the national rural revitalization strategy, the Company has actively participated in ruralrevitalization public welfare undertakings, donated RMB 10,000 to the Pingshan District Charity Association, and contributedto rural development with practical donations, conveying corporate warmth and demonstrating the responsibility andcommitment of a national biopharmaceutical company.

On Mar. 21, 2025, Snibe held a seminar on laboratorymedicine in Kenya.

On Jun. 28, 2025, Snibe held a seminar on laboratorymedicine in Ethiopia.

On Apr. 24, 2025, Snibe co-hosted the Snibe Dayinternational academic lectures on laboratory medicinewith the International Federation of Clinical Chemistry andLaboratory Medicine (IFCC) in Algeria.

On Mar. 14, 2025, Snibe held a seminar on laboratorymedicine in Tanzania.

Empowering global diagnostics talentsThe Company is keenly aware of the importance of technical cooperation and has carried out a number of academicexchange activities in Africa in recent years, regularly inviting well-known lecturers to share their laboratory techniquesand industry experience. These activities have enhanced the diagnostic and treatment capabilities of local medical sta?,promoted mutual learning and exchange of medical technologies, and strengthened in-depth interaction between the twosides in their professional ?elds.

We closely follow the outstanding young researchers and scientists emerging in the ?elds of clinical chemistry and laboratorymedicine. Through our continuous support of the IFCC Young Investigator Award and the IFCC Distinguished Award forLaboratory Medicine and Patient Care, we recognize and encourage young scholars who have made outstanding scienti?cachievements in the fields of clinical chemistry and laboratory medicine, as well as individuals who have made uniquecontributions to improving patient care and generating global impact in the ?eld of clinical medicine.

Key Performance Indicator Table

9493

Key Performance Indicator Table

Direct emissions (Scope 1)Indirect emissions (Scope 2)Total emissions (Scope 1 and 2)Carbon emission intensity per unitof revenue

Tons of CO

equivalentTons of CO

equivalentTons of CO

equivalentTons of CO

equivalent/10,000RMB revenue

452.82

12,288.5412,741.36

0.0324

1,138.7814,213.6615,352.44

0.0339

2,589.9614,481.5217,071.48

IndicatorUnit202320242025

Greenhouse Gas Emissions

Purchased electric powerNatural gas consumptionDiesel consumptionGasoline consumptionDirect energy consumptionIndirect energy consumptionTotal energy consumptionEnergy consumption intensity

kWhm

TonsTonsTons of standard coalTons of standard coalTons of standard coalTons of standard coal/ 10,000 RMB

21,735,492.0051,093.00

12.60

27.30

120.57

2,671.292,791.86

0.0071

27,281,049.8751,719.00 9.89

25.16

114.23

3,352.843,467.07

26,480,307.5555,181.00

12.09

27.33

124.84

3,254.433,379.27

0.0075

IndicatorUnit202320242025Energy source

Environmental indicators

Economic Indicators

Operating revenue

Cost of operations

Total Value of Assets

Asset-liability ratio

Net profit attributable to shareholders

of listed companies

EPS

10,000 RMB10,000 RMB10,000 RMB%10,000 RMBRMB/share

392,965.57106,247.60822,248.88

8.25

165,365.32

2.1054

453,540.45126,653.49961,945.35

10.84

182,845.66

2.3271

IndicatorUnit202320252024

Water intakeWater intake intensityVolume of reject water recovered

m

m

/ 10,000 RMBm

235,533

0.5994

19,396.80

250,22321,679.70244,266

0.5386

20,870.10

IndicatorUnit202320252024Water resource

Biohazard waste

Hazardous waste

General industrial solid waste

Total monetary value of significant fines

Total number of non-monetary sanctions

Cases brought through dispute settlement mechanisms

Number of staff involved

Male employees

Female employees

Male employees in management

Female employees in management

Employees under 30 years old

TonsTonsTons

RMBCasesCases

Persons%%%%%

122.32

2.81

211.46

149.3

2.08

87.00

95.50

0.88

51.60

2,627

64.94

35.06

70.71

29.29

62.31

2,785

63.38

36.62

69.73

30.27

58.42

2,841

63.57

36.43

69.05

30.95

62.44

Indicator

Indicator

Indicator

Unit

Unit

Unit

202520242023

202320252024

202320252024

Waste

Environmental compliance

Diversity and equal employment

Social indicators

457,675.95140,724.23 994,075.80

8.01 162,025.22 2.0621

0.0373

0.0076

0.5467

9695

Key Performance Indicator Table

Employee compensation and benefits

Attraction and Retention of Employees

Employees aged 30-40 years oldEmployees aged 40-50 years oldEmployees over 50 years oldCollege degree or belowUndergraduatesPostgraduatesPhD students

Employee labor contract signing rateEmployee social insurance coverage rate

Number of new employeesTurnover Rate

%%%%%%%

%%

Persons%

33.80

3.43

0.46

29.62

52.87

17.24

0.27

33.09

4.05

0.42

27.49

52.76

19.43

0.32

35.73

5.35

0.50

26.71

52.42

20.43

0.43

12.49

8.21

9.56

Indicator

Indicator

Indicator

Unit

Unit

Unit

202320242025

2023

2023

20252024

20252024

Employee training and developmentTotal training durationTotal number of trainees

HoursTimes

164,366

33,109

96,74333,89986,48213,298

IndicatorUnit202320252024

Diversity and equal employment

Occupational health and safety

Investment amount in environmental and occupational health & safetyCoverage rate of occupational health examination

10,000 RMB%

/

409.5

IndicatorUnit202320242025

Total number of discrimination incidents during the reporting periodCases000

IndicatorUnit202320252024

Anti discrimination

Quality management system certificationExternal regulatory reviewThird party quality system auditOverall satisfaction with customer complaint handlingEvents where fines or penalties are imposed for violations of regulationsEvents subject to warnings due to violations of regulationsEvents that violated the voluntary codeEvents of Product recall quantity

PcsTimesTimes%CasesCasesCasesPcs

IndicatorUnit202320252024

Quality of product and service

Total number of R&D personnelR&D investment amountCumulative number of patent applicationsValid patents grantedValid invention patents grantedChemiluminescence immunoassay reagent projects provided globally

Persons10,000 RMBPcsPcsPcsItems

36,604.71

45,358.80

IndicatorUnit202320252024

Product R&D

Occupational health and safety

Deaths and mortality rate of employee caused by work injuryOccupational injuries excluding deaths and serious injuriesLosses of working hours due to occupational injuries

Persons;%PersonsHours

635.04

1,773.04

1779

IndicatorUnit202320242025

Key Performance Indicator Table

47,776.93

9897

Appendix

Total number of new suppliersNumber of suppliers disqualified due to quality issuesPercentage of the Chinese Mainland suppliers

SuppliersSuppliers%

95.21

95.90

96.30

IndicatorUnit202320242025

Supplier management

Events where fines or penalties are imposed for violations of regulationsEvents subject to warnings due to violations of regulationsEvents that violated the voluntary code

Number of anti-commercial bribery trainingsProportion of employees receiving anti-commercial bribery trainingsProportion of employees signing anti-commercial bribery commitments

CasesCasesCases

Times%%

Indicator

Indicator

Unit

Unit

202320242025

202320242024

Marketing management

Anti-corruption

The total number of confirmed leaks, theft, or loss of customer informationThe total number of confirmed complaints received regarding violations of customer privacy

CasesCases

IndicatorUnit202320252024Customer privacy

Issue Index of "Shenzhen Stock Exchange Self-Regulation Guidelines for ListedCompanies No. 17 - Sustainable Development Report (Trial)"

Environment

Society

Governancerelated tosustainabledevelopment

Addressing Climate ChangePollutant emissionsWaste disposalEcosystem and biodiversity conservationEnvironmental compliance managementEnergy utilizationWater utilizationCircular economyRural revitalizationSocial contributionInnovation-driven developmentEthics of science and technologySupply chain securityEqual treatment of SMEsSafety and quality of products and servicesData security and customer privacy protectionEmployeesDue diligenceCommunications with stakeholdersAnti-commercial bribery and anti-corruptionAnti-unfair competition

Addressing Climate ChangeGreen OperationGreen Operation/Environmental and occupational health and safety managementAddressing Climate ChangeGreen OperationGreen OperationCommunity CommonwealIndustry exchange and cooperation,Community CommonwealFocusing on R&D and InnovationFocusing on R&D and InnovationSupply Chain ManagementSupply Chain Management,Responsible MarketingProduct Quality and Safety,Customer Service QualityCompliance in OperationAttraction and Retention of Talents, Employee Trainingand Development,Occupational Health and SafetyCompliance in OperationESG governanceCompliance in OperationResponsible Marketing

DimensionNo.IssueSection

Key Performance Indicator Table

10099

AppendixAppendix

GRI2：General DisclosuresThe organization and its reporting practices2-12-22-32-4Activities and workers2-62-7Governance2-92-102-112-122-142-162-172-182-20Strategy, policies and practices2-222-232-242-252-26

Organizational detailsEntities included in the organization’s sustainability reportingReporting period, frequency and contact pointRestatements of informationActivities, value chain and other business relationshipsEmployeesGovernance structure and compositionNomination and selection of the highest governance bodyChair of the highest governance bodyRole of the highest governance body in overseeing the management of impactsRole of the highest governance body in sustainability reportingCommunication of critical concernsCollective knowledge of the highest governance bodyEvaluation of the performance of the highest governance bodyProcess to determine remuneration

Statement on sustainable development strategyPolicy commitmentsEmbedding policy commitmentsProcesses to remediate negative impactsMechanisms for seeking advice and raising concerns

ABOUT THIS REPORTABOUT THIS REPORTABOUT THIS REPORTABOUT THIS REPORT, Key Performance Indicator TableSupply Chain Management,Responsible Marketing,Customer Service QualityAttraction and Retention of TalentsCorporate governanceCorporate governanceCorporate governanceCorporate governanceESG governanceESG governance　Corporate governanceCorporate governanceCorporate governanceMESSAGE FROM THE CHAIRMANCompliance in OperationCompliance in Operation, Supply Chain Management,Responsible MarketingCompliance in OperationCompliance in Operation

Indicator No.Indicator NameReport Chapter

GRI Index Table

REGULATING CORPORATE GOVERNANCE,STRICTLYCONTROLLING THE QUALITY OF PRODUCTS ANDSERVICES,TALENT EMPOWERMENT,PROMOTING GREENOPERATION,AppendixESG governanceESG governanceESG governanceESG governanceKey Performance Indicator TableAddressing Climate ChangeCommunity CommonwealSupply Chain ManagementCompliance in OperationKey Performance Indicator TableAddressing Climate Change,Key Performance Indicator TableAddressing Climate ChangeAddressing Climate ChangeAddressing Climate Change,Key Performance Indicator Table

2-27Stakeholder engagement2-29GRI3：Material Topics3-13-23-3GRI201：Economic Performance201-1201-2GRI203：Indirect Economic Impacts203-1GRI204：Procurement Practices204-1GRI205：Anti-corruption205-2GRI206：Anti-competitive Behavior206-1GRI302：Energy302-1302-3302-4302-5

Compliance with laws and regulations

Approach to stakeholder engagement

Process to determine material topicsList of material topicsManagement of material topicsDirect economic value generated and distributedFinancial implications and other risks and opportunities due to climate changeInfrastructure investments and services supportedProportion of spending on local suppliersCommunication and training about anti-corruption policies and proceduresLegal actions for anti-competitive behavior, anti-trust, and monopoly practicesEnergy consumption within the organizationEnergy intensityReduction of energy consumptionReductions in energy requirements of products and services

Indicator No.Indicator NameReport Chapter

AppendixAppendix

GRI303：Water and Effluents303-1303-2303-3303-4GRI305：Emissions305-1305-2305-4GRI306：Effluents and Waste306-1306-2306-3306-5GRI308：Supplier Environmental Assessment308-1308-2SocietyGRI401：Employment401-1401-2GRI403：Occupational Health and Safety403-1403-2

Interactions with water as a shared resourceManagement of water discharge-related impactsWater withdrawalWater dischargeDirect (Scope 1) GHG emissionsEnergy indirect (Scope 2) GHG emissionsGHG emissions intensityWaste generation and significant waste-related impactsManagement of significant waste-related impactsWaste generatedWaste directed to disposalNew suppliers that were screened using environmental criteriaNegative environmental impacts in the supply chain and actions

New employee hires and employee turnoverBenefits provided to full-time employees that arenot provided to temporary or part-time employeesOccupational health and safety management systemHazard identification, risk assessment, and incident investigation

Green OperationGreen OperationGreen Operation, Key Performance Indicator TableGreen OperationAddressing Climate Change, Key Performance Indicator TableAddressing Climate Change, Key Performance Indicator TableAddressing Climate Change, Key Performance Indicator TableGreen OperationGreen OperationGreen OperationGreen OperationSupply Chain ManagementSupply Chain Management

Attraction and Retention of Talents,Key Performance Indicator TableAttraction and Retention of Talents, Employee Training and Development

Environmental and occupational health and safety managementEnvironmental and occupational health and safetymanagement, Occupational Health and Safety

Indicator No.Indicator NameReport Chapter

403-3403-4403-5403-6403-7403-8403-9GRI404：Training and Education404-1404-2404-3GRI405：Diversity and Equal Opportunity405-1GRI406：Non-discrimination406-1GRI416：Customer Health and Safety416-1GRI417：Marketing and Labeling417-1

Occupational health servicesWorker participation, consultation, and communication onoccupational health and safetyWorker training on occupational health and safetyPromotion of worker healthPrevention and mitigation of occupational health and safetyimpacts directly linked by business relationshipsWorkers covered by an occupational health and safetymanagement systemWork-related injuries

Average hours of training per year per employeePrograms for upgrading employee skills and transition assistanceprogramsPercentage of employees receiving regular performance andcareer development reviewsDiversity of governance bodies and employees

Incidents of discrimination and corrective actions taken

Assessment of the health and safety impacts of product andservice categoriesRequirements for product and service information and labeling

Environmental and occupational health and safetymanagement, Occupational Health and SafetyEmployee care and communicationEnvironmental and occupational health and safetymanagement, Occupational Health and SafetyEnvironmental and occupational health and safetymanagement,Occupational Health and SafetyEnvironmental and occupational health andsafety managementEnvironmental and occupational health andsafety managementOccupational Health and Safety,Key Performance Indicator TableEmployee Training and Development,KeyPerformance Indicator TableEmployee Training and DevelopmentEmployee Training and Development, KeyPerformance Indicator TableCorporate governance, Attraction and Retentionof Talents, Key Performance Indicator TableAttraction and Retention of Talents,Key Performance Indicator TableProduct Quality and Safety, CustomerService QualityResponsible Marketing

Indicator No.Indicator NameReport Chapter

Shenzhen New Industries Biomedical Engineering Co., Ltd.Add: Snibe Building,No.23, Jinxiu East Road, Pingshan District, Shenzhen, P.R. ChinaWeb: www.snibe.comE-mail: snibeinfo@snibe.cnZip code: 518122